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ABSTRACT 
Claudia Nelly Generaux: Effects of Parasitic Infection on the Pharmacokinetics  
and Disposition of Pentamidine Analogs 
(Under the direction of Mary F. Paine, Ph.D. and Dhiren R.Thakker, Ph.D.) 
 
 Diamidine analogs of pentamidine are under evaluation as new and safer alternatives 
for treatment of first- and second-stage human African trypanosomiasis (HAT).  Bis-O-
methylamidoxime prodrugs of diamidines depend on hepatic biotransformation for 
generation of the pharmacologically active diamidines.  The goal of this dissertation project 
was to investigate whether trypanosomal infection attenuates biotransformation of bis-O-
methylamidoxime prodrugs, with the consequent potential to alter systemic exposure to 
prodrug and/or active diamidines. 
 Biotransformation of the prodrug DB868 to the active diamidine, DB829, under 
investigation for second-stage HAT, mirrored biotransformation of the prodrug for first-stage 
HAT, pafuramidine, highlighting the central role of biotransformation for bis-O-
methylamidoxime prodrug activation.  In addition to the O-demethylation and 
N-dehydroxylation reactions preceding DB829 generation, a previously unrecognized 
N-demethoxylation reaction was observed in human and rat liver microsomes.  Formation of 
DB829 in cultured primary hepatocytes from both species was rapid; however, basolateral 
export and/or intracellular sequestration limited appearance of DB829 diamidine in culture 
medium. 
 iii
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 In a rat model of first-stage trypanosomiasis, developed and characterized during this 
investigation, infection altered significantly the pharmacokinetics of both the prodrug, 
pafuramidine, and active diamidine, furamidine.  Compared to uninfected animals, systemic 
exposure (AUC) of both prodrug and active diamidine was increased significantly in infected 
animals, by 1.3- and 3-fold, respectively.  The increase in pafuramidine AUC during 
infection was dependent on dose and route of administration, and conformed to expected 
behavior for a blood-flow limited compound according to the well-stirred model of hepatic 
clearance.  The increase in furamidine AUC during infection was explained, in part, by 
decreased biliary excretion of furamidine.  Simulations of decreased enzyme capacity using 
different doses and routes of administration provided a framework for considering the impact 
of infection on pharmacokinetics. 
 This dissertation project showed that trypanosomal infection is capable of altering the 
pharmacokinetics of bis-O-methylamidoxime prodrugs and corresponding diamidines.  
Knowledge gained from this work provides a basis for making predictions of 
pharmacokinetic outcomes during infection and inflammation. 
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INTRODUCTION 
A.  DRUG METABOLIZING ENZYMES AND DRUG TRANSPORTERS 
A.1. Introduction 
 Drug metabolizing enzymes (DMEs) and drug transporters (DTs), together, play an 
essential role in the absorption and disposition of xenobiotics.  Upon entry into the body, 
xenobiotics encounter various DME systems to transform compounds into more water 
soluble and polar compounds that are more easily eliminated from the body (Beale et al., 
2004).  These biotransformations often render the parent compounds pharmacologically 
inactive, preventing their accumulation and potential for toxicity.  In some cases, however, 
metabolic biotransformations are a necessary step to activate a pharmacologically active 
species (i.e., prodrugs) or result in the formation of toxic species (Beale et al., 2004).  As 
with DMEs, DTs are essential in the disposition of xenobiotics.  They are involved in 
facilitating xenobiotic absorption, tissue distribution, and elimination.   
 Drug metabolizing enzymes are categorized into two groups depending on whether 
they carry functionalization reactions or conjugation reactions.  Functionalization, or phase I, 
reactions introduce functional groups to xenobiotics to increase their polarity and make them 
more conducive to conjugation reactions.  Conjugation, or phase II, reactions also increase 
the polarity and water solubility of xenobiotics by attaching polar functionalities to 
compounds (Beale et al., 2004).  Phase I reactions include oxidative, reductive and hydrolytic 
reactions and are carried out by several enzyme families including, but not limited to, 
aldehyde dehydrogenase (ALDH) cytochrome P450 (CYP), flavin monooxygenase (FMO), 
aldo-ketoreductase (AKR) and carboxylesterase (CES).  Enzyme families involved in 
conjugation reactions include UDP-glucuronosyltransferase (UGT), sulfotransferase (SULT), 
and glutathione S-transferase (GST) (Casarett et al., 2008). 
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 Drug transporters are categorized according to their energetics of transport and are 
divided into active and facilitative transporters (Martin and Sinko, 2006).  Active transporters 
use ATP as the energy source to translocate substrates across membranes (i.e., primary active 
transporters).  In addition to being ATP-dependent, some active transporters utilize a co-
substrate (e.g., Na+, K+, H+) to move substrates across membranes (i.e., secondary active 
transporters).  Facilitative transporters do not require energy to move substrates; rather, they 
use a concentration gradient as a driving force to move substrates across membranes.  Two 
superfamilies of transporters comprising both the active and facilitative proteins are most 
often associated with the disposition of most xenobiotics.  These families include the ATP-
binding cassette (ABC) superfamily and the solute carrier (SLC) superfamily. 
 The ABC superfamily is composed of only three families of transporters, including 
the multidrug resistance proteins (MDR), breast cancer resistance proteins (BCRP) and 
multidrug resistance associated proteins (MRP).  Among the SLC transporters families 
include the sodium taurocholate cotransporting polypeptide (NTCP), organic anion 
transporters polypeptide (OATP), organic cation transporters (OCT), peptide transporters 
(PEPT), concentrative nucleoside transporters (CNT), equilibrative nucleoside transporters 
(ENT), and multidrug and extrusion transportes (MATE) (Klaassen and Aleksunes, 2010).   
 In the liver the NTCP, OATP, OCT and CNT transporters are localized in the 
basolateral membrane of hepatocytes and function to take up substrates from blood into 
hepatocytes.  The ABC transporters MDR, BSEP and MRP are efflux transporters that 
function to export substrates from within hepatocytes to systemic circulation (e.g., MRP3, 
MRP4) or to excrete substrates into the bile (MDR, MRP2 and BSEP) (Klaassen and 
Aleksunes, 2010).    
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 Because of their central role in drug absorption and disposition, modulation of DMEs 
and DTs could have profound implications on the pharmacokinetics and pharmacodynamics 
of therapeutic agents.  Some of the ways in which DMEs and DTs could be modulated and 
regulated are presented in the next section.  
A.2. Modulation of DMEs and DTs 
 Various factors could influence the expression and function of DMEs and DTs.  
These proteins can be directly acted on, such in the case of chemical enzyme inhibition or 
their gene expression could be modulated via intermediates (e.g. nuclear receptors), as in 
cases of chemical enzyme induction.  DME inhibition has been extensively studied due to its 
known potential to have large negative impact on safety, as exemplified by potentially deadly 
drug interactions (Davies et al., 1989).  Inhibition primarily affects substrate binding, for 
which various modes of inhibition have been described: competitive, non-competitive, 
uncompetitive and mixed inhibition. Chemical inhibition could be transient (reversible 
inhibition) or have lasting effects (irreversible inhibition), where covalent binding of the 
inhibitor to the enzymes has deleterious effects by removing the inhibitor-bound enzyme 
from the enzyme pool.  Because of the extensive knowledge and good understanding of the 
interaction between inhibitors and DMEs, today is possible to make predictions of 
pharmacokinetic outcomes in vivo (humans) using data generated in vitro (Obach et al., 
1997).  
 In contrast to the effect of inhibition on DME and DT function, regulation of gene 
expression of DME and DT is most often manifested as protein induction.  It is mediated by 
direct binding of xenobiotics to nuclear receptors. Specifically, transcriptional activation of 
target DME and DT genes occurs by binding of nuclear receptors to promoter regions 
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(response elements) of target genes triggering induction of mRNA expression (Xu et al., 
2005; Muntane, 2009).  Among the nuclear receptors known to be involved in protein 
induction are the aryl hydrocarbon receptor (AhR), the constitutive androstane receptor 
(CAR), the pregnane X receptor (PXR), the peroxisome proliferator activated receptors 
(PPAR), the liver X receptor (LXR), the retinoid X receptor (RXR), and the farnesoid X 
receptor (FXR).  Nuclear receptors often form heterodimers with other nuclear receptors in 
order to induce mRNA transcription.  For example, upon binding to the ligand phenobarbital, 
PXR dimerizes with RXR resulting in induced expression of CYP3A.  Nuclear receptors are 
known to activate gene transcription in a coordinated fashion through overlapping target 
specificity (Xu et al., 2005). For example, both the PXR and CAR nuclear transcription 
factors are known to induce phase I enzymes (i.e., CYP) and drug transporters (e.g., P-gp, 
MRP, OATP).  A common consequence of DME induction is loss of efficacy due to 
decreased drug levels at the site of pharmacological action.  However, beneficial side effects 
of induction of DMEs are sometimes seen, as is the case with phenobarbital induction of 
UGT1A1 in Crigler-Najar patients, where hyperbilirubenimia is reduced via an increase in 
UGT1A1 metabolism (Sugatani et al., 2001).   
 For more than three decades it has been recognized that infection and inflammation 
are also capable of modulating the expression and activity of DMEs and DTs (Morgan, 
1997).  A number of examples in various experimental systems have provided insight about 
the agents and conditions that evoke these changes.  As such, this chapter will present the 
knowledge gained in the past several years about the role of infection and inflammation in 
the modulation of DMEs and DTs and the impact of this phenomenon in the clinic. 
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B.  INFLAMMATION AND THE ACUTE-PHASE RESPONSE 
B.1. Introduction 
 The inflammatory response is a mechanism of innate immunity, initiated in response 
to a stimulus such as an infectious or noxious agent, tissue or cell damage (Vassileva and 
Piquette-Miller, 2010).  It involves a complex cascade of events in which effector molecules 
and cells are activated with the goal of containing and removing the harmful agent.  The 
mediators of the inflammatory response include effector molecules such as cytokines and 
nitric oxide, and immune cells, which work in concert to eliminate invading pathogens.  The 
effector molecules are generated by the reticuloendothelial system (RES) (i.e., phagocytic 
cells) at the infection site to signal immune cells (i.e., neutrophils, and monocytes) to move 
to the affected tissue to combat the infection (Janeway, 2005).  Together, effector molecules 
and immune cells initiate the classical clinical signs of inflammation: redness, heat, pain and 
swelling.  
 The inflammatory response, along with other mechanisms of innate immunity (i.e., 
complement activation), successfully remove the pathogen from the body, or contain it at the 
site of infection while adaptive immunity develops.  The adaptive immune response also 
utilizes effector molecules and immune cells to fight infection; however, in contrast to innate 
immunity, which is a more general response, both effectors and immune cells (i.e., T cells 
and B cells) of the adaptive immune response have greater specificity to kill the pathogen 
(Janeway, 2005).  For example, T cells recognize and activate pathogen-containing 
macrophages, triggering their apoptotic mechanisms to induce cell death, or they release 
growth factors for B cell proliferation (TH1 cells and TH2 cells, respectively).  B cells 
produce specific antibodies that neutralize pathogens, activate complement, and opsonize 
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pathogens for phagocytosis and stimulate natural killer cells to kill infected cells.  Although 
some of the same cytokines present during innate immunity are still present during adaptive 
immunity, the main role of cytokines in the adaptive immune response is to regulate 
lymphocyte growth, behavior and functional differentiation (Janeway, 2005). 
B.2. Immune Effectors 
 Immune effectors, including cytokines, are low molecular weight soluble proteins 
produced by various cells including macrophages, dendritic cells, lymphocytes (e.g, natural 
killer cells, and T cells), as well as endothelial and epithelial cells (Bogdan et al., 1992).  
They can act as autocrine, paracrine and endocrine modulators depending on whether the 
target is the cells that produce them, nearby cells or distant cells (Janeway, 2005).  Among 
the various downstream effects produced by cytokines released during innate immunity is 
initiation of the acute-phase response (Ceciliani et al., 2002).  During the acute-phase 
response, the cytokines TNF-α, IL1-β and IL-6, produced by phagocytic cells, act on 
hepatocytes to up-regulate synthesis of acute-phase proteins inducing their levels in serum 
(Figure 1.1).  Concurrent with the up-regulation of liver acute-phase proteins, other proteins 
referred as negative “acute-phase reactants” are down-regulated thereby decreasing their 
concentration in serum.  Acute-phase proteins up-regulated in the liver include C-reactive 
protein, haptoglobin, fibrinogen, serum amyloid protein, mannose binding lectin, lung 
surfactant proteins A (SP-A) and (SP-D), complement C3 and α-1 acid glycoprotein (Sheth 
and Bankey, 2001).  The general function of these proteins is to opsonize pathogens, activate 
the complement pathway or to act as coagulation factors.  Negative acute-phase proteins 
include albumin, antithrombin, transferrin, transthyretin, transcortin and retinol-binding 
protein (Ritchie et al., 1999).  A general function of the negative acute-phase proteins is to 
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aid in the restoration of homeostasis by either increasing cortisol levels (e.g.,transcortin 
suppression) or by increasing coagulation rate (e.g.,suppression of thrombin)(Pugeat et al., 
1989).  
Another inflammatory mediator of immunity is nitric oxide (NO), which is secreted 
by activated macrophages and other mammalian cells to fight infection (Saad et al., 1995).  
NO is synthesized from L-arginine by nitric oxide synthase (NOS).  NO is normally present 
at low levels in the cytosol of macrophages, but upon immunologic stimulus, substantial 
increases of this cytotoxic product has been observed (Nathan and Hibbs, 1991).  NO 
cytotoxic effects have been shown with a variety of pathogens including yeast, bacteria, 
helminthes and parasites.  The microbicidal action of NO is by targeting key iron-containing 
enzymes, such as ribonucleotide reductase (involved in DNA synthesis), and mitochondrial 
enzymes that function within the electron transport chain (Nathan and Hibbs, 1991).   
B.3. Mechanisms of DME and DT Modulation by Inflammatory Effectors 
 As discussed above, immune response mechanisms involve the activation of immune 
cells and mediators that help the host contain the antigen or eradicate it.  Among the immune 
mediators, cytokines and NO have been implicated in the down-regulation of DMEs DTs 
(Abdel-Razzak et al., 1993; Chen et al., 1995; Yaghi et al., 2004; Geier et al., 2005).  The 
primary mechanisms shown to contribute to CYP suppression include loss of gene expression 
and enzyme inactivation.  
DME and DT modulation by cytokines was shown to occur through induction of 
signaling cascade events that ultimately modulate the constitutive expression of the gene 
(Renton, 2004).  This cascade is initiated upon binding of a particular cytokine to their 
respective receptors on the surface of target cells (e.g, hepatocytes), followed by activation of 
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cytosolic transcription factors (e.g., NFK-β, STAT3) or nuclear receptors (e.g., PXR, CAR) 
that are translocated to the nucleus.  In the nucleus, these transcription factors or nuclear 
receptors bind to DNA response elements on target genes to either suppress or induce their 
transcription (Ho and Piquette-Miller, 2006).  A general scheme showing this mechanism of 
DME and DT modulation was proposed by Renton (2004) as depicted in Figure 1.2.  This 
mechanism of down-regulation shares similarities with the ligand-dependent regulation of 
gene expression observed for induction of DMEs and DTs.   
The most commonly studied cytokines capable of mediating DME or DT suppression 
include the pro-inflammatory cytokines TNF-α, IL-1 and IL-6 (Morgan, 1997).  These 
cytokines are the main cytokines in the activation of the acute-phase response (Figure 1.1).  
Interferons, a type of cytokine common to viral infections, also have been studied extensively 
as mediators of CYP modulation, particularly because they are administered therapeutically 
for treatment of hepatitis C and some cancers (e.g, INFα-2β for melanoma) (Israel et al., 
1993; Okuno et al., 1993; Pageaux et al., 1998; Islam et al., 2002).  Additionally, interferons 
are highly induced after vaccine administration, which has often been shown to result in CYP 
suppression and impaired drug metabolism (Kramer and McClain, 1981; Gray et al., 1983; 
Hayney and Buck, 2002).   
Much evidence also has implicated NO as an immune mediator capable of provoking 
CYP loss in inflammation and infection (Khatsenko et al., 1993; Muller et al., 1996; Yaghi et 
al., 2004).  The proposed mechanism by which NO elicits CYP suppression is by direct 
inactivation of the enzyme through binding to the heme iron (Khatsenko et al., 1993).  This 
mechanism has been shown to occur both in vitro using LPS as an inflammatory stimulus 
and in vivo in an animal model of acute pneumonia (Ferrari et al., 2001; Yaghi et al., 2004). 
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C.  ROLE OF IMMUNE EFFECTORS IN ALTERED PHARMACOKINETICS 
C.1. Introduction 
 Numerous studies have established that inflammatory mediators such as cytokines 
and nitric oxide (Peterson and Renton, 1984; Abdel-Razzak et al., 1993; Abdel-Razzak et al., 
1994; Khatsenko et al., 1998; Lee and Piquette-Miller, 2001; Sukhai et al., 2001; Gharavi 
and El-Kadi, 2007) are capable of modulating the expression and activity of DMEs and DTs.  
One of the earliest reports showing the consequences of impaired metabolic activity was 
demonstrated in a pediatric population where theophylline clearance was significantly 
reduced during an influenza outbreak, causing toxic elevations of the drug (Kraemer et al., 
1982).  Since then, a handful of clinical reports associating decreased drug clearance and 
toxicity during episodes of inflammation or infection have emerged in the literature.  At the 
same time, significant efforts to understand the mechanisms and agents that produce these 
changes were launched.  Using a variety of in vitro and in vivo systems, significant progress 
has been made toward increasing the understanding of the mechanisms behind inflammatory 
modulation on DMEs and DTs and its pharmacological consequences.  The next few sections 
highlight specific examples of DME and DT modulation using these systems.  
C.2. Modulation of DMEs and DTs by Immune Effectors In Vitro 
 In vitro studies have been essential to confirm that inflammatory mediators were 
involved in the suppression of DMEs and DTs and to dissect the mechanisms by which 
inflammatory agents and mediators alter the expression and function of these enzymes.   For 
example, using primary human hepatocytes, it was demonstrated that the mRNA of the major 
CYP enzymes (i.e., CYP1A2, CYP2C, CYP2E1, and CYP3A) was down-regulated up to 
40% upon stimulation with the cytokines IL-1β, IL-4, IL-6, TNF-α, and INF- γ, with the 
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exception of CYP2E1, which was induced upon treatment with IL-4 (Abdel-Razzak et al., 
1993).  Similarly, using primary rat hepatocytes, it was shown that the mRNA of Cyp2c11 
was down-regulated by the pro-inflammatory cytokines IL-1, IL-6, and TNF-α.  
Additionally, this study showed that protein suppression followed mRNA suppression and 
that stimulation by two cytokines (i.e., IL1 and IL-6) produced additive effects. 
The contrasting effects of pro-inflammatory cytokines versus anti-inflammatory 
cytokines (i.e., IL-10) were demonstrated in studies with rat hepatocytes, where modulation 
of the expression of enzymes of the CYP4F family was investigated.  CYP4F enzymes were 
up-regulated upon stimulation by pro-inflammatory cytokines, whereas the anti-
inflammatory IL-10 induced suppression of CYP4F expression (Kalsotra et al., 2007). 
Studies by Abdel-Razzak et al, demonstrated that aside from constitutive protein 
levels, induced CYPs also were altered by inflammatory mediators.  For example, it was 
shown that induced CYP1A1 and CYP1A2 from human hepatocyte cultures were down-
regulated by TGFβ-1 (Abdel-Razzak et al., 1994).  Similarly, phenobarbital induced CYPs 
were down-regulated upon stimulation with IL-1β in primary cultures of rat hepatocytes 
(Abdel-Razzak et al., 1995).  Experiments with mouse hepatocytes showed that inflammatory 
agents such as dextran sulfate were not capable of eliciting effects on DME levels alone but 
needed to be co-cultured with Kupffer cells to elicit suppression of CYP levels, indicating 
that factors released by Kupffer cells were the mediators of protein down-regulation 
(Peterson and Renton, 1984).  Supporting Kupffer cell-mediated effects, another study 
showed down-regulation of CYP3A4 activity by IL-2 generated from Kupffer cells in co-
cultures with human hepatocytes (Sunman et al., 2004).    
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Although the studies described above demonstrate convincingly that specific 
cytokines have the ability to down-regulate CYPs, there was no direct evidence showing that 
these inflammatory mediators secreted in vivo diminished activity of CYP enzymes.  To 
address this question, Bleau et al., used serum of humans afflicted with an acute viral 
respiratory infection and serum of rabbits exposed to the inflammatory agent turpentine to 
show that the inflammatory mediators contained in these sera (i.e., IL1β, IL-6 and IFN- γ), 
lowered the total CYP content of human hepatocytes by 40% (Bleau et al., 2000).  
Limited and contrasting results in vitro were reported regarding suppression of phase 
II enzymes.  For instance, in one report it was shown that the conjugating enzyme GST-α 
was up- regulated when IL-4 was incubated with primary cultures of human hepatocytes 
(Langouet et al., 1995).  However, another report using primary pig hepatocytes 
demonstrated the suppression of CYP enzymes and UGT activities by pro-inflammatory 
cytokines (Monshouwer et al., 1996).  Down-regulation of drug transporters mediated by 
pro-inflammatory cytokines was also shown in vitro; however, fewer examples have been 
reported.  In human hepatoma cells (HuH7), IL-6 suppressed the expression and activity of 
MDR1.  However, IL-6 induction of expression and activity of MRP transporters was 
observed with hepatoma cell lines HuH7 and HepG2 (Lee and Piquette-Miller, 2001).  
Studies using human hepatocytes and HepaRG cells showed that the mRNA expression, 
protein levels and activity of the transporter NTCP were down-regulated by IL-1β.  
Additionally, the mRNA expression of the transporters OATP2B1, OATP1B1, OATP1B3, 
MRP2, MRP3, MRP4, BCRP and BSEP was also shown to be down-regulated by IL-1β after 
24h treatment with this cytokine (Le Vee et al., 2008). 
 
 12
C.3. Modulation of DMEs and DTs by Immune Effectors In Vivo 
C.3.1. Effects of DME and DT Modulation in Experimental Animal Models 
 In vivo experimental models are a valuable tool to study the overall effects of 
inflammation and infection on the modulation of DMEs and DTs, as they provide a more 
realistic representation of how the entire system responds to infectious or inflammatory 
insult. Specifically, experimental models overcome the limitations of static in vitro systems, 
where the administration of single cytokines fails to capture the complexity of the 
inflammatory response.  For example, activation of different cytokine cascades and the 
kinetics of cytokine production cannot be duplicated in vitro.  However, these dynamic 
changes can be captured by experimental models, allowing for investigation into the role of 
intensity and duration of cytokine exposure (Kato et al., 2008).   
Several models of inflammation and infection were used to examine DME and DT 
modulation in vivo.  Among the inflammatory agents used to study these effects are LPS, 
turpentine, dextran sulfate and particulate irritants.  All these agents induce the acute-phase 
response, albeit via different cytokine responses depending on the agent involved.  The LPS 
model of inflammation has been the most common model used for examining both DMEs 
and DTs.  Using data compiled from various studies, Yang et. al. (2008) showed that the 
general effect of Escherichia coli LPS challenge on rat hepatic CYP proteins was 
suppression of the majority of CYP enzymes (i.e., Cyp1a1, Cyp1a2, Cyp2c11, Cyp2e1, 
Cyp3a1, Cyp3a2 and Cyp4a1/2).  However, as shown in studies in vitro, some CYPs were 
not affected (i.e., Cyp2c12) and some were up-regulated (i.e., Cyp4a3).  The magnitude of 
suppression was reported to range from 21% to 80% (Yang and Lee, 2008).  Consistent with 
up-regulation of Cyp4a3 reported by Yang, other members of the Cyp4 family (i.e., Cyp4f4 
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and Cyp4f5) have exhibited up-regulation in rats challenged with E. coli LPS (Cui et al., 
2003).  
Effects on drug transporters were also demonstrated in a CNS rat model of 
inflammation, where intracranial LPS administration suppressed the expression of 
P-glycoprotein (mdr1a) at the blood brain barrier (BBB) by 50%.  Interestingly, the effects 
were not limited to the BBB but were also observed in distant tissues such as the liver, where 
P-gp also was suppressed (Goralski et al., 2003).  Other studies with LPS challenge to rats 
had suppressive effects in other organs such as the intestine and placenta (Kalitsky-Szirtes et 
al., 2004; Wang et al., 2005).  
In addition to what has been observed following LPS administration, differential 
effects on CYPs were observed using a collagen-induced model of arthritis in rat.  While 
activities for Cyp1a1 and Cyp2b1/2 decreased by 85% and 50%, respectively, Cyp3a protein 
and activity increased 100% (Ferrari et al., 1993).  In contrast, a detailed study using the 
Freund’s complete adjuvant (FCA) model of arthritis showed that mRNA levels, protein 
levels and catalytic activity of CYPs (i.e., Cyp2b, Cyp2c11 and Cyp2e1) were consistently 
down-regulated, with maximal effects between 24 and 48 h post FCA stimulation.  However, 
no changes were seen for Cyp3a2 mRNA levels or activity (Projean et al., 2005). 
As with inflammatory agents, different infectious organisms, including bacteria, 
viruses and parasites, were used to study the effects of infection on CYP modulation 
(Table 1.1).  Concurrent with results of experimental models using inflammatory stimuli, 
mixed effects on CYP modulation were observed.  For example, up-regulation of hepatic 
Cyp1a1 and Cyp2b1 was observed in an infection of rats with the parasite Taenia 
taeniformis, whereas no change was observed for Cyp2e1 (Montero et al., 2003).  In contrast, 
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parasitic infection with Fasciola hepatica in sheep showed a significant decrease in Cyp3a 
protein expression (Calleja et al., 2000).   
  A recent study investigating the effects of infection on acetaminophen toxicity 
demonstrated that the consequences of suppression of CYP enzymes may not always be 
negative.  This study showed that in a murine model of acute viral hepatitis, suppression of 
Cyp1a2 and Cyp2e1 had hepatoprotective effects from acetaminophen induced injury 
(Getachew et al., 2010).  Cyp2e1 is involved in the metabolism of the toxic N-acetyl-
benzoquinone imine (NAPQI), which reacts with proteins and other molecules to initiate cell 
damage and oxidative stress (Wolf et al., 2007).      
Modulation of CYPs was shown to occur with inflammation triggered by cancer 
(Charles et al., 2006; Kacevska et al., 2008; Robertson et al., 2008; Sharma et al., 2008).  
Moreover, it has been shown recently that activation of the immune response by novel cancer 
drug delivery methods has untoward effects on DMEs.  For example, some recombinant 
adenoviruses used for gene delivery have tropisms for the liver that are likely to elicit 
immune responses and thus affect CYP enzymes.  The hypothesis that recombinant 
adenovirus may modulate CYP enzymes was tested by Callahan et al. (2005).  Results from 
this study showed that rats infected with recombinant adenovirus 5 suppressed Cyp3a1/2 
mRNA expression, protein expression, and activity while Cyp2c11 protein levels were 
significantly increased above control (Callahan et al., 2005).  A follow up study by the same 
group examined the effects of gene therapy on the pharmacokinetics of anti-cancer agent, 
docetaxel, which is eliminated by Cyp3a.  Rats given the combination therapy of 
recombinant adenovirus (AdlacZ or Adp53) and docetaxel showed significantly slower 
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docetaxel elimination compared to rats that were given docetaxel alone (Wonganan et al., 
2009).  
Despite the numerous studies examining the changes elicited by inflammation on 
DMEs at the molecular level, limited data are available on studies investigating the overall 
effects of CYP or transporter down-regulation on the pharmacokinetics of drugs in pre-
clinical species.  From the few studies that have examined the effects of LPS inflammation 
on the pharmacokinetics of drugs (i.e., antipyrine, chlorzoxazone, ipriflavone, midazolam 
and telithromycin), it appears that in general, this inflammatory agent reduces the systemic 
clearance of these drugs compared to control (Rockich and Blouin, 1999; Ueyama et al., 
2005; Chung et al., 2008; Kato et al., 2008; Lee et al., 2008).    
The data presented from in vivo experimental studies show that while the general 
trend for the effect of inflammation and infection on CYP enzymes is down-regulation, 
differential effects may be observed on different subsets of CYPs depending on the 
experimental model used, and the inflammatory agent stimulating the immune response.   
C.3.2. Effects of DME Modulation in Humans 
Recognition that infection and inflammation can elicit changes in drug disposition has 
important implications in human medicine, as it could impact the way drugs are developed 
and monitored.  Some of the clinical outcomes resulting from these changes include reduced 
drug clearance, potentially resulting in exaggerated pharmacological response or toxicity; 
reduced concentrations of therapeutically active compounds, in cases where metabolic 
activation is necessary for the generation of the pharmacologically active agent (e.g., active 
metabolite generated from a prodrug) (Renton, 2005).   
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 Controlled studies implicating suppression of CYPs as a mechanism for altered 
pharmacokinetics in humans are limited; however, several examples with circumstantial 
evidence exist (Table 1.2).  The only two controlled clinical studies available, using LPS as 
the inflammatory stimulus, showed that clearance of the drugs antipyrine, hexobarbital and 
theophylline was significantly reduced in male subjects given LPS compared to those given 
saline.  A subsequent study by the same group showed that these changes were not gender 
specific (Shedlofsky et al., 1994; Shedlofsky et al., 1997).  These seminal studies 
demonstrated that the effects imposed by inflammation on metabolism were not particular to 
animal models and were duplicated in humans.  In addition, some examples of bacterial, viral 
and parasitic infection were reported to decrease drug clearance in humans (Chang et al., 
1978; Sonne et al., 1985; Pukrittayakamee et al., 1997). 
 For enzymes with clinically significant polymorphisms (i.e., CYP2D6, CYP2C19), 
inflammation was shown to diminish CYP levels to such a degree that discordant phenotypes 
were reported in patients afflicted with conditions such as lupus, cancer and active HIV.  In 
one report, a higher frequency of CYP2D6 poor metabolizer (PM) phenotype was observed 
in the patient population suffering from lupus compared to normal subjects.  Similarly, 
cancer patients with the CYP2C19 extensive metabolizer genotype showed a PM phenotype 
(Baer et al., 1986; O'Neil et al., 2000; Williams et al., 2000). 
The above examples are supporting evidence that infection can elicit altered 
pharmacokinetics without resulting in untoward effects of pharmacology and toxicity.  In 
contrast, toxic events were reported in three separate case studies where transient elevations 
of the steady state concentration of clozapine (2- to 3-fold) were observed in patients 
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afflicted by acute respiratory or urinary tract infections (Raaska et al., 2002; de Leon and 
Diaz, 2003; Jecel et al., 2005).  
 As demonstrated by the in vitro and in vivo examples given above, significant 
progress has been made to further our understanding about the mediators and underlying 
mechanisms involved in the modulation of DMEs and DTs during inflammation and 
infection.  However, while the consequences of these changes are recognized to have an 
impact in human medicine, at present it is still unclear how to predict the manner in which a 
particular infectious agent or inflammatory episode may alter the pharmacokinetics and 
disposition of a particular drug.  The challenge arises from the inability to predict the degree 
of the modulation, the differential responses of specific CYPs and drug transporters (e.g., 
suppression vs. induction) to the particular infectious or inflammatory stimulus, coupled with 
the complexity of the inflammatory response and its dynamic nature. 
D.  HUMAN AFRICAN TRYPANOSOMIASIS 
D.1. Overview 
 Human African trypanosomiasis (HAT), also known as sleeping sickness, is caused 
by Trypanosoma brucei subspecies (WHO, 2010).  The disease is transmitted to humans by 
the bite of the tsetse fly and distributes in regions of sub-Saharan Africa inhabited by this 
vector.  Infections by the T. b. rhodesiense subspecies are prevalent in the southeastern 
region of sub-Saharan Africa whereas infections with T. b. gambiense occur at a higher 
incidence in western regions of sub-Saharan Africa.  HAT has two defined stages during 
disease progression.  In the first-stage, trypanosomes are confined to the hemolymphatic 
system while in second-stage parasites invade the CNS.  Symptoms of first-stage infection 
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are flu-like and include headache, malaise, fever and lymphoadenopathy (Sternberg, 2004).  
Symptoms of second-stage are more serious and include motor and sensory disorders 
accompanied by neurological degeneration leading to sleep abnormalities, seizure and 
comma.  Although both first- and second-stage symptoms are present in patients afflicted by 
both Rhodesian and Gambian forms of the disease, the rate of disease progression from first- 
to second-stage is markedly different depending on the subspecies involved.  Second-stage 
symptoms of T. b. rhodesiense are characterized by rapid onset and are detectable within 
weeks to months, whereas the development of second-stage T. b. gambiense symptoms may 
take months to years.   Without treatment, HAT is fatal (Barrett et al., 2007). 
 African trypanosomes elicit a rapid innate immune response upon entry into the host, 
which is characterized by macrophage activation and release of the immune effectors such as 
NO and pro-inflammatory cytokines TNF-α and IL-1 (Sternberg, 2004).  Adaptive immunity 
is initiated by activation of the humoral response and clearance of opsonized parasites by the 
reticuloendothelial system (Sternberg, 2004).  Unfortunately, the adaptive immune response 
is not sufficient to clear the parasite completely from the host, as the parasite employs the 
process of antigenic variation to evade the immune response (Janeway, 2005).  African 
trypanosomes are coated with a variant surface glycoprotein (VSG) attached to their cell 
membrane (Sternberg, 2004).  This protein is highly antigenic and easily recognized by the 
immune system.  Upon initial infection, antibodies are raised against the VSG of the first 
population of parasites.  During antigenic variation, a small number of trypanosomes switch 
their VSG gene and express a new antigenic coat, enabling the parasites to stay ahead of the 
host defenses.  While the host eliminates the first variant, the new population of parasites 
displaying new VSG is unaffected (Donelson et al., 1998).  
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D.2. Current Chemotherapy 
The process of antigenic variation presents a challenge for the development of 
vaccines against HAT, limiting the treatment for this disease to chemotherapy.  A handful of 
drugs are currently available for the treatment of HAT (Figure 1.3).  However, these drugs 
are associated with toxicities or impractical dosing regimens (Fairlamb, 2003).  For the first-
stage disease, the drugs pentamidine and suramin are available.  For second-stage disease, 
melarsoprol and eflornithine are used as monotherapy, and nifurtimox is used in combination 
with eflornithine when melarsoprol is ineffective.  
D.2.1. Pentamidine 
 Pentamidine is a highly soluble aromatic diamidine used for the treatment of first-
stage T. b. gambiense infection.  Pentamidine is administered parenterally via intramuscular 
injection at a dose between 4 mg/kg daily for 7-10 days (Nok, 2003).  Pentamidine is taken 
up into trypanosomes via three different transport systems, including the aminopurine 
transporter (P2), the high-affinity pentamidine transporter (HAPT1) and the low affinity 
pentamidine transporter (LAPT1) (Barrett et al., 2007).  Accumulation of pentamidine in 
trypanosomes is rapid and extensive, reaching up to millimolar concentrations (Mathis et al., 
2006).  It has been shown that the drug targets organelles containing negative charged 
moieties, including membrane phospholipids, polyphosphates in acidocalcisomes, RNA, 
DNA, and DNA containing organelles such as the kinetoplast (Mathis et al., 2006); however, 
the exact mechanism of action is unknown (Barrett et al., 2007).  Pentamidine is metabolized 
in the liver, with only 12% cleared by the kidney unchanged.  Plasma protein binding for 
pentamidine is approximately 70% (Brunton et al., 2006).  The drug distributes extensively to 
tissues, with large amounts accumulating in the liver, kidney, adrenals and spleen.  The 
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terminal half-life of pentamidine was shown to range between 2-4 weeks (Bronner et al., 
1991).  Intramuscular administration has shown to be associated with the development of an 
abscess at the site of injection.  Side effects of pentamidine include hypoglycemia, 
hypotension, tachycardia and nephrotoxicity (Barrett et al., 2007).   
D.2.2. Suramin 
 Suramin is a large polysulfonated naphthylamine closely related to the naphthalene 
dyes trypan blue and trypan red.  It is used primarily against first-stage T. b. rhodesiense 
infections and is sometimes given in combination with pentamidine to treat early-stage T. b. 
gambiense infections (Fairlamb, 2003).  Suramin is administered as a slow intravenous 
infusion as a regimen of five individual doses, with each dose given every 3-7 days for a 
period of 3 weeks (Brunton et al., 2006).  The uptake of suramin into the trypanosomes is 
unknown, but it has been hypothesized that it is taken up by endocytosis bound to low 
density lipoprotein (LDL) via the LDL receptor.  The trypanocidal action of suramin remains 
unknown, but it has been proposed that glycolytic enzyme inhibition could account, at least 
in part, for its mode of action (Fairlamb, 2003).  Suramin is eliminated from the body 
primarily by renal clearance (80%), with little hepatic metabolism.  As a polyanionic 
compound, suramin is highly bound to albumin (99.7%) and has low tissue distribution.  It 
has a long terminal elimination half-life of approximately 90 days.  As with pentamidine, 
suramin is associated with adverse effects, including headache, skin hypersensitivity, 
nephrotoxicity and neurological complications (Brunton et al., 2006).  
D.2.3. Melarsoprol 
 The arsenic-containing melarsoprol was used, until recently (see NECT combination 
therapy below), as first line therapy for the treatment of second-stage T. b. rhodesiense and 
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T. b. gambiense infections.  It must be administered intravenously, three times daily or four 
times daily for a period of three to four weeks (Fairlamb, 2003).  Following intravenous 
administration, melarsoprol is bioconverted to the active melarsen oxide.  Melarsen oxide is 
taken up into the trypanosome by the same aminopurine transporter (P2) that takes up 
pentamidine, although involvement of the HAPT1 transporter has also been suggested.  Once 
in the trypanosome, melarsen oxide conjugates with the thiol containing trypanothione, 
forming the complex Mel T.  Mel T inhibits the trypanothione reductase enzyme, disrupting 
the essential thiol-redox balance within the trypanosome, ultimately killing the parasite 
(Fairlamb, 2003).  Melarsoprol is converted to melarsen oxide in the plasma, and the 
metabolite is cleared rapidly, with an elimination half-life of 3.5 h (Brunton et al., 2006).  
Despite being distributed to the brain minimally (2% of plasma maximal levels), melarsen 
oxide effectively kills CNS parasites.  Severe adverse effects are reported for melarsoprol, 
which can lead ultimately to coma and death.  These events occur in melarsoprol treated 
patients that develop severe post-treatment reactive encephalopathy, with an incidence of 5-
10% of cases, of which 50% die (Legros et al., 2002).   
D.2.4. Eflornithine 
Eflornithine is an analogue of the amino acid ornithine.  It is used for the treatment of 
second-stage T. b. gambiense infections.  As with other HAT drugs, the dose regimen for 
eflornithine is impractical.  The drug must be given as 2-h intravenous infusions QID over a 
period of 7 to 14 days (Barrett et al., 2007).  Eflornithine kills the parasite by binding 
irreversibly to ornithine decarboxylase (ODC), which is essential in polyamine biosynthesis.  
Although not selective to the parasite, the consequences of irreversible ODC binding by 
eflornithine in host cells is thought to be ameliorated by induction of other polyamine 
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biosynthesis pathways and uptake of extracellular polyamines (Fairlamb, 2003).  The major 
pathway of eflornithine elimination is by renal clearance, with 80% of the drug excreted 
unchanged.  The elimination half-life is approximately 3 h.  Eflornithine does not bind to 
proteins in the plasma (Brunton et al., 2006).  Cerebrospinal fluid (CSF) to plasma ratio was 
reported to be in excess of 90%, affording the drug’s excellent characteristics to kill central-
nervous system (CNS) trypanosomes (Burri and Brun, 2003).  Although eflornithine therapy 
is not life-threatening, several untoward effects have been reported, including seizures, 
anemia, diarrhea and leucopenia (Barrett et al., 2007).   
D.2.5. Nifurtimox 
 Nifurtimox is a small nitrofuran, registered for the treatment of Chagas’ disease, or 
American trypanosomiasis.  This drug has been used against second-stage T. b. gambiense 
infections as compassionate treatment in relapsed cases after melarsoprol therapy (Fairlamb, 
2003).  Nifurtimox is administered orally, as 8-20 mg/kg daily for up to 120 days.  Nitro 
partial reduction, coupled with generation of reactive oxygen species and superoxide anions, 
are thought to be the mechanism by which nifurtimox exerts its trypanocidal action 
(Fairlamb, 2003).  Following oral administration, the time to maximum nifurtimox 
concentration was reported to be 3.5 h and the elimination half life ~3h. Nifurtimox is 
thought to undergo extensive first-pass metabolism, with less than 0.5% of the dose excreted 
unchanged in urine (Brunton et al., 2006).  Toxicities associated with nifurtimox include 
neurological and gastrointestinal disorders (Priotto et al., 2006). 
The use of combination therapy for the treatment of second-stage HAT has recently 
proven successful.  A clinical trial with Nifurtimox-Eflornithine Combination Therapy 
(NECT) conducted in Congo showed that this combination was a much safer alternative 
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compared to melarsoprol monotherapy and had an improved dosing regimen compared to 
eflornithine monotherapy (Priotto et al., 2006).  NECT therapy was recently approved in 
2009 for use against second-stage HAT.  Despite achievement of this milestone in HAT 
medicines, choices for chemotherapy are still far from satisfactory.  Moreover, recent reports 
of resistance against eflornithine (Balasegaram et al., 2009) raise concerns about the lasting 
advantages of NECT.  Hence, there is great urgency to devote efforts to the discovery and 
development of new HAT therapies.    
D.3. Development of New Chemotherapy 
D.3.1. Pentamidine Analogs 
Some progress has been made over the last few years in finding new chemical entities 
that are potent against African trypanosomes.  One such agent, the pentamidine analog 
furamidine, and its prodrug pafuramidine (Figure. 1.4), successfully entered clinical 
development for the treatment of first-stage HAT.  Unfortunately, the development of 
pafuramidine and furamidine was discontinued due to renal toxicity associated with the drug 
(Wenzler et al., 2009).  Despite this drawback, other diamidines have shown outstanding in 
vitro activity against both sub-species of trypanosomes, T. b. rhodesiense and T. b. 
gambiense.  In vitro IC50 values for the diamidines DB820 and DB829 were <10 ng/mL 
against the STIB900wt strain of T. b. rhodesiense.  The IC50 values against the T. b. 
gambiense isolates, STIB930, ITMAP141267 and K03048 were <40 ng/mL, comparable to 
melarsoprol (IC50 <10 ng/mL) against the same strains.  The physicochemical properties of 
diamidines render these molecules impermeant to biological membranes.  Calculated pKa 
values range from 9 – 11 (MarvinSketch 5.1.3-2, 2008, ChemAxon 
http://www.chemaxon.com).  Accordingly, diamidines exist as charged species at 
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physiological pH, and when given orally, have low oral bioavailability due to poor 
absorption, resulting in a lack of efficacy (Boykin et al., 1995).  As a consequence, a prodrug 
strategy was utilized to make these compounds more suitable for oral delivery, the preferred 
and most practical route of administration, especially in rural areas of endemic countries.   
D.3.2. Diamidine Prodrugs 
Prodrugs are defined as inactive therapeutic agents that are transformed into one or 
more active metabolites (Ettmayer et al., 2004).  Pafuramidine and the bis-O-
methylamidoxime aza analogs DB844 and DB868 were designed as prodrugs of the 
diamidines furamidine, DB820, and DB829, respectively (Ismail et al., 2006) (Figure 1.4).  
These prodrugs were created by masking the positive charge of the amidine functional 
groups with O-alkyl moeities, resulting in increased lipophilicity and intestinal permeability, 
and in turn, improved absorption and oral bioavailability (Zhou et al., 2002; Saulter, 2005).    
Biotransformation of the bis-O-methylamidoxime prodrugs to the active diamidines 
requires a series of oxidative and reductive enzymatic reactions.  The biotransformation of 
the prodrug pafuramidine to furamidine (Figure 1.5) involves oxidative catalysis by CYP 
enzymes and reductive catalysis by the cytochrome b5/NADH-cytochrome b5 reductase 
system (Saulter et al., 2005; Wang et al., 2006).  Some of the intermediate metabolites of the 
three prodrugs also are prodrugs, since the desirable physicochemical properties are retained.  
For example, upon oral administration, the M1 metabolite of pafuramidine is efficacious in 
the first-stage mouse model of trypanosomiasis, and the M1 metabolites of DB844 and 
DB868 were efficacious in both the first-stage and second-stage mouse model of 
trypanosomiasis (Wenzler et al., 2009). 
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The biotransformation of the bis-O-methylamidoxime prodrugs of pentamidine 
analogs occurs primarily in the liver, where the metabolites are eliminated via biliary 
excretion and/or transported back into systemic circulation (Midgley et al., 2007).  Tissue 
distribution data from rats given a single oral dose (10 mg/kg or 27 µmol/kg) of the prodrug 
pafuramidine indicated that the diamidine (furamidine) was retained extensively in the liver, 
as illustrated by a liver to plasma ratio of 1300:1.  In the liver furamidine was found to be 
associated with the mitochondrial, nuclear and microsomal fractions (Midgley et al., 2007).  
Extensive accumulation of diamidines in organs like the liver and kidney raise concerns 
regarding the potential for toxicity, particularly if accumulation occurs over extended periods 
of time.  However, retention/accumulation of diamidines in organs such as the brain might be 
desirable for second-stage HAT, as the primary obstacle for drug delivery to the CNS is the 
BBB.  It is possible that efficacy of the prodrugs DB844 and DB868 in the second-stage 
mouse model of trypanosomiasis reflects passive entry of prodrugs into the brain, followed 
by in situ conversion to the active diamidines and retention of the cationic drugs within the 
CNS.  Alternatively, the liver-generated diamidine enters the brain via an unidentified carrier 
mediated mechanism.  Furamidine and pentamidine were recently shown to be substrates of 
the human facilitative organic cation transporter 1 (hOCT1) in Chinese hamster ovary (CHO) 
cells stably transfected hOCT1 (Ming et al., 2009).  The expression of this transporter in the 
blood brain barrier of humans are reported to be low (Zhang et al., 1997), which could 
explain in part the lack of efficacy of pafuramidine toward late-stage infection.  Considering 
the potency of diamidines against African trypanosomes and the optimal properties of some 
molecules to penetrate the brain, this class of drugs represents a promising alternative for the 
treatment of second-stage HAT. 
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E.  OVERVIEW OF PROJECT 
 DMEs and DTs are known to be modulated by pro-inflammatory cytokines in various 
tissues, including organs that are central to drug elimination such as the liver and kidney 
(Renton, 2005).  The extent of modulation has been shown to vary depending on the degree 
of inflammation, source of insult, and experimental model used to study these changes 
(Montero et al., 2003; De-Oliveira et al., 2010; Getachew et al., 2010).  The current 
understanding is that infectious or inflammatory episodes will down-regulate DMEs and DTs 
(Morgan et al., 2008).  However, mixed effects (e.g., up-regulation and down-regulation) 
were observed for different subsets of CYP enzymes and drug transporters.  In spite of the 
recognition of the occurrence of these modulatory effects on DMEs and DTs during 
infection, limited data are available on studies investigating the overall effects of CYP and 
transporter down-regulation on the pharmacokinetics of drugs.  At present it is not possible to 
predict prospectively the overall effects that infection or inflammation will have on the 
pharmacokinetics of a compound.   
 Diamidines are among the few chemical entities currently in development for the 
treatment of the deadly disease human African trypanosomiasis (Figure 1.4) (Barrett et al., 
2007).  Bis-O-methylamidoxime prodrugs of diamidines require enzymatic biotransformation 
to generate the pharmacologically active compound (Zhou et al., 2004).  Moreover, because 
diamidines are charged molecules at physiological pH and are not able to passively diffuse 
across membranes, they rely on transporters for elimination and to reach their 
pharmacological site of action (Ming et al., 2009).  As such, modulation of the metabolizing 
enzymes and/or drug transporters involved in the disposition of diamidines and their 
prodrugs may have profound implications on the pharmacokinetics and pharmacological 
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effects of these agents.  Accordingly, the goal of this dissertation project was to: 1) ascertain, 
in a rat model of first-stage trypanosomiasis, whether trypanosomal infection would diminish 
the conversion of the prodrug pafuramidine into the active diamidine furamidine and 2) 
determine, in this model, the effect of trypanosomal infection on the pharmacokinetics of the 
orally and intravenously administered bis-O-methylamidoxime prodrug pafuramidine and its 
active diamidine metabolite furamidine.  The results of this investigation helped clarify 
questions regarding the impact of trypanosomal infection on the development of this class of 
compounds and furthered our understanding on the role of infection on drug disposition by 
providing a framework for recognizing compounds which may be sensitive to the impact of 
infection based on their pharmacokinetics and route of administration.   
Central hypothesis: Trypanosomal infection will alter the pharmacokinetics of bis-O-
methylamidoxime prodrugs and the corresponding diamidine active metabolites due to down-
regulation of drug metabolizing enzymes.  To test this hypothesis, in vitro experiments using 
rat and human hepatic enzymes and in vivo experiments in a rat model of first-stage HAT 
were conducted as outlined in the following specific aims: 
 
Specific Aim 1: Characterize the hepatic biotransformation pathway of the bis-
O-methylamidoxime prodrug DB868 to the diamidine active metabolite DB829 
in humans and rats using in vitro systems 
Hypothesis: Metabolic activation of the prodrug DB868 to the active drug DB829 
involves sequential oxidation and reductive reactions prior the generation of DB829. 
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To test this hypothesis, multiple in vitro tools (i.e., purified/recombinant CYP 
enzymes, liver microsomes and sandwich-cultured hepatocytes) and analytical systems (i.e., 
HPLC/UV and HPLC/MS/MS) were used to characterize and identify the intermediate 
metabolites in the DB868 to DB829 conversion by both humans and rat hepatic enzymes.  
The in vitro tools used for this specific aim are well characterized and routinely used to 
examine drug metabolism and hepatic disposition.  Additionally, kinetic modeling was used 
to determine the rate of formation of intermediate metabolite.  It was postulated that the 
DB868 biotransformation would mirror the biotransformation of the analog prodrug 
pafuramidine in which oxidative and reductive steps preceded the generation of the active 
diamidine furamidine.  
 
Specific Aim 2: Determine the effect of trypanosomal infection on the 
pharmacokinetic behavior of orally and intravenously administered 
pafuramidine and metabolically formed furamidine in a rat experimental model 
of first-stage trypanosomiasis 
Hypothesis: Trypanosomal infection is expected to decrease the clearance and 
increase the exposure of the prodrug pafuramidine, resulting in diminished exposure 
of the active drug furamidine.  
The effects of trypanosomal infection in vivo were addressed with the following two 
sub-aims: 
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2.1 Develop and characterize a rat model of first-stage trypanosomiasis 
To mimic first-stage HAT, Sprague-Dawley rats were infected with the S427 strain of 
T. b. brucei (non-human infective strain).  After determining the virulence and course 
of parasitemia in this experimental model, the changes elicited by the infection on the 
liver and kidney were evaluated.  Specifically, histopathologic and molecular changes 
(i.e., measured by liver and kidney biochemical markers) were examined. 
2.2 Evaluate the pharmacokinetics of orally and intravenously administered 
pafuramidine and metabolically formed furamidine in the rat experimental model 
of first-stage trypanosomiasis  
Plasma concentrations of pafuramidine and furamidine were determined 
following intravenous and oral administration of pafuramidine.  Non-compartmental 
analysis was used to obtain relevant pharmacokinetic parameters.  It was postulated 
that trypanosomal infection will down-regulate drug metabolizing enzymes such that 
measurable changes in the pharmacokinetic parameters of the prodrug pafuramidine 
and furamidine would be observed in infected animals compared to controls.  An 
increase in pafuramidine systemic exposure of at least 1.2-fold was expected, in 
infected animals, with a commensurate decrease in furamidine exposure.    
 
 F. FIGURES 
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Figure 1.1 Acute-phase response.  Pathogens induce macrophage activation and 
production of the pro-inflammatory cytokines TNF-α, IL-1 and IL-6, which in turn induce 
the synthesis of acute-phase proteins by the liver. 
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Figure 1.2. Proposed pathways for modulation of CYPs during inflammation and 
infection.  Inflammatory stimuli trigger the synthesis of the immune response effectors, 
cytokines and nitric oxide (NO).  Cytokines down-regulate CYP gene and protein expression 
through the involvement of transcription and nuclear factors (e.g., PXR, CAR, HNF, 
NF-κB).  NO, generated by nitric oxide synthase (NOS2), down-regulates CYPs by directly 
inactivating protein function.  Figure was reproduced from Renton, 2004 with permission 
(Renton, 2004). 
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Figure 1.3.  Chemical structures of current human African trypanosomiasis (HAT) 
chemotherapies.  Treatments for first- and second-stage HAT are shown on left- and right-
hand side, respectively. 
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Figure 1.4. Chemical structures of diamidines and their corresponding bis-O-methylamidoxime prodrugs.
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Figure 1.5. Proposed biotransformation of the prodrug pafuramidine leading to the formation of the active diamidine furamidine. 
 
 G. TABLES 
 
Table 1.1 Infectious organisms capable of DME modulation in preclinical species 
Infectious Organism Species Effect1 Reference 
Bacteria    
Chlamydia trachomatis Mice CYP1A ↓, CYP2B ↓ (49%)c 
(Khatsenko et 
al., 1998) 
Pseudomonas aeruginosa Rats CYP2J4 ↓(42%) c (Yaghi et al., 2004) 
Corynobacterium parvum Mice 
CYP2C↓(50%) b, 
CYP3A ↓(60%) b 
CYP4A↓(90%) b, 
CYP2E↔ b 
(Richardson et 
al., 2006) 
Parasites    
Trypanosoma brucei gambiense Mice CYP ↓ (14%)
 a 
(40%) c 
(Shertzer et al., 
1981) 
Trypanosoma brucei gambiense Vole CYP ↓ (60%) a (Shertzer et al., 1982) 
Fasciola hepatica Sheep CYP3A↓(23%)
b 
GST↔c 
(Calleja et al., 
2000) 
Plasmodium berghei Mice 
CYP1A↓ (40%)c, 
CYP2B↓(50%)c 
CYP2A5↑ (100%)c 
(De-Oliveira et 
al., 2010) 
Viruses    
Encephalomyocarditis virus Rats CYP3A↓ (50%)
 b c 
Cytochrome b5↓ (40%) b (Renton, 1981) 
Adenovirus  Rats CYP3A2 ↓ (47%)c (Wonganan et al., 2009) 
Adenovirus (viral hepatitis) Mice CYP1A2↔
b, CYP2E1↓ 
(90%) b 
(Getachew et 
al., 2010) 
1. Effect on protein (magnitude of modulation).   
a. Total protein 
b. Protein expression 
c. Enzyme activity 
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Table 1.2 Effects of DME modulation by infection or inflammatory agents in humans 
Infection or 
Inflammatory Agent Drug Outcome Reference 
Adenoviral Infection Theophylline ↑ t½ (1.6-fold) (Chang et al., 1978) 
Asthma Theophylline ↓ Cl (2-fold) (Kraemer et al., 
1982) 
BCG Vaccine Theophylline ↓Cl (1.4-fold) 
↑ t½ (1.2-fold) 
(Gray et al., 1983) 
Pneumonia Antipyrine ↓Cl (1.5-fold) (Sonne et al., 1985) 
Systemic Lupus 
Erythematosus 
Debrisoquine ↑ CYP2D6 PM phenotype 
frequency (21% patients vs 
8% healthy) 
(Baer et al., 1986) 
IL-6  Cyclosporin ↑ Css (3.3-fold) (Chen et al., 1994) 
Influenza Vaccine Chlorzoxazone ↔Cl (Kim and 
Wilkinson, 1996) 
Endotoxin Antipyrine, 
Hexobarbitone, 
Theophylline 
↓Cl (1.3-fold) 
↓Cl (1.2-fold) 
↓Cl (1.2-fold) 
(Shedlofsky et al., 
1994; Shedlofsky et 
al., 1997) 
Malaria Quinine ↓Cl (2.4-fold) (Pukrittayakamee et 
al., 1997) 
Advanced Cancer Omeprazole  ↑ CYP2D6 PM phenotype 
frequency (25% patients vs 
3% healthy) 
(Williams et al., 
2000) 
HIV (active illness) Dextromethorphan Shift from CYP2D6 EM to 
PM phenotype (3% PM to 
7%) 
(O'Neil et al., 2000) 
Rheumatoid Arthritis S-Verapamil 
R-Verapamil 
↓Cl/F (2.2-fold) 
↓Cl/F (1.5-fold) 
(Mayo et al., 2000) 
CHF Caffeine 
Mephenytoin 
↓CYP1A2 activity 
↓CYP2C19 activity 
(Frye et al., 2002) 
Pneumonia Clozapine ↑ Css (3.3-fold) (Raaska et al., 
2002) 
Respiratory Infection Clozapine ↑ Css (2-fold)  (de Leon and Diaz, 
2003) 
Urinary Tract Infection Clozapine ↑ Css (2.2-fold) (Jecel et al., 2005) 
BCG. Corynebacterium parvum, and Bordetella pertussis 
IL-6. Interleukin 6 
HIV. Human Immunodeficiency Virus 
CHF.  Congestive Heart Failure 
t½. Half life 
Cl. Systemic Clearance 
CL/F. Oral Clearance 
Css. Steady-State concentration 
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CHAPTER 2 
 
 
 
 
IN VITRO BIOTRANSFORMATION OF THE ANTITRYPANOSOMAL PRODRUG 
2, 5-BIS [5-(N-METHOXYAMIDINO)-2-PYRIDYL] FURAN (DB868) BY HUMAN 
AND RAT ENZYMES: A COMPARTMENTAL MODELING APPROACH TO 
ELUCIDATE METABOLIC CONVERSION TO THE ACTIVE DRUG 2, 5-BIS 
(5-AMIDINO-2-PYRIDYL) FURAN (DB829)  
 
 
 
 
 
 
 
 
This chapter will be submitted to the Journal of Pharmacology and Experimental 
Therapeutics and is formatted in the style of this journal. 
A.  ABSTRACT 
 DB868 is the prodrug of the antitrypanosomal diamidine DB829 and a potential 
candidate drug for treatment of second-stage human African trypanosomiasis (HAT).  Oral 
administration of DB868 in a murine model of second-stage HAT was 100% effective, 
indicating in vivo metabolic activation.  To date, the biotransformation of DB868 is 
unknown; accordingly, this study characterized the phase-I biotransformation of DB868 in 
liver microsomes and sandwich-cultured hepatocytes from humans and rats (HLMs, RLMs 
and HSCHs, RSCHs, respectively).  DB868 generated four NADPH-dependent metabolites 
(M1-M4) which corresponded to O-demethylated, and N-dehydroxylated products based on 
mass spectrometry analysis.  M1 formation in HLMs followed Michaelis-Menten kinetics 
(Km = 11 µM), whereas a two-enzyme model described the kinetics of M1 in RLMs (Km = 
0.5 µM, high affinity component).  M1 formation was catalyzed by CYP1A2, CYP3A and 
CYP4F2 in humans, and CYP1A2, CYP2D2 and CYP4F1 in rats.  M2 formation in HLMs 
exhibited allosteric kinetics via CYP1A2 (CLmax ≈ 2 µL/min/mg protein); whereas M2 
formation in RLMs was negligible.  Kinetic analysis of the DB868 metabolic pathway gave 
an insight into an unusual N-demethoxylation reaction which was confirmed experimentally.  
In HLMs, DB829 was negligible after 180 min incubations but formed readily in hepatocytes 
of both species, with the majority of the compound sequestered intracellularly.  Collectively 
this study shows extensive hepatic metabolism of DB868 in humans and rats with four phase-
I metabolites generated before DB829; however, despite the importance of metabolism 
activating the prodrug hepatocyte data suggests that systemic availability of DB829 is limited 
by intracellular binding and efflux rather than metabolism.   
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B.  INTRODUCTION 
 Human African trypanosomiasis (HAT) is a neglected parasitic disease that afflicts 
exclusively the world’s poorest populations (Barrett, 2007).  According to the latest reports 
by the World Health Organization, 36 countries in sub-Saharan Africa are considered 
endemic for the disease (WHO, 2010).  HAT is caused by the parasite Trypanosoma brucei, 
which is transmitted to the host by the bite of the Tsetse fly.  The disease is characterized by 
two defined stages.  During the first stage of the infection, the trypanosomes are confined to 
the hemolymphatic system; symptoms include headache, malaise, fever, joint pain 
(Sternberg, 2004).  The second stage of the infection begins once the trypanosomes have 
migrated to the central nervous system (CNS), initiating deterioration of neurological 
function, which includes disruptions in the sleep/wake cycle, hence the name “sleeping 
sickness” (Sternberg, 2004).  Without treatment, progressive CNS damage leads to coma and 
eventually, death. 
 Current therapeutic agents for the treatment of HAT are scarce and are associated 
with moderate to severe side effects, as well as impractical dosing regimens (Fairlamb, 
2003).  The two drugs that are approved for the first-stage infection are pentamidine and 
suramin.  Both must be given parenterally, over a course of at least seven days (pentamidine) 
to four weeks (suramin) (Barrett, 2007).  Moreover, due to an inability to enter the CNS, 
neither agent is effective against the second-stage infection.  As with the first-stage infection, 
only two drugs are approved for the second-stage infection: melarsoprol and eflornithine.  
The arsenic-containing melarsoprol must be administered intravenously, three to four times 
daily, for a period of three to four weeks.  Moreover, 5-10% of the melarsoprol treated 
patients suffer severe post-treatment reactive encephalopathy, of which 50% die (Legros et 
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al., 2002).  Although eflornithine therapy is not life-threatening, the drug must be 
administered intravenously as multiple infusions daily, usually every six hours for two weeks 
(Barrett et al., 2007).  Studies with eflornithine in combination with nifurtimox (a drug for 
the treatment for Chagas disease) as an alternative first-line therapy for the treatment for 
second stage HAT showed promise (Priotto et al., 2006) and in 2008 the Nifurtimox-
Eflornithine Combination Therapy (NECT) was approved; however, emergence of resistance 
against this eflornitine has recently been reported (Balasegaram et al., 2009).  Currently, no 
drugs are in development for the second stage HAT, hence the discovery and development of 
new treatments especially with orally administered medication, is of high urgency. 
 An analog of pentamidine, 2,5-bis(5-amidino-2-pyridyl) furan (DB829), is an 
aromatic diamidine that has shown excellent in vitro activity against different sub-species of 
trypanosomes, including Trypanosoma brucei gambiense, the subspecies causative of second 
stage HAT.  The in vitro potency of DB829 against three T. b. gambiense isolates, including 
STIB930, ITMAP141267 and K03048, was comparable to that of melarsoprol, as measured 
by IC50 values of <40 ng/mL (Fairlamb, 2003; Wenzler et al., 2009).  Moreover, 
intraperitoneal administration of DB829 in the GVR35 CNS murine model (20 mg/kg for 10 
days), which mimics the second-stage HAT, showed a 100% cure rate (Fairlamb, 2003; 
Wenzler et al., 2009).   
 The two positive charges on diamidines (calculated pKas range from 9-11) render 
these compounds impermeant to biological membranes via passive diffusion; thus when 
given orally these dications have low bioavailability due to poor absorption, resulting in a 
lack of efficacy (Boykin et al., 1995).  To improve the oral bioavailability of DB829, the 
prodrug DB868 was prepared by masking each amidino group of the DB829 molecule with 
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O-methoxy functional groups (Figure 2.1) (Ismail et al., 2003).  In vivo studies showed that 
DB868 had a 100% cure rate in the GVR35 CNS murine model of HAT at an oral daily dose 
of 100 mg/kg for 5 days (Wenzler, 2009) indicating that the prodrug was orally bioavailable 
and that it was activated to DB829 in vivo sufficiently to achieve therapeutic efficacy.  
However, despite these positive results in mice, it is unknown whether the activation of the 
prodrug to DB829 will be sufficient in other preclinical species or in humans to achieve 
therapeutic efficacy. 
Accordingly, the goal of this investigation was to characterize the in vitro 
biotransformation of the prodrug DB868 to the active drug DB829 with microsomes and 
hepatocytes prepared from humans and rats.  The results of these studies will help guide the 
preclinical and clinical evaluation of DB868 for the treatment of second stage HAT. 
C.  METHODS 
 Chemicals and Reagents. DB829, d6-DB829, DB840 (M2), DB868 lot D, d6-
DB868, DB1217 (M3), and DB1679 (M1), were synthesized in the laboratory of D.W. 
Boykin (Ismail et al., 2003; Mohamed and David, 2006).  Pooled male rat and mixed gender 
human liver microsomes (RLMs and HLMs, respectively) were obtained from XenoTech, 
LLC (Lenexa, KS).  All human and rat recombinant enzymes were derived from insect cells 
(SUPERSOMES™) and were obtained from BD Gentest (Woburn, MA). The human 
recombinant enzymes CYP1A2, CYP2D6, CYP3A4 as well as the rat recombinant enzymes 
CYP1A2, CYP2D1 and CYP2D2 were co-expressed with NADPH-cytochrome P450 
reductase.   The human recombinant enzyme CYP4F2, and the rat recombinant enzymes 
CYP2A1, CYP2A2, CYP2B1, CYP2C6, CYP2C11, CYP2C13, CYP2E1, CYP3A1 were co-
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expressed with NADPH cytochrome P450 reductase and cytochrome b5.  Purified rat 
CYP4F1, CYP4F4, CYP4F5 and CYP4F6 were a gift from Dr. Deanna Kroetz (University of 
California San Francisco). Dubelcco’s modified Eagle’s Medium (DMEM, without phenol 
red), and purified recombinant human NADPH-cytochrome P450 reductase were obtained 
from Invitrogen (Carlsbad, CA).  Human and rat sandwich culture hepatocytes (HSCHs and 
RSCHs, respectively) were obtained from Cellz Direct (Durham, NC).  Acetonitrile and 
HPLC-grade water were purchased from Fisher Scientific (Pittsburgh, PA).  1-
Aminobenzotriazole (ABT), ammonium formate, catalase, dilauroylphosphatidylcholine, 
dimethyl sulfoxide (DMSO), formic acid, glucose 6-phosphate, glucose 6-phosphate 
dehydrogenase, methanol, β-NADPH, sodium cholate and trifluoroacetic acid (TFA) were 
obtained from Sigma-Aldrich (St. Louis, MO).   
 Metabolite Profiling and Structure Identification Experiments.  Incubation 
mixtures contained HLMs or RLMs (0.5 mg/mL), potassium phosphate buffer (100 mM, pH 
7.4), MgCl2 (10 mM), and the prodrug DB868 (15 µM).  The total incubation volume was 
500 µL. The mixtures were warmed to 37°C, and the reactions were initiated by the addition 
of β-NADPH (2 mM).  Incubations were performed in duplicate.  Reactions were terminated 
at 0, 5, 15, 30, 60, 90, 120 and 180 min by removing 50-µL aliquots from the incubation 
mixture and adding to an equal volume of ice-cold acetonitrile.  Proteins were precipitated by 
centrifugation (3000 rpm for 5 min), and the supernatant was analyzed for prodrug, active 
metabolite, and intermediate metabolites by HPLC/MS/MS.  
 Metabolite Quantification Experiments.  Incubation mixtures contained HLM or 
RLM (0.5 mg/mL), potassium phosphate buffer (100 mM, pH 7.4), MgCl2 (10 mM), NADP+ 
(1 mM), glucose 6-phosphate (5 mM), glucose 6-phosphate dehydrogenase (1 unit/ml), and 
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the prodrug DB868 (10 µM).  The NADPH-generating system was used in this case to ensure 
that cofactor was not depleted by 180 min.  However, similar results were obtained using 
NADPH (2 mM) in a repeat experiment.  DB868 was dissolved in DMSO such that the final 
solvent concentration was 0.5% (v/v).  Incubations were performed in triplicate.  The total 
incubation volume was 250 µL. The reactions were initiated at 10-sec intervals by the 
addition of the NADPH-generating system.  Reactions were terminated at 0, 2.5, 5, 10, 15, 
30, 45, 60, 90, 120 and 180 min by the addition of ice-cold acetonitrile (125 µL).  Proteins 
were precipitated by centrifugation (3000 rpm for 10 min), and the supernatant was analyzed 
for prodrug, active metabolite, and intermediate metabolites by HPLC-UV. 
 Enzyme Kinetic Experiments  Incubation mixtures contained HLMs or RLMs (0.5 
mg/mL), potassium phosphate buffer (100 mM, pH 7.4), MgCl2 (10 mM), NADPH (2 mM), 
and either DB868 (0.1 - 100 µM) or M1 (0.1 - 25 µM).  DB868 and M1 were dissolved in 
DMSO such that the final solvent concentration was 0.5% (v/v).  Incubations were performed 
in triplicate.  The total incubation volume was 250 µL for incubations with DB868 or M1. 
The reactions were initiated by the addition of the NADPH (2 mM).  The reactions were 
terminated at 5 min for incubations containing HLMs or at 10 min for incubations containing 
RLMs.  The reactions were stopped with acetonitrile (125 µL) containing d6-DB868 which 
was the internal standard. Proteins were precipitated by centrifugation (3000 rpm for 10 
min), and the supernatant was analyzed by HPLC/MS/MS.  The metabolites M1 and M3 
were quantified when DB868 was the substrate and M2 and M3 were quantified when M1 
was the substrate. All primary metabolites were evaluated under initial rate conditions such 
that the substrate consumption was < 20%.   
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 Time-Dependent Inhibition Experiments.  To test whether M3 was an N-
demethoxylation product of DB868, the suicide CYP inhibitor ABT (Ortiz de Montellano 
and Mathews, 1981) was used to abolish M1 formation which was known to be a precursor 
of M3.  Incubations were carried out according to the methods described by (Linder et al., 
2009) with minor modifications.  Briefly, primary incubations mixtures contained HLMs or 
RLMs (1 mg/mL primary incubation or 0.5 mg/mL secondary incubation), ABT (1 mM, 
primary incubation) or DB868 (10 µM secondary incubation), potassium phosphate buffer 
(100 mM, pH 7.4), MgCl2 (10 mM) and NADPH (2 mM).  All incubations were carried out 
at 37°C.  Control primary incubations contained water in place of β-NADPH.  At 0 or 30 
min, aliquots were removed from primary incubation and placed in secondary incubations 
(10-fold dilution).  Secondary incubations were carried out for 5 min with HLMs or 10 min 
with RLMs, and were stopped with ice-cold acetonitrile (100 µL).  Proteins were precipitated 
by centrifugation (3000 rpm for 10 min), and the supernatant was analyzed for M1 and M3 
quantification by HPLC-UV.   
 Recombinant Enzyme Experiments.  The incubation mixtures contained select 
human or rat recombinant enzymes (final concentration 0.1 pmol/µL), potassium phosphate 
buffer (100 mM, pH 7.4), MgCl2 (10 mM), β-NADPH (2 mM), and either DB868 or M1 
(final concentration 5 µM).  Human recombinant CYP1A2, CYP2D6, CYP3A4, and 
CYP4F2 were examined based on preliminary data excluding the involvement of CYP2C9, 
CYP2C19 and CYP2E1, whereas in rat, recombinant enzymes CYP1A2, CYP2A1, CYP2A2, 
CYP2B1, CYP2C6, CYP2C11, CYP2C13, CYP2D1, CYP2D2, CYP2E1 and CYP3A1 were 
examined.  DB868 and M1 were dissolved in DMSO such that the final solvent concentration 
was 0.5% (v/v).  The total incubation volume was 200 µL.  The reactions were initiated by 
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the addition of NADPH (2 mM) and were terminated at 15 min by the addition of ice-cold 
acetonitrile (100 µL).  Proteins were precipitated by centrifugation (3000 rpm for 10 min), 
and the supernatant was analyzed by HPLC/UV for M1 when DB868 was the substrate or 
M2 when M1 was the substrate. 
 Purified Rat CYP4F Experiments.  Incubations with purified rat CYP4F proteins 
were carried out using the methods of Xu et.al. (2004) with minor modifications (Xu et al., 
2004).  Briefly, incubation mixtures containing CYP4F (5 pmol), cytochrome b5 (5 pmol), 
NADPH-cytochrome P450 reductase (50 pmol), catalase (10 µg/ml), 
dilauroylphosphatidylcholine (20 µg/ml), and sodium cholate (0.2 mg/mL) were incubated 
for 10 min at 37°C prior the addition of potassium phosphate buffer (100 mM, pH 7.4), 
MgCl2 (10 mM), NADPH (2 mM), and DB868 (final concentration 5 µM).  The total 
incubation volume was 100 µL.  The reactions were initiated by the addition of the NADPH 
(2 mM) and were terminated at 30 min by the addition of ice-cold acetonitrile (50 µL).  
Proteins were precipitated by centrifugation (3000 rpm for 10 min), and the supernatant was 
analyzed for M1 by HPLC-UV. 
 Metabolism of DB868 in Sandwich-Cultured Rat Hepatocytes.  To assess whether 
the negligible levels of DB829 formation in HLMs and RLMs was a limitation of this in vitro 
system, DB868 was incubated with sandwich-culture hepatocytes prepared from humans and 
rats.  The metabolic activities of the major CYP enzymes as well as phase II enzymes are 
maintained in sandwich cultured hepatocytes (Kern et al., 1997).  Additionally, unlike 
suspended hepatocytes (Bow et al., 2008), hepatocytes cultured in a sandwich configuration 
have the advantage of expressing exteriorized efflux transporters on both the basolateral and 
apical membranes (Chandra and Brouwer, 2004) allowing to discern the extent of 
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intracellular, and extracellular concentrations of intermediate and active metabolites.  Human 
(HSCHs) and rat  (RSCHs) hepatocytes were cultured in 24-well plates or 12-well plates, 
respectively, and the experiments were carried out on either the fifth (HSCHs) or fourth day 
post seeding (RSCHs).  On the day of the experiment, the culture medium was removed from 
wells and the hepatocytes were rinsed three times with warm DMEM.  Incubations were 
started by the addition of DB868 in DMEM to the wells (10 µM final concentration).  At 
each time point (i.e., 0.5, 2, 4 and 24 h), medium was collected from wells and stored in 
microcentrifuge tubes at -80°C until further processing.  The remaining medium was 
aspirated from the wells, and the wells were rinsed three times with ice-cold DMEM to stop 
the reaction.  A chilled methanol 0.1% TFA solution containing d6-DB868 and d6-DB829 as 
internal standards, was added to the wells, and the contents were scraped off into 
microcentrifuge tubes.  The tubes were vortexed briefly (10 min) and were stored at -80°C 
until further processing.  Intracellular and extracellular samples were analyzed for DB868 
and phase I metabolites by HPLC/MS/MS.  Total protein content was determined by the 
Bradford method (Bio-Rad Laboratories, Hercules, CA). 
 HPLC-UV Chromatography.  Chromatographic analysis of DB868 and its phase I 
metabolites was performed on an Agilent 1100 Series HPLC system (Palo Alto, CA) using 
methods described by (Wang et al., 2006) with minor modifications.  Briefly, DB868 and 
metabolites were separated using a Zorbax SB-CN (5 µm, 2.1 x 150 mm) column equipped 
with a Zorbax SB-CN guard column (5 µm, 4.6 x 12.5 mm) obtained from Agilent (Palo 
Alto, CA).  Quantification of DB868 and metabolites was achieved using an external 
calibration curve and comparison of peak areas to those of authentic standards (with the 
exception of M4, for which no authentic standard was available).  
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 Analysis of DB868 Metabolites by HPLC-ion Trap Mass Spectrometry.  DB868 
was incubated with HLMs and RLMs for 180 min, as described above.  The quenched 
reaction mixtures were analyzed by HPLC-UV-FLD-MS, and HPLC-UV-FLD-auto MSn.  
The HPLC-MS was, in all cases, an Agilent 1100 system comprised of an autosampler, 
binary pumps, column heater, diode array detector, fluorescence detector, and ion trap mass 
spectrometer.  The HPLC was controlled by Chemstations software (Agilent, version A.9), 
while the ion trap was controlled by Trap Software (Bruker, version 4.1).  Analytes were 
eluted by reverse phase chromatography using a Zorbax SB-CN (5 µm, 2.1 x 150 mm) 
column equipped with a Zorbax SB-CN guard column (5 µm, 4.6 x 12.5 mm) obtained from 
Agilent, (Palo Alto, CA) at a flow rate of 0.35 mL/min.  The mobile phases were prepared 
with 35 mM formic acid and 15 mM ammonium formate in 100% water (mobile phase A), or 
80:20 acetonitrile:water (mobile phase B).  The mobile phase gradient started with 5% 
mobile phase B and increased linearly to 60% over 22 min.  A sharp increase to 100% 
occurred over 30 sec and was maintained for the next 2.5 min.  The column was equilibrated 
at 5% organic for the next 4 min.  The injection volume was 40 µL.  The column temperature 
was 25°C.  The UV absorbance was monitored at 359 nm, and fluorescence was monitored 
using an excitation of 359 nm and an emission of 462 nm.  When the mass spectrometer was 
used, the eluent passed from the FLD directly to the ion trap equipped with an electrospray 
source.  Data from the ion trap was collected in positive ion mode as either MS-only or as 
auto MSn total ion chromatograms.  MS-only detection was used to determine the m/z to be 
included in MSn analysis in subsequent injections.  Based upon MS data and known 
metabolism of analogous compounds, proposed intermediate metabolites were synthesized.  
Confirmation of the proposed metabolites involved matching both the retention times and the 
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fragmentation patterns of analytes found in metabolism samples and of purified analytical 
standards. 
 Quantification of DB868 and Metabolites by HPLC-mass Spectrometry.  
Quantification of DB868, and metabolites was perfomed on an Applied Biosystems ABI4000 
mass spectrometer with TurboIonspray® source (Applied Biosystems, Foster City, CA).  The 
typical sample injection volume was 4 µL (Leap CTC thermostatted autosampler, Carrboro, 
NC).  Wash solvents for the syringe and injection loop were 50:50 (wash A) and 80:20 (wash 
B) methanol:water with 0.1% formic acid.  The analytes were eluted from an Aquasil C18 
column (dp = 5 µm, 2.1 x 50 mm; Thermo Electron Corporation, San Jose, CA) by a 
Shimadzu solvent delivery system (Columbia, MD) using a mobile phase gradient.  Mobile 
phase A consisted of 0.1% formic acid in 100% water while mobile phase B consisted of 
0.1% formic acid in 100 % methanol.  The mobile phase gradient began with a 0 - 0.5 min 
hold at 10% B; 0.5 - 4.0 min linear gradient to 90% B; 4.0 - 5.0 min hold at 90% B, 5.0 - 5.5 
min linear gradient to 10% B, 5.5 - 6.0 min hold at 10% B.  The flow rate was 0.5 mL/min 
with the exception of the 90% B wash, when the flow was increased to 1.2 mL/min.  Eluent 
from 0 -0.8 min was diverted to waste while eluent from 0.8 - 4.2 min was directed to the 
mass spectrometer.  The total runtime, including equilibration, was 6 min per injection.  The 
mass spectrometer was operated in positive ion mode using multiple reaction monitoring: 
DB868, 367.1 320.2 m/z; M1, 353.2 306.2 m/z; M2, 339.2 306.2 m/z; M3, 336.8 290.2 
m/z; M4, 323.2 290.2 m/z; DB829, 307.3 290.2 m/z; d6-DB868, 373.1 323.2 m/z; and d6-
DB829, 313.3 396.2 m/z;.  With the exception of M4, operator controlled parameters were 
optimized by direct infusion of analytical standards.  Calibration curves for DB868, M1, M2, 
and M3 were constructed as peak area ratios of analyte d6-DB868.  Calibration curves for 
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DB829 were constructed as peak area ratios of DB829: d6-DB829.  Tuning, operation, 
integration and data analysis were performed using Analyst® software v.1.4.1 (Applied 
Biosystems).  The wide dynamic range (0.1-100 µM) of DB868 used in the enzyme kinetic 
experiments made the quantification of M1 difficult by HPLC/MS-MS, due to ion-
suppression of the d6-DB868 internal standard at high concentrations of DB868.  This 
difficulty was overcome by cross-validating the M1 calibration curve between the HPLC-UV 
and HPLC/MS/MS platforms (range of overlapping concentrations 50 to 10000 nM). 
Kinetic Modeling.  A kinetic modeling approach was used to assess the 
consequences of both parallel and sequential reactions on the rates of metabolic activation of 
DB868, which provided a more representative picture of intermediate metabolite formation 
in vivo.  This approach gave insight into a rare metabolic pathway which was not discerned 
using traditional approaches (e.g., mass spectrometry structural identification and knowledge 
of common metabolic steps).  The model was structured according to the proposed pathway 
described for the analog prodrug DB289 (Zhou et al., 2004) and included the substrate 
DB868, and the metabolites M1, M2 and M3 (Figure 2.5A).  M4 was omitted from the model 
as this metabolite was not quantified due to lack of an authentic standard.  The rate constants 
k1, k2 and k3 were used to represent degradation of the prodrug or generation of the 
metabolites M3 and M2, respectively.  It was assumed that all processes were unidirectional 
and that there was no inhibition in the metabolic steps.  The DB868, M1, M2 and M3 RLM 
data were fit simultaneously using initial estimates obtained from pilot depletion experiments 
with DB868 and M1 (data not shown).  The final model selection was based on standard 
criteria including visual inspection, residual analysis, and parameter precision.   The software 
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WinNonlin 5.0.1 (Pharsight, Mountain View, CA) was used for model development and data 
analysis.   
Data Analysis.  Unless otherwise indicated all data are presented as mean ± SD.  
First-order rate constants and enzyme kinetic experiments parameters are shown as mean 
estimates and percents of coefficient of variance (%CVs).   
Kinetics of metabolite formation: The kinetic parameters for the M1 formation by HLMs 
were estimated using the Michaelis-Menten equation, where Vmax, is the maximal velocity, 
Km is half the maximal velocity and S is the substrate concentration. 
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M1 formation by RLMs was best described by a two-enzyme kinetic system; where Vmax1 
and Km1 are the maximal and half the maximal velocities for the first enzyme; Vmax2 and Km2 
are the maximal and half the maximal velocities for the second enzyme; and S is the substrate 
concentration. 
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M2 formation by HLMs exhibited allosteric kinetics and was estimated using the Hill 
equation  
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Where Vmax, is the maximal velocity, S50 represents half the maximal velocity, n is the Hill 
coefficient and S is the substrate concentration.  Clmax was determined from these parameters 
as follows: 
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A mechanistic description of the allosteric effect was also assessed by estimating two distinct 
affinities of the ligand for two binding sites (i.e., Vmax1, Km1 and Vmax2, Km2) (Korzekwa et 
al., 1998). 
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All data fits were performed with the software WinNonlin 5.0.1 (Pharsight, Mountain View, 
CA). 
Statistical analysis for the time-dependent inhibition experiments was done using one-way 
ANOVA with the Bonferroni test for multiple comparisons. Differences were deemed 
significant if p < 0.05. 
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D.  RESULTS 
 Identification of the Metabolites of 2, 5-Bis [5-(N-methoxyamidino)-2-pyridyl] 
furan (DB868).  The biotransformation of the prodrug DB868 (Figure 2.1) was NADPH-
dependent in both humans and rats (Figure 2.2).  After a 180-min incubation, four 
intermediate metabolites, designated M1, M2, M3, and M4, were produced in addition to the 
formation of the active diamidine, DB829.  In both the UV (Figure 2.2) and the total ion (not 
shown) chromatograms, the prodrug and intermediate metabolites eluted at 18.5 (DB868), 
14.5 (M1), 12.3 (M3), 10.5 (M2), and 8.3 (M4) min.  DB829 was formed in trace amounts by 
HLMs, with a retention time of 5.8 min, whereas none was detected in reaction mixtures 
involving RLMs.  
 Identification of metabolites from microsomal incubations was accomplished using 
HPLC separation coupled with ion trap MS/MS analysis in positive ionization mode.  Full 
scan analysis of incubations of DB868 with HLMs or RLMs gave molecular ions [M+H]+ at 
m/z  367 (DB868), 353 (M1), 337 (M3), 339 (M2) and 323 (M4).  The ion at m/z  307 
(DB829) was only detected in full scans with HLMs (Table 2.1).  Fragmentation of the 
prodrug gave one major product at m/z 320 and two minor products at m/z 336 and 290.  The 
MS3 of m/z 320 yielded a major ion at m/z 273 and a minor ion at m/z 289.  The most 
abundant products of MS2 and MS3 corresponded to a loss of 47 Da, presumably derived 
from the loss of the neutral molecules NH3 and O=CH2 by a rearrangement of a six-
membered transition state (Zhou et al., 2002).  The fragmentation patterns observed for 
DB868 in the microsomal incubations were similar to those obtained from the DB868 
authentic standard. 
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 M1 was the most abundant metabolite detected in incubations with HLMs and RLMs 
(Figure 2.2).  The M1 molecular ion at m/z 353 was 14 Da less than the parent, indicating 
metabolic loss of a methyl group.  Fragmentation of the M1 molecular ion at m/z 353 
produced one major ion at m/z 306 and two minor products at m/z 336 and 289.  Similar to 
the prodrug, the ion at m/z 306 was formed by a loss of 47 Da.  The product ion at m/z 306 
fragmented further into an ion at m/z 289, corresponding to the loss of an –OH radical.  The 
molecular ion for M2 at m/z 339 was 28 Da less than the molecular ion of DB868 and was 14 
Da less than the molecular ion of M1, indicating a de-methylation of M1.  The major MS2 
product of m/z 339 was at m/z 322, a loss of 17 Da, which was most likely the loss an –OH 
radical.  The MS3 for this fragment ion produced a major fragment at m/z 306.  The 
molecular ion of M3 at m/z 337 was 16 Da less than the molecular ion of M1, possibly due to 
a loss of an -OH group and protonation of the amidino group.  The MS2 of m/z 337 yielded a 
major fragment at m/z 290, and the MS3 of this fragment led to the product ion at m/z 273.  
Like the prodrug and M1, the ion at m/z 290 was 47 Da less than the molecular ion at m/z 
337.  Further fragmentation to m/z 273 was presumably from loss of the -NH2 radical.  The 
molecular ion of M4 at m/z 323 was 16 Da less than the molecular ion of M2 and 14 Da less 
than the molecular ion of M3, potentially by loss of an -OH group from M2 or loss of a CH3 
group from M3.  The molecular ion at m/z 323 was fragmented only once due to its low 
intensity.  This fragmentation produced a major product at m/z 306 and two small products at 
m/z 290 and 278.  Fragmentation of the active metabolite DB289 was not possible due to low 
levels at the 180 min incubation time point (HLM samples) that did not lie within the 
threshold for MSn analysis; however, the retention time matched that of the authentic 
standard in UV chromatograms.  The structural determination of the metabolites in the 
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DB868 biotransformation pathway was confirmed by comparison of HPLC retention times 
and fragmentation patterns with those of authentic standards, with the exception of M4 for 
which no authentic metabolite was available.    
 Biotransformation of DB868 to the active drug by human and rat liver 
microsomes.  Incubations of DB868 (10 µM) with HLMs and RLMs showed differential 
extents and rates of metabolite formation.  The concentration-time profiles of microsomal 
incubation mixtures showed that HLMs metabolized DB868 nearly completely in 180 min 
compared to only 43% depletion of the substrate by RLMs (Figure 2.4).  In both species, the 
O-demethylation product of DB868 (M1) was the major metabolite formed, accounting for 
approximately 43% (HLM) and 30% (RLM) at 180 min of the initial concentration of 
prodrug.  The O-demethylation product of M1, (M2) was detected readily in incubations with 
HLM but was formed in negligible amounts in incubations with RLM over the 180-min 
incubation period, accounting for ~40% and 0.1% respectively, of initial DB868 
concentrations.  After 180 min incubation, the monomethoxy-monoamidine metabolite (M3) 
accounted for 15% and 6.4% of the initial concentration of the prodrug, in incubations with 
HLMs and RLMs, respectively.  Trace amounts of the monooxime-monoamidine metabolite 
(M4) were detected in incubations with both species; however, quantification of this 
metabolite was not possible due to the lack of an authentic standard.  The near complete mass 
balance achieved by quantifying metabolites M1-M3 at 180 min indicate that M4 accounted 
for a very small percentage of the initial prodrug concentration in both species.  Only trace 
amounts of the diamidine, DB829, were detected in UV chromatograms of 180 min 
incubations with HLMs, suggesting a very slow conversion of intermediate metabolites into 
DB829 (Figure 2.2) in liver microsomal samples.   
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 The rates of conversion of the prodrug to the intermediate metabolites were 
determined by kinetic modeling and enzyme kinetic experiments.  Kinetic modeling of the 
RLM data described the data for DB868, M1 and M2 data adequately; however, the early 
time points for M3 were largely underestimated.  The addition of a process representing 
direct formation of M3 from DB868 significantly improved the model fit to the M3 data 
(Figure 2.5B) suggesting the possibility of an additional metabolic process involved in the 
generation of M3.  The relative rates of formation of M1 in RLMs were several fold faster 
compared to M2 and M3 as reflected by the magnitude in apparent clearances (Clapp) (Table 
2.2).  A similar approach was used to determine the relative rates of metabolite formation in 
HLMs.  The rat model described the DB868, M1 and M3 human data well; however, large 
discrepancies were observed between the predicted fit and the M2 data (fit not shown).  As 
such enzyme kinetic experiments were conducted to understand the enzyme kinetic of 
intermediate metabolite formation.  
 Michaelis-Menten kinetics best described the formation of M1 by HLMs (Figure 
2.6A).  In RLMs, M1 formation was best described by two-enzyme Michaelis-Menten 
kinetics. The Eadie-Hofstee plot of these data depicted the characteristic concave curve of a 
two enzyme system (Figure 2.6B).  Formation of M2 in HLMs was best described by 
sigmoidal kinetics (Figure 2.6C).  Additional analysis of the HLM M2 data using the 
Korzekwa equation (Equation 6) yielded kinetic parameters for both the low and high affinity 
ligands of the allosteric process (Table 2.3).  The kinetic parameters Km and Vmax for the 
formation of M2 in RLMs were not recoverable because saturation was not achieved during 
the experiment (Figure 2.6D).  Similarly, saturation was not achieved for M3 formation by 
either HLMs or RLMs when M1 was the substrate.   
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 Time-dependent Inhibition Experiments Demonstrate Direct N-demethoxylation 
of DB868 for the Generation of M3.  Kinetic modeling with HLMs and RLMs suggested a 
direct reduction from DB868 to M3.  This would imply that the CYP-mediated oxidative 
demethylation of DB868 to M1 is not required for the formation of M3 from DB868.  To test 
this hypothesis, formation of M3 in the presence of mechanism-based CYP inhibitor, ABT 
(Ortiz de Montellano and Mathews, 1981), was examined.  For both HLMs (Figure 2.7A) 
and RLMs (Figure 2.7B), formation of M1 was reduced when CYP enzymes were inhibited 
by ABT, however, the formation of M3 increased under these experimental conditions, 
clearly establishing that formation of M1 was not obligatory for the formation of M3. 
 Human and Rat Enzymes Involved in the O-demethylation Steps of the DB868 
Metabolic Pathway.  Studies with human recombinant enzymes showed that the DB868 O-
demethylation was not catalyzed by CYP2C9, CYP2C19 and CYP2E1 (data not shown), but 
was catalyzed by CYP1A2, CYP3A4 and CYP4F2; whereas, the M1 O-demethylation was 
catalyzed by CYP1A2, (Figure 2.8A).  Experiments with rat recombinant enzymes and 
purified rat CYP4F showed that DB868 O-demethylation was catalyzed by CYP1A2, 
CYP2D2, and CYP4F1 (Figure 2.8B).  Since the M1 O-demethylation (M2) in RLMs was 
negligible the enzymes responsible for this reaction were not examined.  
 Metabolic Activation of DB868 in Human and Rat Hepatocytes Yields 
Measurable DB829 Levels.  To assess whether the incomplete metabolic activation of 
DB868 in liver microsomes was a limitation of the in vitro system, metabolic activation of 
DB868 by sandwich-cultured hepatocytes from humans (HSCHs) and rats (RSCHs) was 
evaluated.  Incubations of DB868 (10 µM) with HSCHs showed nearly complete depletion of 
the prodrug from the medium after 4h; whereas approximately half of the dose remained in 
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the medium at 4 h when DB868 was incubated with RSCHs (Figure 2.9).  As with HLMs and 
RLMs, M1 was detected readily in the medium of HSCHs and RSCHs with amounts peaking 
at 4 h.  As expected, M2 formation in HSCHs was extensive, as evidenced by amounts 
accumulated in the medium; whereas negligible amounts were detected in experiments with 
RSCHs at 24 h.  Appreciable amounts of M3 were detected in both the medium and lysate of 
HSCHs and RSCHs during the course of the incubation, with the highest amounts detected in 
the medium at 24h.  Time dependent intracellular formation of DB829 was observed in both 
HSCHs and RSCHs with little amounts detected in the medium for up to 24 h (Figure 2.9).  
E.  DISCUSSION 
 Second stage HAT, also known as sleeping sickness, begins once the trypanosomes 
penetrate the CNS.  The disease represents approximately 90% of all HAT cases reported 
(WHO 2010) and is fatal if left untreated.  Until recently, melarsoprol and eflornithine were 
the only drugs approved as first line treatment for second stage HAT.  Although effective, 
both drugs have a number of safety and practical concerns.  For example, melarsoprol causes 
death in 5% of patients (Chappuis et al., 2005) and eflornithine, although not life-threatening, 
has an impractical administration regimen with 14 day around the clock infusions.  In 2008, 
the nifurtimox-efllornithine combination therapy (NECT) was approved as a much safer and 
practical alternative to melarsoprol or eflornithine mono-therapy, however, emergence of 
resistance to eflornithine has been reported (Balasegaram et al., 2009) and remains a concern.  
Based on these complications, the development of new alternatives to treat second-stage 
HAT is of high urgency.   
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 The pentamidine analog, DB829, has demonstrated efficacy in a mouse model of 
second stage HAT (Fairlamb, 2003; Wenzler et al., 2009).  However, due to the dicationic 
nature of the amidine moieties at physiologic pH, DB829 is absorbed poorly into the 
systemic circulation when administered orally.  To improve the extent of absorption, a 
prodrug strategy was utilized, in which the O-methyl moieties were used to mask the amidine 
functional groups, creating DB868.  This prodrug was 100% effective when administered 
orally to the murine model of second stage infection suggesting effective biotransformation 
in vivo. 
 To understand how the prodrug is metabolically converted to the active drug, DB829, 
the in vitro biotransformation pathway of this compound was characterized using liver 
microsomes and sandwich-cultured hepatocytes (SCH) prepared from humans and rats.  In 
both HLMs and RLMs, four NADPH-dependent intermediate metabolites were detected 
(M1-M4).  M1, M2, and M4 were produced via O-demethylation of DB868, M1, and M3, 
respectively; whereas M3, M4, and DB829 were produced via dehydroxylation of M1, M2, 
and M4, respectively (Table 2.1).  These assignments were based on extensive LC/MSn data, 
and are consistent with the knowledge of common metabolic reactions and assignments of 
the metabolites of an analogous prodrug, DB289 (Zhou et al., 2004), which was in 
development for the treatment of first stage HAT (Fairlamb, 2003; Wenzler et al., 2009).    
 DB868 was metabolized extensively by both liver microsomes and hepatocytes of 
humans and rats, indicating that hepatic metabolism will contribute to its conversion to the 
active drug, DB829, and to its systemic clearance.  As assessed by the formation of M1, 
which is the primary metabolite of DB868, the disappearance of the prodrug caused by 
HLMs and RLMs was comparable, with Clint values (calculated as the ratio of Vmax to Km) of 
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31 and 24 µL/min/mg protein, respectively.  However, based on Km values of 11 and 0.5 µM 
for human and rat, respectively, saturation of metabolism in rats is expected to occur at much 
lower concentrations compared to humans.  This conclusion is supported by the change in 
magnitude of Clapp, when DB868 was incubated at a concentration of 10 µM.  At this 
concentration, the Clapp in HLMs and RLMs was 15 and 2.3 µL/min/mg protein, respectively, 
representing enzymes operating at approximately one-half and one-tenth of the respective 
Clint values (Table 2.2).  These observations suggest that, in vivo, the hepatic metabolism of 
DB868 in rats will be more easily saturable compared to that in humans.  However, because 
DB868 binds extensively to plasma proteins in both species (Yan, unpublished observations), 
saturation of metabolism is unlikely to occur in vivo.  
 The O-demethylation of DB868 (M1 formation) was catalyzed most efficiently by 
human recombinant CYP4F2, followed by CYP1A2 and CYP3A4 (Figure 2.8A).  These 
results are consistent with those reported by Wang and colleagues (2006), who showed that 
the O-demethylation of the analog prodrug, DB289, also is catalyzed most efficiently by 
CYP4F2.  In contrast to observations with human enzymes, the O-demethylation of DB868 
was catalyzed by rat CYP2D2, CYP1A2 and CYP4F1.  Whether CYP2D2 or CYP4F1 is the 
primary enzyme catalyzing this reaction in unclear because the velocities of M1 formation 
were obtained from two different systems (e.g., rat recombinant enzymes versus purified 
enzymes), in which the ratio of cytochrome b5, P450 reductase and CYP content vary. 
 A noticeable species difference in the biotransformation of DB868 was the extent of 
M2 formation at the end of the 180-minute incubation period, where the amount of M2 
formed by HLMs was 25-fold greater than that formed by RLMs (Figure 2.4).  This 
difference could be explained by the distinct differences in the kinetic processes driving M2 
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formation in both species, where allosteric kinetics governs M2 formation by HLMs (CLmax 
= 3.2 µL/min/mg protein) in contrast to linear unsaturable kinetics observed when RLMs are 
used (Clint= 0.3 µL/min/mg protein) (Figure 2.7).   CLmax is a surrogate for Clint for enzymes 
that exhibit allosteric kinetics (Witherow and Houston, 1999), representing the maximal 
activity of an enzyme before reaching saturation.  Based on graphical analysis of the CLapp 
versus substrate (M1) plot (not shown) the value of Clmax for M2 (3.2 µL/min/mg protein) 
would correspond to a concentration of substrate (M1) of ~15 µM which is unlikely to occur 
in vivo.  A less conservative value of CLint  (1.8 µL/min/mg protein) for the allosteric 
formation of M2, derived from the Korzekwa equation, correspond to concentrations of M1 
of approximately 2 µM (from CLapp versus substrate plot) that would be more likely to occur 
in vivo (Table 2.3) (Korzekwa et al., 1998; Tracy, 2006).  CYP enzymes that have been 
shown to have substrates whose metabolism exhibit allosteric kinetics include CYP1A2 and 
CYP3A4 (Hutzler et al., 2001; Atkins, 2004; Cameron et al., 2007; Isin et al., 2008).  In 
HLMs, M2 formation was catalyzed most efficiently by CYP1A2, consistent with the 
allosteric behavior of this enzyme with other substrates, such as α-napthoflavone, pyrene, and 
1-hydroxypyrene (Sohl et al., 2008).   
 An unexpected finding derived from kinetic modeling of DB868 and intermediate 
metabolites was that M3 generation not only occurred from M1 N-dehydroxylation but also 
via N-demethoxylation of DB868.  Time-dependent inhibition studies with the non-specific 
CYP inhibitor ABT showed that inhibition of CYP-mediated formation of M1 did not reduce 
M3 formation, suggesting that M3 could be formed independently from M1 formation 
(Figure 2.6).  The significant increase in M3 observed after 30 min pre-incubations with ABT 
in the presence or absence of NADPH needs to be further investigated but points to possible 
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enzyme activation by ABT.  To the authors’ knowledge, N-demethoxylation reactions are 
rare with mammalian enzymes, although such reactions have been described in 
environmental research, where soil bacteria and fungi were demonstrated to be efficient in 
degrading N-methoxy containing phenylurea herbicides (e.g., linuron and metobromuron) 
(Berger, 1998; Badawi et al., 2009).  It is hypothesized that in microsomes the reductase 
system cytochrome b5 and NADPH P450 reductase could carry out N-demethoxylation 
reactions, since incubations of DB868 with recombinant CYP4F2 enzymes that were co-
expressed with NADPH P450 reductase and cytochrome b5 formed M3 in the presence of 
NADPH (data not shown).    
 The phase I metabolism of DB868 in sandwich-cultured hepatocytes from humans 
and rats was similar to that by microsomes with the exception that DB829 was formed 
readily in cells.  Extensive depletion of DB868 from the medium was observed with 
hepatocytes of either species (half-life 1h and 3.6 h in HSCH and RSCHs, respectively).  M1, 
M2 and M3 were detected in the medium of HSCHs; whereas only M1 and M3 were present 
in the medium of RSCHs during the incubation time.  The absence of M2 in the medium of 
RSCHs suggests that the rat may not be an adequate toxicological model for the development 
of DB868.  Higher extent of M3 formation was observed in hepatocytes of both species when 
compared to M3 formation by microsomes, perhaps due to precursors of M3 having access to 
mitochondrial reductases not present in microsomes.  For example, it has been shown that 
mitochondrial cytochrome b5 and b5 reductase efficiently reduce amidoximes to amidines 
(Saulter et al., 2005).  Similarly, it has been shown that a benzamidoxime reductase in the 
outer membrane of mitochondria is capable of efficiently activating N-hydroxylated prodrugs 
to amidines (Clement et al., 2005; Havemeyer et al., 2006).  The higher amounts of M3 in 
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hepatocytes could correlate to the observed higher extent of DB829 formation in hepatocytes 
compared to microsomes, given that M3 is an upstream precursor of DB829 in both species.  
Similarly, differences in the extent of M2 formation between species contributed to the 
approximately 10-fold difference in intracellular DB829.   
 Collectively, this study shows that DB868 is efficiently biotransformed by both 
human and rat hepatic enzymes to the active diamidine, DB829.  In particular, larger 
amounts of DB829 formed in human hepatocytes, suggest that in vivo generation of DB829 
will unlikely be limited by metabolism.  However, extensive intracellular accumulation of 
DB829 points to the importance of intracellular binding and hepatic efflux transporters on the 
basolateral membrane in influencing the availability of DB829 in systemic circulation.  
Additionally, this study highlights the value of kinetic analysis in giving insight into novel 
metabolic pathways or processes maybe not recognized using traditional techniques. 
F.  FIGURES 
 
 
 
 
Figure 2.1 Chemical structures of the prodrug DB868 and active diamidine drug, DB829. 
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Figure 2.2 Representative HPLC-UV chromatograms depicting peaks for DB868 (18.5 
min) and intermediate metabolites M1 (14.5 min), M2 (10.5 min), M3 (12.3 min), and M4 
(8.3 min).  The chromatograms show analysis of 180 min-incubations of DB868 (10 µM) 
with human or rat liver microsomal fractions (HLM or RLM respectively; 0.5 mg/mL) in the 
presence (top and middle) or absence (bottom) of NADPH.  Trace amounts of DB829 (5.8 
min) are detected in the UV-chromatogram of incubations with HLMs.  A similar profile to 
the RLM control was observed for the 0-NADPH HLM control (not shown). 
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Figure 2.3 Proposed biotransformation of the prodrug DB868 leading to the formation of 
the active diamidine DB829. 
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Figure 2.4 Concentration-time profiles of DB868 and intermediate metabolites.  DB868 
(○) and intermediate metabolites M1 (◊), M2 (∆), M3 (□) were formed in incubation of 
DB868 with human and rat liver microsomes (HLMs and RMLs, respectively).  HLMs (A) or 
RLMs (B) were incubated with DB868 (10 µM) for up to 180 min and the intermediate 
metabolites were quantified by HPLC-UV.  Quantification of the M4 metabolite was not 
possible due to a lack of an authentic standard.  Concentrations of DB829 were below the 
lower limit of quantification.  Symbols represent the mean ± SD of triplicate determinations. 
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Figure 2.5 Biotransformation of DB868 by liver microsomal fractions.  (A) Model 
scheme representing the biotransformation of DB868 by liver microsomal fractions. The 
first-order rate constants k1, k2, k3 and k4 denote the formation of intermediate metabolites 
M1, M2 and M3, respectively, by RLMs.  In incubations with HLMs, the formation of M2 
was best described by an allosteric process (B) Concentration-time profile of DB868 (●) and 
intermediate metabolites (M1(♦), M2(▲), and M3(■)) formed by incubation with rat liver 
microsomes (RLMs). Symbols represent experimental data ± SD of triplicate determinations.  
The solid lines indicate the fit of the final rat model (shown above) to the data.  The dashed 
line depicts the large underprediction of M3 when the rate constant k4 is omitted from the 
model.   
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Figure 2.6 Rates of M1 and M2 formation in human and rat liver microsomes.  Plots 
showing the rates of M1 and M2 formation by human liver microsomes (HLMs) (top) and rat 
liver microsomes (RLMs) (bottom).  M1 formation data are from incubations of HLMs or 
RLMs (0.5 mg/mL) with DB868 (0.1-100 μM) for 5 min or 10 min, respectively.  M2 
formation data are from incubations of HLMs with M1 (0.1- 25 μM) for 5 min.   All 
reactions were started with NADPH (2 mM).  M1 formation by HLMs was best described by 
a single-enzyme Michaelis-Menten equation while M1 formation by RLMs was best 
described by a two-enzyme equation. M2 formation by HLMs was best described by the Hill 
equation. M2 formation by RLMs did not reach saturation at the concentrations examined. 
Insets show Eadie-Hofstee plots characteristic of a single enzyme system (A), a biphasic 
system (B), and an allosteric system (C).  Symbols represent the mean ± SD of triplicate 
determinations 
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Figure 2.7 Time-dependent inhibition of DB868 N-demethoxylation in human and rat 
liver microsomes.  Direct N-demethoxylation of DB868 shown by time-dependent inhibition 
experiments with human liver microsomes (HLMs) (A) or rat liver microsomes (RLMs) (B).  
HLMs or RLMs (5 mg/ml) were treated with ABT (1 mM) in the absence (left panels) or 
presence (right panels) of NADPH (2 mM).  Aliquots were removed from the primary 
incubation mixtures at 0 and 30 min and were added to secondary incubations (10-fold 
dilution) containing DB868 (10 μM) and NADPH (2 mM).  Bars represent the rate of 
formation of M1 (white bars) and M3 (black bars) and are the means ± SD of triplicate 
determinations (***p < 0.001). 
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Figure 2.8 Human and rat CYP enzymes responsible for M1 and M2 formation.  The top 
panels show select human recombinant CYP enzymes incubated with DB868 (A; left panel) 
or M1 (A; right panel) for 15 min.  The bottom panels show rat recombinant CYP enzymes 
incubated with DB868 (B; left panel) for 15 min or purified rat CYP4F enzymes (B; right 
panel) incubated with DB868 for 30 min.  All reactions were started with NADPH (2 mM). 
Bars represent the mean of duplicate determinations. 
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Figure 2.9 DB868 and phase I metabolites in incubations with human and rat sandwich 
culture hepatocytes.  DB868 (10 µM) was incubated with human sandwich culture 
hepatocytes (HSCHs) (A) or rat sandwich culture hepatocytes (RSCHs) (B) at 37°C for up to 
24 h.  Amounts of DB868 (○) and metabolites (M1 (◊), M2 (∆), M3 (□), and DB829 (●)) 
were quantified from medium (A and B; left panels) and cell lysate (A and B; right panels) 
removed at select incubation time points (0.5, 2, 4 and 24 h). The data represent the mean ± 
SD of 4 (RSCHs) to 6 (HSCHs) determinations.   Quantification of the M4 metabolite was 
not possible due to a lack of an authentic standard.   
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G.  TABLES 
Table 2.1 Protonated molecular ions of the prodrug DB868 and its metabolites, mass shifts and MSn fragmentations 
 
Compound MW [M+H]+ ∆ Mass shift Proposed Structural Assignment MS→MS2, MS3 
DB868 366 367 NA 367→320, 273 
M1 352 353 -14 
 
353→306, 289 
M2 338 339 -28 
 
339→322,306 
M3 336 337 -30 
 
337→290, 273 
M4 322 323 -44 
 
323→306 
84
NA: Not applicable 
Dashed lines on structures represent proposed fragmentation sites. 
 
 
 
 
Table 2.2 Apparent first-order rate constants for the metabolism of DB868 (10 µM) in HLM and RLM 
 
Species Parameter (min-1) Estimate (%CV) Clapp (μL/min/mg protein) 
HLM k1 0.0300 (5.6) 15.00 
 k
k
k
k
k
k
2 0.0002 (18) 0.10 
 3 0.0060 (7.6) 3.00 
 4 0.0057 (15) 2.86 
RLM k1 0.0046 (2.6) 2.32 
 2 0.0007 (52) 0.32 
 3 0.0006 (36) 0.30 
 4 0.0005 (25) 0.28 
Data are the mean parameter estimates and their coefficient of variation obtained by non-linear regression using WinNonlin 5.0.1 (Pharsight, 
Mountain View, CA). 
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Table 2.3 Enzyme kinetic parameters for the formation of M1 and M2 in HLM and RLM 
 
Species Pathway 
Vmax 
(pmol/min/mg 
protein) 
Km (μM) S50 (μM) n 
Clint 
(μL/min/mg 
protein) 
Clmax 
(μL/min/mg 
protein) 
HLM 868→M1 340 (4.5) 11 (6.7)   30.9  
 M1→M2 (Hill) 184 (12)  18 (3) 1.7 (0.2)  3.2  
 M1→M2 (Korzekwa) 82.4 (52) 46.9 (39)   1.8  
 M1→M2 (Korzekwa) 184 (12) 0.15 (23)   1226.6  
RLM 868→M1 11.8(26) 0.5 (34)   23.6  
 868→M1 70 (14) 27 (36)   2.6  
Data are mean parameter estimates and their coefficient of variation obtained by non-linear regression using WinNonlin 5.0.1 (Pharsight, 
Mountain View, CA).  Clmax: Obtained from graphical analysis of Clapp versus substrate (M1) plot (Witherow and Houston, 1999) 
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CHAPTER 3 
 
 
 
 
TRYPANOSOMAL INFECTION ALTERS THE PHARMACOKINETICS AND 
DISPOSITION OF THE ANTIPARASITIC AGENT FURAMIDINE AND ITS 
PRODRUG PAFURAMIDINE IN RATS 
 
 
 
 
 
 
 
 
 
 
This chapter will be submitted to the journal Antimicrobial Agents and Chemotherapy and is 
formatted in the style of this journal. 
A. ABSTRACT 
 Cytokines generated during infection and inflammation have been demonstrated to 
mediate down-regulation of many drug metabolizing enzymes (DMEs) and transporters.  The 
consequences of such down-regulation often are manifested as altered drug clearance or 
exposure, which may lead to untoward, or even toxic, or sub-therapeutic outcomes.  A 
prodrug of the potent antitrypanosomal agent furamidine, evaluated for the treatment of 
human African trypanosomiasis, requires biotransformation for activation.  It was 
hypothesized that trypanosomal infection would decrease conversion of pafuramidine to 
furamidine due to down-regulation of DMEs, leading to ineffective concentrations of active 
metabolite.  Pafuramidine systemic exposure (AUC) was 1.3-fold higher in infected animals 
compared to controls, following an oral dose that saturated metabolism (25 µmol/kg) 
(p<0.01).  In contrast, no elevation in AUC was observed in infected animals receiving an 
oral dose within the linear pharmacokinetic range (7.5 µmol/kg) or when pafuramidine was 
administered intravenously (1.45 µmol/kg).  A marked increase in furamidine systemic AUC 
(up to 3-fold) and prolonged half-life (up to 2-fold) was observed in infected compared to 
control animals regardless of route of administration and dose.  A significant decrease in the 
rate of furamidine biliary excretion in infected rats (12-fold from control) (p<0.05) may 
explain the observed increase in systemic furamidine exposure.  These results demonstrate 
that trypanosomal infection can alter the pharmacokinetics of both pafuramidine and 
furamidine, suggesting down-regulation of both hepatic CYP enzymes involved in 
pafuramidine clearance and canalicular transporters involved in furamidine biliary excretion.  
Sub-therapeutic circulating concentrations of furamidine in infected populations may not be 
of concern. 
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B. INTRODUCTION 
 Infection-related changes in pharmacokinetics of drugs were recognized in the clinic 
more than two decades ago, with a case of reduced theophylline clearance in children 
infected with influenza.  Diminished clearance led to drug-related toxicity and was linked to 
decreased function of CYP enzymes during infection due to inflammatory cytokines (21).  
Other clinical examples of altered pharmacokinetics as a result of infection or inflammation 
have since been reported (23, 29, 30, 36, 37, 45).  Numerous in vitro studies have focused on 
understanding mechanisms by which infection alters expression and function of drug 
metabolizing enzymes.  Particular attention has centered on investigating effects of pro-
inflammatory cytokines (4, 19, 32, 33).  For example, direct challenge with the pro-
inflammatory cytokines IL1-β, IL-6, TNF-α and INF-γ suppressed mRNA expression of 
major CYPs 1A2, 2C, 2E1 and 3A4 in primary cultures of human hepatocytes (1).  Similarly, 
CYP2E1 was down-regulated during LPS-induced inflammation in the rat (2).  Inflammatory 
cytokines also are capable of modulating phase II enzymes and drug transporters (13, 15).  
TNF-α and IL-1 were associated with significant reduction of sulfotransferase (Sult) 2a1 in a 
murine model of LPS-inflammation (19).  Likewise, TNF-α and IL-6 had profound effects 
on mRNA expression and function of basolateral and canalicular transporters in human 
hepatocytes (39). 
 Human African trypanosomiasis (HAT) is a parasitic disease endemic to sub-Saharan 
Africa.  It is caused by the flagellated protozoan Trypanosoma brucei.  HAT has two distinct 
stages: first-stage and second-stage.  First-stage is defined by an acute infection and the 
presence of trypanosomes in the blood and lymph.  Second-stage begins once parasites 
invade the central nervous system, and is diagnosed by the detection of T. brucei subspecies 
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in cerebrospinal fluid.  Second-stage symptoms are more severe than first-stage symptoms 
(e.g., general malaise, fatigue and headaches) and include neurological abnormalities that 
affect the wake-sleep cycle (38).  Without drug treatment, HAT is fatal.  Current 
chemotherapy for treatment of either stage is scarce.  In addition, available drugs are 
associated with impractical dosing regimens and unacceptable toxicity.  For example, 
melarsoprol used until recently as first line treatment for second-stage HAT, must be 
administered intravenously and requires three or four times daily administration for a period 
of three or four weeks (3).  This arsenic containing compound also causes post-treatment 
reactive encelopathy in 10% of patients, half of which die.  As with other neglected diseases, 
there is little monetary incentive for pharmaceutical companies to develop new and safer 
drugs for HAT.  Thus, only a few public sector institutions are involved discovery and 
development of drugs to treat this deadly disease.   
 Pafuramidine is a prodrug of the potent antitrypanosomal agent, furamidine, which 
was in development for treatment of first-stage HAT (Figure 3.1).  In 2008, phase III clinical 
trials were completed in which pafuramidine was tested as the first oral treatment for first-
stage HAT; however, during an extended phase I clinical trial in healthy volunteers 
evaluating the safety and tolerability of pafuramidine, development was halted due to liver 
toxicity and unforeseen delayed nephrotoxicity (28).  Nothwithstanding the observed 
toxicity, pafuramidine and other diamidine prodrugs in development for the treatment of 
second-stage HAT have suitable pharmacokinetic characteristics for oral administration.  
Pharmacokinetic studies with rats and monkeys showed that pafuramidine undergoes 
extensive first-pass metabolism with minor contributions (<10%) by non-hepatic routes (24).  
Metabolic activation of pafuramidine occurs in the liver, through a complex metabolic 
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pathway that includes O-demethylation and N-hydroxylation reactions (47).  The primary 
metabolite of pafuramidine, an O-demethylation product, is catalyzed by CYP4F2 in human 
liver microsomes, while reductive intermediate metabolites were shown to be products of the 
cytochrome b5/NADH b5 reductase system (34, 41).  Intestinal first-pass metabolism of 
pafuramidine is believed to be minimal compared to hepatic first-pass metabolism, as 
reflected by the reported intrinsic clearance for M1 formation (pafuramidine-O-
demethylation) of human intestinal and liver microsomes (0.27 and 7.6 ml/min/mg protein, 
respectively).  Additionally, pafuramidine was shown to have high absorptive permeability in 
Caco-2 cell monolayers (Papp = 32.2 x10-6 cm/s) (42, 46).  The unbound fraction (fu) of 
pafuramidine and furamidine in rat plasma was 0.01 and 0.2, respectively (24).  After 
intravenous or oral administration of pafuramidine, furamidine was observed in rats and 
monkeys as early as 30 min post-dose, indicating rapid formation in the liver.  Among the 
elimination pathways of furamidine, biliary excretion and glucuronidation were reported as 
important components, with renal excretion having a minor contribution.  In both rats and 
monkeys, tissue binding was shown to be a major component of furamidine disposition, as 
demonstrated by extensive accumulation of furamidine in tissues, including liver and kidney 
(24).   
 Based on the known effects of infection on DMEs, and that furamidine requires 
biotransformation of pafuramidine, it was hypothesized that down-regulation of DMEs 
during infection would decrease clearance of pafuramidine and yield sub-therapeutic 
concentrations of the active metabolite furamidine.  This investigation aimed to evaluate the 
effects of trypanosomal infection on the pharmacokinetics of pafuramidine and furamidine in 
a rat experimental model of first-stage HAT.  An improved understanding of the effects of 
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trypanosomal infection on the pharmacokinetics of these agents will help guide development 
of diamidine analogs and prodrugs for the treatment of HAT.   
C. MATERIALS AND METHODS 
 Materials.  Pafuramidine and furamidine were synthesized in the laboratory of Dr. 
David  Boykin (Georgia State University, Atlanta, GA) as described previously (18).  Heat 
inactivated fetal bovine serum, (10% v/v), 1% hypoxanthine, L-cysteine, thymidine prepared 
in sodium hydroxide, penicillin/streptomycin, bathocuproine disulfonic acid, 
β-mercaptoethanol and pyruvate were purchased from  Sigma-Aldrich (St. Louis, MO).   
 Animals. Cannulated male Sprague-Dawley rats (226-250 g) were purchased from 
Charles River Laboratories (Raleigh, NC) and were maintained in single cages on standard 
rodent chow and water ad libitum.  Animals were acclimated for seven days prior to 
experiments.  All experiments followed protocols in accordance with the guidelines for the 
use of live animals approved by the Institutional Animal Care and Use Committee of the 
University of North Carolina at Chapel Hill.   
 In vitro cultivation of parasites.  T. b. brucei S427, an isolate from Uganda (1960) 
(43), was cultivated in modified Iscove’s medium (HMI-18) as described by Hirumi and 
Hirumi (17).  Parasites were grown in Corning 10-mL (25-cm2) cell culture flasks (Corning 
Inc. Corning, NY) and were passaged every 2-3 days until cell densities reached 
approximately 106 trypanosomes/mL.    
 Characterization of T. b. brucei infection in Sprague-Dawley rats.  
Histopathology and biochemical markers of liver and kidney function were determined to 
assess potential biochemical and physiologic changes elicited by the infection.  Three groups 
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of ten jugular vein cannulated (226 - 250 g) rats were separated into control (n=4) and 
infected animals (n=6).  Each group was designed to capture changes in organ function at 
early, medium and high parasitemia (group 1, 2 and 3, respectively) based on preliminary 
experiments that defined the time course of the infection.  On day 0, rats were inoculated 
intraperitoneally with T. b. brucei S427 (4 x 104 cells) or injected with vehicle (400 µL) 
(HMI-18 medium).  To evaluate the time course of the infection, parasitemia was determined 
daily by counting trypanosomes from a drop of jugular vein blood under a microscope and 
averaging the counts of least 20 fields at a 400X magnification.  Blood was collected daily 
from the jugular vein.  Blood collections were divided between lithium heparin-coated tubes 
(200 µL) or EDTA-coated tubes (30 µL) for plasma and blood clinical analysis, respectively.  
Blood in heparin tubes was separated from plasma by centrifugation at 3000 rpm (1500 x g) 
in a Marathon 8K centrifuge (Fisher Scientific, Pittsburgh, PA) for 10 min.  Animals were 
euthanized with carbon dioxide at days 3, 5 and 6 (groups 1, 2, and 3, respectively), and 
livers and kidneys were excised.  A portion of each organs was sectioned and stored in 10% 
neutral formalin buffer for hematoxylin and eosin (H&E) staining, ensuring that the same 
section was obtained from all animals.  The remaining portion of each organ was frozen 
immediately on dry ice and stored at -80°C.    
 Histology and light microscopy.  Liver and kidney sections were immersed in 10% 
neutral formalin buffer for at least 24 h before processing.  Slices of liver or kidney of 3-6 
mm in thickness were embedded in paraffin wax and sectioned at 3 µm for H&E staining 
prior examination by microscopy with an Olympus BX61 fluorescent microscope on bright 
field mode with color camera (Olympus America, Center Valley, PA).  Liver and kidney 
sections were examined for changes in tissue architecture, presence of focal areas of necrosis, 
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tissue congestion and inflammation.  All histological samples were processed at the UNC 
Animal Histopathology Core Facility (Chapel Hill, NC).   
 Hematological and serum markers.  Blood collected in EDTA tubes was 
maintained at 4°C until analysis with a veterinary hematology system (HESKA Corporation, 
Loveland, CO).  Plasma collected in heparin coated tubes was maintained at 4°C until 
analysis for biochemical markers.  Total protein, alanine aminotrasterase (ALT), total 
bilirubin (BIL), blood urea nitrogen (BUN), and serum creatinine (SCR) were analyzed on a 
VITRO 350 Chemical Analyzer (Ortho-Clinical Diagnostics, Rochester, NY) by the UNC 
Animal Clinical Chemistry and Gene Expression Facility (Chapel Hill, NC).   
 Pharmacokinetic experiments.  Double jugular and femoral vein cannulated male 
Sprague-Dawley rats (n=6) were infected with T. b. brucei S427 (104 cells) or treated with 
vehicle (HMI-18).  Intravenous administration of prodrug.  On day four post-inoculation, 
animals were administered pafuramidine intravenously (1.45 μmol/kg) as a 30-min infusion 
through the femoral vein cannula.  The dose was formulated as a solution of D-α-tocopheryl 
polyethylene glycol 1000 succinate, citric acid, ethanol, and 0.9% saline according to 
methods described previously (24).  Blood (0.2 mL) was collected from a jugular vein at 
0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12 and 24 h after the infusion was stopped, and the samples were 
maintained at 4°C until separated from plasma by centrifugation at 3000 rpm (1500 x g) for 
10 min.  Plasma was removed from red blood cells, taking care to ensure that the buffy coat, 
which in addition to white blood cells contains trypanosomes in infected samples, was not 
disrupted.  Additionally, an aliquot of the plasma (10 µL) from infected samples was 
examined microscopically to ensure the absence of trypanosomes.  Plasma was stored at 
-20°C until further processing.  Plasma samples were prepared for HPLC/MS/MS analysis by 
 98
adding 200 µL of 7:1 (v/v) methanol:water 0.1% trifluoroacetic acid (v/v) containing 30 nM 
d8-pafuramidine and d8-furamidine as internal standards to an aliquot of plasma (25 µL).  
After vortexing, this mixture was centrifuged at 3000 rpm (1500 x g) for 10 min at 4°C.  The 
supernatant (170 µL) was removed and evaporated for (~25 min) in a 96-well plate nitrogen 
evaporator (Evaporex EVX-192, Apricot designs, Monrovia, CA).  Samples were 
reconstituted with a mixture of 15% (v/v) methanol: water 0.1% trifluoroacetic acid, vortexed 
and transferred to vials for quantification of pafuramidine and furamidine by HPLC/MS/MS 
(described below). 
 Oral administration of prodrug.  Dose escalation studies with pafuramidine were 
conducted in uninfected animals to assess pharmacokinetic linearity.  Jugular vein cannulated 
rats (n= 4) were administered pafuramidine by oral gavage (2.5, 7.5 and 25 μmol/kg) in a 
suspension of 70:30 (v/v) acidified water: (70:30 v/v) Tween 80:ethanol.  To assess the 
effects of infection after oral administration of pafuramidine, pharmacokinetic studies with 
infected and uninfected rats were carried out at two different doses.  The doses selected were 
either within or above the linear range (7.5 and 25 μmol/kg, respectively).  Jugular vein 
cannulated rats (n=6 per group) were infected with T. b. brucei S427 (104 cells) by 
intraperitoneal injection or treated with vehicle (HMI-18).  Four days post-inoculation, rats 
were administered pafuramidine by oral gavage at either 7.5 or 25 μmol/kg in the same oral 
formulation described above.  For both dose escalation and experiments with infected 
animals, blood (0.2 mL) was collected from a jugular vein at 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12 
and 24 h after pafuramidine administration and was stored at 4°C until separated from plasma 
by centrifugation at 3000 rpm (1500 x g) for 10 min.  Plasma was stored at -20°C until 
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samples were processed (according to the methods described above) for quantification of 
pafuramidine, M1 or furamidine by HPLC/MS/MS analysis (described below).   
 In situ bile duct cannulation experiments:  To determine whether biliary 
elimination of furamidine was impaired during trypanosomal infection, in situ bile 
cannulation experiments were conducted according to the methods described by Lee et.al., 
(2002) with modifications (22).  Male Sprague-Dawley rats (n=3) were infected 
intraperitoneally with T. b. brucei S427 (104 cells) or treated with vehicle (HMI-18).  On day 
four post-inoculation, animals were anesthetized by intraperitoneal administration of 
ketamine and xylazine (cocktail) at a dose of 75 mg/kg and 10 mg/kg, respectively.  A small 
polyethylene tube (PE-10) was used to cannulate the common bile duct for bile collection.  
After bile flow was established, a 7.5 µmol/kg dose of pafuramidine (prepared in the same 
oral formulation described above) was administered directly into the duodenum.  
Immediately after dosing, bile was collected at 10 min intervals for 60 min.  Body 
temperature was monitored using a Traceable digital thermometer (Fisher Scientific, 
Pittsburgh, PA) and was maintained between 36-37°C using a Sunbeam heating pad (Jarden 
Corporation, Providence, RI).  Bile samples were maintained at 4°C for the duration of the 
experiment and were stored at -20°C until processing for furamidine quantification.  Bile 
collections were prepared for HPLC/MS/MS analysis by diluting 1:50 (v/v) with 7:1 (v/v) 
methanol:water 0.1% trifluoroacetic acid (v/v) containing 60 nM d8-furamidine as internal 
standard.  
 HPLC-mass spectrometry analysis. Reconstituted samples were analyzed by liquid 
chromatography with detection by tandem mass spectrometry with no further manipulation.  
A Shimadzu solvent delivery system (Columbia, MD, USA), a Leap HTC Pal thermostated 
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autosampler (Carrboro, NC USA), and an Applied Biosystems API 4000 triple quadruple 
mass spectrometer with a TurboIon ion source (Applied Biosystems, Foster City, CA, USA) 
were used for these analytical studies.  Tuning, operation, integration and data analysis were 
performed using Analyst® software v.1.4.1 (Applied Biosystems, Foster City, CA, USA).  
Standard curves for pafuramidine, furamidine, and M1 were prepared for each analytical run 
using appropriate matrix (i.e., plasma).  The standard curves ranged from 1 -1000 nM and the 
lower limit of quantification was 5 nM.  The sample injection volume was 4 µl.  Following 
injection, analytes were eluted from an Aquasil C18 column (dp = 5 µm, 2.1 x 50 mm; 
Thermo Electron Corporation, San Jose, CA) using a mobile phase gradient.  Mobile phase A 
consisted of 35 mM formic acid with 15 mM ammonium formate in 100% water, and mobile 
phase B consisted of 35 mM formic acid with 15 mM ammonium formate in 80:20 v/v 
acetonitrile: water.  The mobile phase gradient was as follows: 0 - 0.8 min hold at 10% B; 0.8 
- 7.0 min linear gradient to 80% B; 7.0 - 7.6 min linear gradient to 100% B; 7.6 - 8.5 hold at 
100% B, 8.5 - 8.6 min linear gradient to 10% B, 8.6 -10.0 min hold at 10% B.  The flow rate 
was 0.35 ml/min.  Total run time, including equilibration, was 10 minutes per injection.  All 
eluent was directed to the mass spectrometer.  The mass spectrometer was operated in 
positive ion mode using multiple reaction monitoring: pafuramidine, 365.1→334.1 m/z; 
furamidine, 305.3→288.1 m/z; M1, 351.1→320.1 m/z; d8-furamidine, 313.3→296.1 m/z; d8-
pafuramidine, 373.1→242.0 m/z.  
 Pharmacokinetic Analysis.  Pharmacokinetics of pafuramidine and furamidine were 
evaluated by noncompartmental methods using WinNonlin (v5.2; Pharsight, Mountain View, 
CA).  The first-order elimination rate constant (k) was determined from linear regression of 
the terminal phase of the concentration-time curve (using a minimum of three data points).  
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Terminal half-life (t½) was calculated as ln 2/k.  The linear trapezoidal (linear interpolation) 
method was used for the calculation of the area under the curve (AUC0-t) from the time of 
dosing to the last measurable concentration.  Area under the curve extrapolated to infinity 
(AUC0-∞) was calculated as (AUC0-t + Clast pred/k), where (Clast pred) was the last predicted 
concentration.  Systemic clearance (CL) was calculated as dose/AUC0-∞ following 
intravenous administration.  The volume of distribution at steady state (Vss) was estimated 
using MRT0-∞ * CL, where MRT is the mean residence time extrapolated to infinity.  
Maximum concentration (Cmax) and the time to achieve Cmax (Tmax) following oral 
administration were reported as observed median and range.  Apparent oral clearance (CLpo) 
was calculated as dose/AUC0-∞.  Values of AUC0-∞ that were extrapolated >25% were not 
reported.    
 Statistical Analysis.  One way ANOVA with a post-hoc Dunnett’s test for multiple 
comparisons was used to evaluate the difference in hematological and serum markers values 
at different days of infection compared to control.  Comparisons between pharmacokinetic 
parameters between infected and un-infected controls were made using Student’s t-tests.  
Repeated measures ANOVA was used for comparisons of biliary excretion rate and bile flow 
between infected and uninfected groups.  For all statistical methods, differences were deemed 
significant if p-values were <0.05.  Statistical analyses were performed using GraphPad 
InStat 3.06 (GraphPad Software, San Diego, CA, USA) and R version 2.11.1 (Vienna, 
Austria)   
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D. RESULTS 
 Trypanosoma brucei brucei infection in Sprague-Dawley rats.  Time course of 
parasitemia.  Blood parasite counts in infected rats from groups 1-3 were recorded daily.  
Trypanosomes were not visible microscopically until day three post-infection. Parasitemia 
increased exponentially on days 3 and 4 and peaked on day 5.  Only two animals survived to 
day 6 post-infection, and their parasitemia was lower than peak counts (Figure 3.2).   
 Histological Evaluation:  Minimal changes in the architecture of the liver and kidney 
tissues of infected animals were observed at day 3 (group 1) or day 5 (group 2) post-infection 
compared to uninfected controls.  Mild infiltration of inflammatory cells was evident in both 
tissues at day 5 post-infection (Figure 3.3).  Tissues from the infected animals of group 3 
showed an increased number of inflammatory cells infiltrating the parenchyma; however, no 
focal areas of necrosis or other pathological signs were evident at this time point (not shown).  
 Hematological and biochemical markers.  In both groups 1 and 2, no significant 
differences were observed in RBC counts or HCT values between infected and uninfected 
controls (Tables 3.1 and 3.2).  The WBC counts in group 1 showed a marked decrease at day 
3 post-infection, with a reduction of about 45% from control values.  The WBC counts in 
group 2 increased up to 63% from control on day 2 followed by a decrease sharp decrease 
beginning at day 3 resulting in up to 70% decrease from control values by day 5 post-
infection.  Groups 1 and 2 showed no significant elevations in ALT, BIL, total protein, BUN 
and SCR until day 3 post-infection (Table 3.2).  However, at day 5 post-infection ALT and 
BUN levels increased 9- and 1.4-fold, respectively.  BIL values in infected animals of groups 
1 and 2 showed an increasing trend as the infection progressed; however, it was not possible 
to ascertain whether there was a statistical difference between infected and infected controls 
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because most of the control values were below the limit of quantification (<0.1) and thus no 
standard deviation values were available. 
 Pharmacokinetic experiments.  Dose escalation study.  To determine linearity in the 
dose-exposure relationship of pafuramidine in uninfected rats, a dose-escalation study was 
conducted at three dose levels.  A proportional increase in exposure (AUC0-12) was observed 
from 2.5 and 7.5 µmol/kg, whereas a greater than proportional increase was observed at 
25 µmol/kg.  The mean apparent oral clearance (Clpo) of pafuramidine at 2.5, 7.5, and 25 
µmol/kg was 8.0 (0.3), 12 (36), and 4.8 (14) L/h/kg, respectively (presented as geometric 
means and coefficient of variances).  The active metabolite to pafuramidine AUC0-12 ratio 
was relatively constant at approximately 0.5 (Figure 3.4). 
 Pharmacokinetics of pafuramidine and furamidine after intravenous infusion. A rapid 
decline of pafuramidine from plasma was observed in both uninfected and infected animals 
(Figure 3.5).  The pafuramidine concentration-time profile of the control animals showed 
biphasic decay, while a monoexponential decay profile was observed for the infected 
animals.  Significant differences (p<0.05) in both the t½ and Vss were observed in infected 
animals compared to controls, where the Vss was 2.1-fold lower and the t½ 2.6-fold shorter in 
infected animals compared to controls.  No significant changes in systemic clearance (CL) or 
exposure (AUC0-12) were observed between groups (Table 3.3).  For furamidine, the AUC0-6 
was significantly greater (p < 0.01) in infected animals compared to uninfected controls 
(Table 3.3).     
 Pharmacokinetics of pafuramidine and furamidine after oral administration of 7.5 
µmol/kg pafuramidine.  Pafuramidine was absorbed readily in both uninfected and infected 
rats, with a median Tmax of 1 h in both groups (Figure 3.6).  Although no statistically 
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significant differences were observed, there was a tendency for both the median Cmax and 
AUC0-12 of pafuramidine to be higher in infected animals.  Similarly, both the t½ and CLpo of 
pafuramidine in infected animals tended to be lower compared to controls.  No significant 
differences were observed when comparing pharmacokinetic parameters of M1 in infected 
and uninfected animals; however, like pafuramidine there was a tendency toward higher 
AUC0-12 in infected animals.  The median Cmax and Tmax of furamidine in infected rats were at 
least twice the corresponding values in control rats; likewise, the geometric mean AUC0-12 
and t½ of furamidine in infected rats were at least twice the corresponding values in control 
rats (Table 3.4).    
 Pharmacokinetics of pafuramidine and furamidine after oral administration of 25 
µmol/kg pafuramidine.  The median Cmax , Tmax, and the t½ geometric mean of pafuramidine 
were similar in the both the infected and uninfected groups.  In contrast, significant 
differences in pafuramidine exposure (p<0.01) were observed in the infected group compared 
to uninfected control, with a 1.3-fold higher exposure (AUC0-24) in the infected rats (Figure 
3.7).  Consistent with the increased pafuramidine exposure in infected animals a significant 
decrease in the exposure of the M1 metabolite was observed in infected animals compared to 
controls (AUC0-12) (Figure 3.8).  Differences in the pharmacokinetic profiles of furamidine 
between infected and uninfected animals were also observed.  In infected animals the 
furamidine AUC0-24 was significantly (p<0.001) higher compared to uninfected controls with 
a 1.9-fold increase in exposure in the infected animals.  The profile of elimination of 
furamidine changed from formation-rate limited to elimination-rate limited.  No meaningful 
differences were observed in the median Cmax, Tmax, and the t½ geometric means of 
furamidine between uninfected and infected rats (Table 3.4).  
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 Biliary excretion of furamidine.  Comparison of biliary excretion rate between 
infected animals and uninfected animals showed significant differences (p <0.05) when 
averaged across the entire time interval (0 - 60 min).  Additionally, the difference in biliary 
excretion rates changes significantly with respect to time (p<0.001) (Figure 3.9).  
Furthermore, the average bile flow was not significantly different between groups.  However, 
bile flow changed significantly for both groups with respect to time (p<0.001) (Figure 3.10).    
E. DISCUSSION 
 Infectious agents have been demonstrated to modulate the clearance of drugs via 
down-regulation or induction of drug metabolizing enzymes (31).  The consequences of 
down-regulation often are exemplified by untoward side effects or drug-related toxicity due 
to accumulation of systemic drug concentrations (21).  In vitro studies have demonstrated 
that pro-inflammatory cytokines are in part responsible for down-regulation of drug 
metabolizing enzymes, including members of the CYP superfamily (12).  The varied effects 
of down-regulation with respect to the degree and specificity of CYP enzymes affected make 
it difficult to ascertain what the overall effects of disease and infection would be on 
pharmacokinetics of a compound (8, 26, 27).   
 The compound pafuramidine is a prodrug for the potent antitrypanosomal agent 
furamidine.  In liver microsomes it was shown that the biotransformation pathway of 
pafuramidine consists of a series of oxidative and reductive enzymatic reactions that lead to 
the generation of furamidine via four phase-I intermediates (M1-M4) (34, 41, 47).  
Pharmacokinetic studies with rats and monkeys also showed extensive pafuramidine 
metabolism, with detection of intermediate metabolites and furamidine the in plasma of both 
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species following intravenous and oral administration (24).  Since metabolic 
biotransformation is essential to the formation of the active diamidine, prior to this 
investigation it was a concern that trypanosomal infection could diminish the formation of 
furamidine to sub-therapeutic levels.  Accordingly, it was hypothesized that infection would 
decrease the metabolic activation of pafuramidine thus affecting the concentrations of 
furamidine in infected animals.  This hypothesis was tested by conducting pharmacokinetics 
studies to examine both pafuramidine and furamidine, in a rat model of first-stage HAT.   
 Characterization of the experimental model of infection was conducted to ascertain 
that potential pharmacokinetic changes observed in infected animals were not a reflection of 
major organ damage due to the trypanosomal infection.  Accordingly, determination of the 
time course of the parasitemia was conducted, as well as an evaluation of the histology and 
biochemical markers of the major eliminating organs liver and kidney.  The characterization 
showed that inoculation with 104 cells induced an acute infection that had a single wave of 
parasitemia peaking at day five, followed by death at day six post-infection.  The short 
course of the infection coupled with the single wave of parasitemia indicated that the S427 
strain is highly virulent even when inoculated at a low density of parasites (104).  This 
response mimics the short length of infection observed in humans during first-stage HAT and 
is in contrast to the response of infections with other T.b. brucei strains (i.e., AnTat 1.1E) that 
elicit multiple waves of parasitemia characteristic of second-stage HAT (6, 16, 38). 
 Despite the virulence, hematological tests at different days of infection showed no 
evidence of anemia or changes in hematocrit compared to control animals.  These 
observations are in contrast to reports of decreased RBC counts in rat experimental models of 
trypanosomal infection and may be due to the short duration of the infection in this study (up 
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to 5 days) compared to studies in other laboratories where measurements were taken at 11-12 
days post-infection (11).  A significant decrease in WBC was apparent beginning on day 4 
post-infection, consistent with reports of leucopenia in other infections due to migration of 
neutrophils and lymphocytes from the blood to the site of infection.  Moderate elevation in 
ALT was observed at days 4 and 5 post-infection consistent with increased rate of hepatocyte 
turnover during inflammation in other types of infection (e.g., viral hepatitis) (14).  Minor 
BUN elevations were observed at day 5 post-infection concurrent with inflammation at peak 
parasitemia.  These biochemical changes were not commensurate with the histopathological 
results, where there were negligible to no effects on organ histology and hence function.  
Based on these results and the time-course of parasitemia, day four post-infection was 
selected for the conduct of the pharmacokinetic studies. 
 Pharmacokinetic dose-escalation studies showed a supra-proportional increase in 
exposure (AUC0-12) at 25 µmol/kg, indicating saturation of pafuramidine metabolism 
considering that the predominant clearance mechanism is metabolic.  The furamidine to 
pafuramidine AUC0-12 ratio remained relatively constant at ~0.5 for all three doses, 
suggesting decreased elimination of furamidine at the highest dose.  Based on these results, 
experiments with infected and uninfected animals were carried out at both a sub-saturating 
and saturating dose of pafuramidine (7.5 and 25 µmol/kg, respectively).  The dose for the 
intravenous administration was selected to match the lowest dose (1 mg/kg or 2.7 µmol/kg) 
given to rats by Midgley et al. (2007) and was given as an intravenous infusion because a 
bolus dose led to overt toxicity (24).  This dose was likely to be saturating since 
pafuramidine concentrations approximated the concentrations observed following the 25 
µmol/kg from dose escalation studies. 
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 When pafuramidine was given intravenously as a 30 min infusion, no significant 
differences were observed in systemic exposure (AUC0-12), or CL between the control and 
infected animals, as expected for a compound whose clearance approaches liver blood flow 
(44).  Consistent with the definition of a compound with blood-flow limited clearance the 
extraction ratio (E) of pafuramidine was 0.75 (44).  This value was obtained using the  
relationship E =  CLH/Q where Q represents hepatic blood flow in the rat (3.3 L/h/kg) (7) and 
CLH is the hepatic clearance of pafuramidine calculated according to the well-stirred model 
equation.  
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H ClQ
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•
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In this equation, Clint is the total intrinsic clearance (Clint=fu●Clint) equivalent to the Clpo (11 
L/h/kg) (35) from the linear oral dose 7.5 µmol/kg (Table 3.4).  These calculations work 
under the assumption of complete absorption (fa=1) of pafuramidine, which can be inferred 
from studies in Caco-2 cells that showed that the Papp value of pafuramidine is comparable to 
that of propanolol (32.2 x 10- 6 cm/s and 30.8 x 10-6 cm/s, respectively) which was shown to 
have complete intestinal absorption (40, 46).  Hence, because pafuramidine clearance is 
blood flow limited, a decreased metabolic capacity due to infection was unlikely to cause 
discernable changes in pafuramidine systemic exposure between control and infected animals 
following intravenous administration.  
 Results from oral administration studies showed significant differences in 
pafuramidine systemic exposure (AUC0-24) between infected and control animals after the 25 
µmol/kg dose, where a 1.3-fold higher exposure was observed in infected animals compared 
to uninfected controls.  This difference was attributed to a decreased metabolic clearance in 
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infected animals induced by the infection.  However, after the 7.5 µmol/kg oral dose no 
statistical meaningful differences were observed in the exposure of pafuramidine (AUC0-12) 
between infected and uninfected controls animals.  The discrepancy between oral doses 
stems from the fact that the clearance of pafuramidine is capacity limited where small 
changes in enzyme capacity may not be appreciated under linear conditions but can be more 
clearly discerned under saturating conditions.  Mathematically this can be demonstrated via 
the Michaelis-Menten equation:  
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SVv
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Where v is velocity, Vmax is the maximal velocity, S is the substrate concentration, and Km is 
the substrate concentration at half the maximal velocity.  When S is much less than Km, v is 
dependent on Vmax/Km ● S and it is assumed that the enzyme pool well exceeds the substrate 
concentration, whereas under saturating conditions (S >> Km) v is dependent on Vmax.  
Consistent with the interpretation above, M1 exposure (AUC0-12) in infected animals 
following a saturating oral dose of pafuramidine was significantly lower (p <0.05) compared 
to control, whereas M1 exposure between infected and control animals showed no significant 
difference following a sub-saturating oral dose of pafuramidine.     
 A reduced pafuramidine metabolic clearance was expected to reduce systemic levels 
of furamidine.  Unexpectedly, an increase in furamidine exposure of as much as a 3-fold was 
observed in infected animals compared to controls irrespective of the route of administration.  
These results suggested that a mechanism involved in the hepatic disposition of furamidine is 
altered during infection.  To date the hepatic disposition of furamidine has not been studied 
in detail.  However, mass balance studies with radiolabeled pafuramidine show that various 
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mechanisms are involved in the hepatic disposition of furamidine including biliary 
elimination, organ sequestration, metabolic glucuronide conjugation, and basolateral export 
into systemic circulation.  Among these mechanisms biliary elimination and organ 
sequestration accounted for the most important mechanisms of furamidine disposition (24).  
As a polar molecule, furamidine relies on drug transporters to enter and exit cells (25).  
Altered protein expression in one of these transporters was a potential explanation for the 
observed results.  Recently, down-regulation of mRNA and protein expression of the biliary 
efflux transporters MRP2 and BSEP were shown to be mediated by the pro-inflammatory 
cytokines IL-6 and TNF-α in human hepatocytes (39), supporting the notion that infection 
could have an effect on the elimination of furamidine. 
 In situ bile duct cannulation experiments with control and infected animals showed 
that trypanosomal infection causes a significant decrease (p < 0.05) in the biliary excretion of 
furamidine (Figure 3.8) indicating that altered biliary excretion due to trypanosomal infection 
may in part explain the observed increased exposure of furamidine in infected animals.  
Previous studies have established that significant increases in plasma exposure can result 
from a reduction in biliary excretion.  Studies with Mrp2-deficient rats showed that, 
compared to control, the major polar metabolites of troglitazone, troglitazone-sulfate (TRO-
sulf) and troglitazone-glucuronide (TRO-gluc), were elevated in plasma by 2- and 50-fold, 
respectively (20).  Moreover, it was demonstrated that compensatory up-regulation of 
basolateral transporters (i.e., Mrp3) occured during cholestatic conditions in response to 
diminished or abolished canalicular transporters such as Mrp2, indicating that enhanced 
basolateral excretion is possible under conditions of canalicular transport impairment (9, 10, 
48).   
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 Despite the observed changes in furamidine biliary excretion rate during the in situ 
bile cannulation experiments with infected animals, additional mechanisms may also 
contribute to the increase in plasma exposure of furamidine.  Down-regulation of phase II 
enzymes including UGT1A4, UGT2B4 and UGT2B7 was observed in human liver tissues 
with extensive inflammation, suggesting that decreased conjugation of furamidine also could 
occur (5).  Furamidine glucuronide conjugates were not detected in either control or infected 
animals in the in situ bile cannulation experiments (0-60 min) perhaps due to the short 
duration of the study.  Another important component in furamidine disposition is hepatic 
accumulation.  Following pafuramidine oral administration (10 mg/kg or 27 µmol/kg) to 
healthy rats, a 1300:1 furamidine liver to plasma ratio was observed 24 h post dose (24).  
These results were consistent with large amounts of furamidine detected 24 h pafuramidine 
post-dose (7.5 µmol/kg) in the livers of both infected and uninfected animals during the 
present investigation (data not shown).  Hence, small perturbations in tissue binding may be 
expected to increase the unbound fraction of furamidine and have effects on the overall 
elimination of furamidine (24).  To the authors’ knowledge, no reports have demonstrated 
that infection could alter the tissue binding capacity of any chemical. 
 Results of the current work suggest that trypanosomal infection can alter the 
pharmacokinetics and disposition of the prodrug pafuramidine and active metabolite, 
furamidine.  As hypothesized, trypanosomal infection decreased metabolic clearance of 
pafuramidine, resulting in significantly higher exposure compared to control.  Despite the 
enhanced pafuramidine exposure in infected animals, the magnitude of change was modest 
and is unlikely to be of toxicological concern.  Trypanosomal infection also increased the 
systemic exposure of the active furamidine, alleviating concerns of sub-therapeutic levels of 
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this active metabolite during infection.  This work also highlights that during infection, 
changes in pharmacokinetics of high extraction compounds would be more readily 
recognized under saturating conditions and will likely be less discernible when drug 
concentrations are within the linear range.      
 
F. FIGURES 
 
 
Pafuramidine
Furamidine
 
 
 
 
 
Figure 3.1 Chemical structures of prodrug and active diamidine. 
 114
 
 
0 1 2 3 4 5 6 7
0
25
50
75
100
125
Group 2
Group 3
Group 1
Days post-infection
Pa
ra
si
te
m
ia
 
Pa
ra
si
te
m
ia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Time course of parasitemia in T. b. brucei infected Sprague-Dawley rats.  
Data represent mean parasitemia levels ± SD in rats infected with 4 x 104 T. b. brucei (S247) 
three days post infection, (▲) group 1 (n=6); five days post-infection (○) group 2 (n=6); and 
six days post-infection, (●) group 3 (n=6 except for the last time point n=2).  Blood parasites 
were counted using a light microscope (objective X40).  
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Figure 3.3 Representative histology slides of liver and kidney sections of T. b. brucei 
infected Sprague-Dawley rats and un-infected controls.  (A)  Liver section of a control rat.  
Typical architecture of the liver with parenchymal cell chords irradiating from the portal 
triad.  H&E, objective X10. (B) Infected liver at day 3 post-infection (group 1). Parenchymal 
cells show normal architecture with chords irradiating from central vein. Presence of 
inflammatory cells is seen in the bottom right corner of the central vein opening.  No areas of 
focal necrosis or tissue damage are observed.  H&E, objective X10.  (C) Infected liver at day 
5 post-infection (group 2).  Presence of inflammatory cells is evident around the portal triad 
with mild infiltration into the parenchymal tissue.  H&E, objective X10.  (D) Section of the 
renal cortex of a control rat.  Glomerulus and proximal tubules show normal architecture. 
H&E, objective X10.  (E) Infected kidney at day 3 post-infection (group 1). No changes are 
observed from control.  H&E, objective X40.  (F) Infected kidney at day 5 post-infection 
(group 2). Minimal presence of interstitial inflammation.  H&E, objective X10.   
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Figure 3.4 Relationship between pafuramidine and furamidine exposure (AUC0-12) and 
dose in control and T. b. brucei infected Sprague-Dawley rats.  Black bars (pafuramidine) 
and white bars (furamidine) represent the mean ± SD. 
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Figure 3.5 Pafuramidine (A) and furamidine (B) mean plasma concentration-time 
profiles in control (●) or T. b. brucei infected (○) Sprague-Dawley rats following a 1.45 
µmol/kg intravenous infusion (30 min).  The data represent mean ± SD of at least four 
animals. 
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Figure 3.6 Pafuramidine (A) and furamidine (B) mean plasma concentration-time 
profiles in control (●) or T. b. brucei infected (○) Sprague-Dawley rats following oral 
administration of a 7.5 µmol/kg dose.  The data represent mean ± SD of at least four animals. 
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Figure 3.7 Pafuramidine (A) and furamidine (B) mean plasma concentration-time 
profiles in control (●) or T. b. brucei infected (○) Sprague-Dawley rats following oral 
administration of a 25 µmol/kg dose.  The data represent mean ± SD of at least five animals. 
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Figure 3.8 Mean M1 plasma concentration-time profiles in control (■) or T. b. brucei 
infected (□) Sprague-Dawley rats following oral administration of a 7.5 µmol/kg (A) or a 
25 µmol/kg (B) pafuramidine dose.  The data represent mean ± SD of at least four animals. 
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Figure 3.9 Biliary excretion rates of furamidine in control and infected Sprague-Dawley 
rats following intraduodenal administration of 7.5 µmol/kg pafuramidine.  Bars represent the 
mean excretion rate ± SD of n=3 rats at each collection interval (with the exception of 40-50 
n=2).  Significantly lower biliary excretion rates were seen in infected rats compared to 
controls p< 0.01.  ND. Not detected. 
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Figure 3.10 Bile flow in control and infected Sprague-Dawley rats.  Bars represent the 
mean bile flow ± SD of n=3 rats at each collection interval (with the exception of 40-50 n=2). 
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G. TABLES 
Table 3.1 Summary of hematological and biochemical marker values of liver and kidney 
function in control and T. b. brucei infected Sprague-Dawley rats (group1). 
 
  Day of Infection 
Marker (unit) Controla Day 1b Day 2b Day 3b 
White Blood Cells (103/µL) 11.3 (2.5) 11.1 (2.6) 10.7 (2.1) 6.2 (2.4)** 
Red Blood Cells (106/µL) 6.6 (0.4) 6.8 (0.6) 6.8 (0.4) 6.2 (1.5) 
Hematocrit (%) 36.0 (2.2) 36.7 (2.3) 36.2 (1.5) 33.6 (7.7) 
Alanine Aminotransferase (IU/L) 39.9 (7.2) 56.3 (25.6) 51.7 (26.9) 42.2 (12.6) 
Total Bilirubin (mg/dL) <0.1 (ND) 0.3 (0.2) 0.2 (0.0) 0.5 (0.6) 
Total Protein (g/dL) 5.4 (0.5) 5.6 (0.7) 5.6 (0.7) 5.6 (0.8) 
Blood Urea Nitrogen (mg/dL) 13.8 (1.6) 16.2 (3.1) 14.8 (3.0) 14.2 (3.7) 
Serum Creatinine (mg/dL) 0.3 (0.1) 0.3 (0.2) 0.3 (0.1) 0.3 (0.1) 
 
a. Data represent mean of n=12 animals (±SD). 
b. Data represent mean of n=6 animals  (±SD).  
ND: Not determined (the values of ten out of 12 rats were <0.1). 
** Significant at p < 0.01. 
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Table 3.2 Summary of hematological and biochemical marker values of liver and kidney function in control and T. b. brucei 
infected Sprague-Dawley rats (group 2). 
 
  Day of Infection 
Marker (unit) Controla Day 1b Day 2b Day 3b Day 4b Day 5b 
White Blood Cells (103/uL) 11.3 (2.5) 16.4(7.8) 18.4 (9.4)* 7.9 (2.6) 7.1 (1.7) 3.4 (2.3)* 
Red Blood Cells (106/uL) 6.6 (0.4) 6.6 (0.2) 6.9 (0.3) 6.6 (1.3) 6.6 (0.6) 6.1 (0.8) 
Hematocrit (%) 36.0 (2.2) 35.7 (1.1) 37.7 (1.6) 36.4 (7.1) 35.6 (2.6) 33.0 (4.1) 
Alanine Aminotransferase (IU/L) 39.9 (7.2) 49.0 (10.7) 42.3 (10.7) 47.7 (16.8) 144.7 (54.4)* 358 (178)** 
Total Bilirubin (mg/dL) <0.1 (ND) <0.1 (ND) 0.2 (0.0) 0.6 (0.7) 0.4 (0.4) 0.2 (0.1) 
Total Protein (g/dL) 5.4 (0.5) 5.5 (0.9) 6.6 (3.5) 5.8 (0.9) 5.6 (0.7) 5.9 (0.7) 
Blood Urea Nitrogen (mg/dL) 13.8 (1.6) 14.8 (2.3) 13.5 (1.6) 12.5 (1.9) 17.2 (2.9) 20.4 (5.4)** 
Serum Creatinine (mg/dL) 0.3 (0.1) 0.4 (0.1) 0.3 (0.1) 0.3 (0.1) 0.2 (0.0) 0.3 (0.1) 
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a. Data represent mean of n=12 animals (±SD). 
b. Data represent mean of n=6 animals (±SD).  
ND: Not determined (the values of ten out of 12 rats were <0.1). 
* Significant at p < 0.05. 
** Significant at p < 0.01. 
 
 
Table 3.3 Pharmacokinetic parameters of pafuramidine and furamidine after intravenous 
administration of 1.45 µmol/kg pafuramidine to control and infected rats 
 
 Controla Infecteda 
Pafuramidine  
AUC 0 -12 (µmol*h/L) 0.65 (17) 0.58 (23) 
AUC 0 - ∞ (µmol*h/L) 
Vss (L/kg) 
0.74 (13) 
8.11 (50) 
0.59 (24) 
3.85 (18)* 
CL (L/h/kg) 1.95 (12) 2.45 (22) 
t½ (h) 4.67 (59) 1.80 (36)* 
Furamidine  
Cmax (µmol/L) [median (range)] 0.08 (0.06-0.11) 0.13 (0.10-0.20)** 
Tmax (h) [median (range)] 0.25 (0.08-0.5) 0.25 (0.08-1) 
AUC 0 -6(µmol*h/L) 0.12 (23) 0.19 (23)** 
AUC 0 - ∞ (µmol*h/L) 
Vss (L/kg) 
0.17 (40) 
N/A 
ND 
N/A 
CL (L/h/kg) N/A N/A 
t½ (h) 4.07 (66) 1.78 (8.2)** 
 
a. Data represents the geometric mean and CV% of n=6 unless otherwise indicated.  
ND: Not determined.  Estimated parameter did not meet acceptance criterion (extrapolated area 
>25%).  
N/A: Not applicable 
* Significant at p <0.05. 
** Significant at p <0.01. 
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Table 3.4 Pharmacokinetic parameters of pafuramidine, M1 and furamidine after oral 
administration of 7.5 and 25 µmol/kg pafuramidine to control and infected rats 
 Controla Infecteda 
Pafuramidine   
Dose (µmol/kg) 7.5 7.5 
Cmax (µmol/L) [median (range)] 0.24 (0.09 - 0.5) 0.33 (0.13 - 0.62) 
Tmax (h) [median (range)] 1 (0.5 - 2) 1 (0.5 - 2) 
AUC 0 -12 (µmol*h/L) 0.58 (88) 1.00 (42) 
AUC 0 - ∞ (µmol*h/L) 0.67 (82) 1.09 (37) 
CLpo (L/h/kg) 11 (90) 6.9 (45) 
t½ (h) 3.9 (87) 2.4 (44) 
M1  
Cmax (µmol/L) [median (range)] 0.17 (0.03 - 0.27) 0.19 (0.076-0.26) 
Tmax (h) [median (range)] 2 (1 – 4) 1 (0.5 – 2) 
AUC 0 -12 (µmol*h/L) 0.37 (71) 0.63 (26) 
AUC 0 - ∞ (µmol*h/L) 0.45 (64) 0.75 (16) 
t½ (h) 2.8 (40) 3.2 (69) 
Furamidine   
Cmax (µmol/L) [median (range)] 0.03 (0.01 - 0.05) 0.08 (0.05 -0.15) 
Tmax (h) [median (range)] 1 (0.5 -1) 2 (2 -12) 
AUC 0 -12 (µmol*h/L) 0.15b 0.47 (53) 
AUC 0 - ∞ (µmol*h/L) 0.17b ND 
t½ (h) 3.7b 8.8 (80) 
Pafuramidine   
Dose (µmol/kg) 25 25 
Cmax (µmol/L) [median (range)] 1.88 (1.00 - 2.07) 1.72 (1.5 - 2.2) 
Tmax (h) [median (range)] 1 (0.5-1) 1(1-1) 
AUC 0 -24(µmol*h/L) 5.49 (9) 7.41 (16)** 
AUC 0 - ∞ (µmol*h/L) 5.55 (8.1) 7.43 (15)** 
CLpo (L/h/kg) 4.50 (7.4) 3.37(14) 
t½ (h) 3.3 (41) 2.8 (13) 
M1  
Cmax (µmol/L) [median (range)] 0.78 (0.55-0.97) 0.31 (0.29-0.76) 
Tmax (h) [median (range)] 1 (0.5-1) 1 (0.5-2) 
AUC 0 -12 (µmol*h/L) 2.40 (21) 1.64 (10)** 
AUC 0 - ∞ (µmol*h/L) 2.54 (22) 1.74 (15)* 
t½ (h) 2.4 (34) 2.6 (57) 
Furamidine  
Cmax (µmol/L) [median (range)] 0.57 (0.33-0.77) 0.72 (0.62 - 1.0) 
Tmax (h) [median (range)] 2 (1 - 4) 1 (1 - 4) 
AUC 0 -24(µmol*h/L) 3.13 (15) 6.01 (19)*** 
AUC 0 - ∞ (µmol*h/L) 3.28 (14) 6.76 (19)*** 
t½ (h) 5.3 (25) 7.3 (34) 
a. Data represents the geometric mean and CV% of at least six animals unless otherwise indicated. 
b. Data was obtained from mean analysis of n=4.  At 12 h the data of only two rats was above the 
lower limit of quantification. 
ND: Estimated parameter did not meet acceptance criteria (extrapolated area >25%).  
* p<0.05, **p<0.01, ***p<0.001
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CHAPTER 4 
 
 
 
 
A SEMI-PHYSIOLOGIC PHARMACOKINETIC MODEL PREDICTS THE 
EFFECTS OF DECREASED ENZYME CAPACITY ON DRUG EXPOSURE 
 
 
 
 
A. INTRODUCTION 
 Pharmacokinetic studies described in this dissertation (Chapter 3) showed that dose 
and route of administration were important factors to discern the effects of decreased enzyme 
capacity triggered by infection, resulting in altered pharmacokinetics.  The observations 
conformed to the concepts of the well-stirred model of hepatic clearance (Shand et al., 1975).  
With these concepts, predictions of the effects of decreased enzyme capacity, due to infection 
or inflammation, on systemic exposure were generated by simulating different scenarios 
where doses in the linear and saturating range of metabolism were administered orally or 
intravenously.  Predictions from simulations representing impaired metabolism were 
compared to simulations representing baseline metabolic capacity.  Results supported our 
experimental observations, where the maximum change in magnitude of exposure occurred 
when a compound was given orally and the dose given saturated metabolism. 
B. METHODS 
 A semi-physiologic pharmacokinetic model was developed according to methods 
described by Kanamitsu et al. with modifications (Kanamitsu et al., 2000).  For simulations 
of intravenous administration, the model included three compartments representing the portal 
vein, liver and blood (Figure 4.1).  For simulations of oral administration the same model 
was used with the exception that the gut lumen compartment was added (Figure 4.2).  The rat 
physiologic parameters used were obtained from available literature and are listed in Table 
4.1, and the pharmacokinetic parameters are listed in Table 4.2.  Drug doses were selected to 
represent drugs with high hepatic extraction (E > 0.7) or low hepatic extraction (E < 0.3), 
where extraction (E) represents the ratio of hepatic clearance to blood flow (Shand et al., 
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1975).  The value of liver blood flow (Q) used to calculate hepatic clearance was 20 mL/min 
(Houston and Carlile, 1997).  High and low intrinsic clearance (Clint) values were according 
to the ranges defined by Houston (1997), where a high extraction drug Clint ranged from 50-
10000 mL/min, and a low extraction drug Clint ranged from 0.1-10 mL/min, normalized to 
the standard weight of a rat (0.25 kg) (Houston and Carlile, 1997).  Values for Vmax and Km 
were selected to generate either high or low Clint values (Table 4.2).  Since the model 
included a liver compartment, a temporal description of the drug concentration in this 
compartment was incorporated.  Metabolic saturation was defined when concentrations in the 
liver reached values above the set Km.  The following assumptions were made: 1) absorption 
was a first-order process, 2) hepatic metabolism was the sole means of systemic clearance, 3) 
metabolism was governed by Michaelis-Menten kinetics, 4) drug partitions to blood and 
tissue equally (Kp =1), and 5) plasma protein binding was negligible (fu=1).  Simulations 
were performed using the software Berkeley Madonna v8.3.18 (University of California at 
Berkeley, Berkely, CA). 
C. RESULTS 
 Simulations suggested that the most drastic changes in systemic exposure will occur 
when a high extraction drug is administered orally at concentrations that saturate metabolic 
clearance.  Modest changes are expected to occur for drugs that are high or low extraction, 
and are dosed orally, with resulting systemic concentrations that do not saturate metabolism.  
Minimal changes are expected to occur in most scenarios when drugs are administered 
intravenously.  Results for all simulations are presented in Tables 4.3 and 4.4, and a scheme 
summarizing all possible scenarios is presented in Figure 4.3.
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D. DISCUSSION 
 It has been widely recognized that infectious disease and inflammation elicits down-
regulation of DMEs, resulting in decreased protein expression or decreased enzyme capacity.  
The consequences of DME down-regulation have clinical implications and were recently 
reported to affect drug development.  In the clinic down-regulation of DMEs is often 
manifested as decreased drug clearance/increased exposure of drugs with the potential of 
causing untoward side effects or toxicity (Kraemer et al., 1982; de Leon and Diaz, 2003).  In 
drug development down-regulation of DMEs has been reported as a source of increased 
pharmacokinetic variability (Schmith and Foss, 2010).  Despite the significant progress that 
has been made to understand the molecular mechanisms of DME down-regulation, to date 
there is not a strategy to predict the changes that this phenomenon will have on drug 
pharmacokinetics.  Based on results obtained from pharmacokinetic studies described in this 
dissertation work and pharmacokinetic concepts of the well-stirred model of hepatic 
clearance, predictions of relative changes in systemic drug exposure were generated by 
simulating different scenarios of dose and route of drug administration.  Simulations were 
focused on predicting changes in systemic exposure as opposed to systemic clearance, since 
systemic exposure is most often associated with driving pharmacological drug action or side 
effects.  Predictions of systemic drug exposure in a system where enzyme capacity was 
decreased by 25% were compared to predictions from a system working at baseline enzyme 
capacity.   A 25% decrease in enzyme capacity was selected as a conservative estimate of 
DME down-regulation during inflammation or infection; however, studies have shown that 
decreased CYP protein expression induced by different infectious stimuli could range from 
20-90% (Table 1.1).  Thus the exposure changes obtained from these predictions potentially 
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underestimate the degree of exposure change that may occur in cases of greater enzyme 
down-regulation.   
 Model predictions showed that the largest changes in systemic exposure (2.3-fold) are 
expected when a high extraction drug is administered orally at a dose that saturates metabolic 
clearance.  These results were consistent with the experimental observations described in 
Chapter 3, where significant increases in pafuramidine (a high extraction drug) exposure was 
observed in infected animals compared to uninfected controls when this agent was 
administered at an oral dose that saturated metabolism.   To the authors’ knowledge there are 
no examples in the literature describing similar observations, potentially due to the large 
number of low extraction or metabolically stable drugs, which often have favorable 
pharmacokinetic properties as therapies for oral administration.  
 Model predictions for high or low extraction drugs given orally at sub-saturating 
doses of metabolism showed modest changes in systemic drug exposure, consistent with 
exposure changes reported in the literature.  For example, a modest elevation in systemic 
exposure (1.3-fold) was reported for the low extraction drug quinine when it was 
administered to patients with chronic liver disease at a dose that achieved systemic 
concentrations that did not saturate metabolism (Cmax =10 µM; Km=105 µM) (Auprayoon et 
al., 1995; Zhao and Ishizaki, 1997).   Although systemic exposure values were not reported, 
three independent studies showed modest transient elevations in the steady-state 
concentration of clozapine (2- to 3-fold) in patients temporarily afflicted with infectious 
disease.  In the case of pafuramidine, there was a trend for increased systemic exposure in 
infected animals compared to controls when the drug was dosed at sub-saturating 
concentrations; however, the increase was not statistically significant.   
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 Model predictions showed minimal changes in systemic exposure for either low or 
high extraction drugs that were dosed intravenously, suggesting that in most cases down-
regulation of DMEs will not have effects on the exposure of drugs whose dose regimen is via 
intravenous injection.   The simulations were consistent with experimental observations for 
pafuramidine when it was dosed intravenously, where no changes in systemic exposure were 
observed in infected animals compared to controls.  
 The implications of altered systemic exposure of drugs need to be made in the context 
of therapeutic index.  For example, even in cases in which large systemic exposure changes 
are expected, if the therapeutic index of a drug is large the clinical implications of the 
changes will be negligible.  Conversely, in cases where small or modest changes in systemic 
exposure are expected, untoward effects may be experienced in the case of a narrow 
therapeutic index drug, thus making the modest changes predicted by these simulations for 
low extraction drugs potentially important.  This was exemplified by two clinical examples 
involving theophylline and clozapine, both low extraction compounds, where decreased 
metabolism due to infectious disease resulted in moderate to severe toxicity, despite 
exhibiting only modest changes (2- to 3-fold) in steady-state concentrations.   
 Simulations conducted to predict the effect of decreased enzyme capacity on drug 
systemic exposure supported experimental observations described in this dissertation 
(Chapter 3).  Predictions show that minimal effects on pharmacokinetics will be observed 
when drugs are given intravenously, regardless of whether the drug is high or low extraction.  
Modest to significant changes will be observed when a drug is dosed orally, with the most 
significant effects on drugs that are high extraction and are given at doses that saturate 
metabolism.  Taken together, this analysis shows that, impaired drug metabolism due to 
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decreased enzyme capacity (25%) modestly affects drug exposure (maximum observed 
change 2.3-fold).  These results may explain why there are few examples of altered 
pharmacokinetics of drugs in the clinic taking into consideration the promiscuity of infection 
and inflammation in human disease.  
 
E. FIGURES 
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Figure 4.1 Model used for simulations of intravenous administration of drug.  X0 
represents dose, Q represents blood flow, Vmax represents the maximum velocity and Km 
represents the half maximum velocity. 
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Figure 4.2 Model used for simulations of oral administration of drug.  X0 represents dose, 
Q represents blood flow, Vmax represents the maximum velocity and Km represents the half 
maximum velocity. 
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Figure 4.3 Scheme depicting the effects of decreased enzyme capacity (25%) on the AUC of drugs.  Values represent 
AUCinfected/AUCcontrol.  IV: Intravenous administration, PO: Oral administration, HE: High Extraction and LE: Low Extraction 
 
 F. TABLES 
 
Table 4.1 Physiological parameters used for semi-physiologic pharmacokinetic model  
Parameter Value Units Reference 
Body weight  (BW) 0.250 Kg  
Liver blood flow (Qliv) 17.08 mL/min (Brown et al., 1997) 
Gastrointestinal blood flow (Qgut) 7.32 mL/min (Brown et al., 1997) 
Liver Partition Coefficient (Kp) 1   
Liver Volume (Vliv) 9.15 mL (Brown et al., 1997) 
Portal Volume (Vportal) 1 mL (Kanamitsu et al., 2000) 
Systemic Volume (Vsyst) 18.5 mL (Brown et al., 1997) 
 
 
 
 
 
 
 
 
Table 4.2 Pharmacokinetic parameters used for simulations of oral and intravenous 
administration 
 Control Enzyme Capacity 25% Decrease Enzyme Capacity 
 HE LE HE LE 
Vmax(µmol/min) 120 10 90 7.5 
Km (µmol/mL) 2 2 2 2 
Clint (mL/min) 60 5 45 3.75 
fa  1 1 1 1 
fu 1 1 1 1 
ka (1/min) 0.03 0.03 0.03 0.03 
HE High Extraction 
LE Low Extraction 
Vmax Maximum velocity 
Km Half maximum velocity 
Clint Intrinsic clearance 
fa Fraction absored 
fu Unbound fraction 
ka First-order rate constant for absorption 
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 Table 4.3 Results of simulation for intravenous administration 
 
Control Enzyme Capacity 
Dose 
(µmol/kg) 
Saturating 
or Linear 
Dose 
Hepatic 
Extraction
Cmax, liver 
(µmol/mL)
Cmax, blood 
(µmol/mL)
AUC blood 
(µmol•min/mL) 
AUC 
ratio 
35 Linear 0.10 0.47 0.51 - 
700 Saturating HE
a 3.05 9.46 13 - 
35 Linear 0.25 0.47 2.2 - 
700 Saturating LE
b 5.6 9.5 93 - 
25% Decrease Enzyme Capacity 
Dose 
(µmol/kg) 
Saturating 
or Linear 
Dose 
Hepatic 
Extraction
Cmax, liver 
(µmol/mL)
Cmax, blood 
(µmol/mL)
AUC blood 
(µmol•min/mL) 
AUC 
ratioe 
35 Linear 0.12 0.47 0.57 1.12 
700 Saturating HE
c 3.55 9.46 15 1.15 
35 Linear 0.25 0.47 2.2 1.00 
700 Saturating LE
d 5.7 9.5 123 1.32 
HE High Extraction 
LE Low Extraction 
a. Vmax = 120 µmol/min, Km = 2 µmol/mL 
b. Vmax = 10 µmol/min, Km = 2 µmol/mL 
c. Vmax = 90 µmol/min, Km = 2 µmol/mL 
d. Vmax = 7.5 µmol/min, Km = 2 µmol/mL 
e. Ratio of AUC for 25% decreased enzyme capacity over AUC for matched control 
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Table 4.4 Results of simulation for oral administration 
 
Control Enzyme Capacity 
Dose 
(µmol/kg) 
Saturating 
or Linear 
Dose 
Hepatic 
Extraction
Cmax, liver 
(µmol/mL)
Cmax, blood 
(µmol/mL)
AUC blood 
(µmol•min/mL) 
AUC 
ratio 
800 Linear 0.09 0.09 3.2 - 
16000 Saturating HE
a 6.55 6.52 157 - 
800 Linear 1.10 1.10 50 - 
16000 Saturating LE
b 100.2 100.2 6220 - 
25% Decrease Enzyme Capacity 
Dose 
(µmol/kg) 
Saturating 
or Linear 
Dose 
Hepatic 
Extraction
Cmax, liver 
(µmol/mL)
Cmax, blood 
(µmol/mL)
AUC blood 
(µmol•min/mL) 
AUC 
ratioe 
800 Linear 0.13 0.12 4.4 1.38 
16000 Saturating HE
c 12.7 12.7 355 2.26 
800 Linear 1.43 1.43 72 1.44 
16000 Saturating LE
d 107.4 107.4 7175 1.15 
HE High Extraction 
LE Low Extraction 
a. Vmax = 120 µmol/min, Km = 2 µmol/mL 
b. Vmax = 10 µmol/min, Km = 2 µmol/mL 
c. Vmax = 90 µmol/min, Km = 2 µmol/mL 
d. Vmax = 7.5 µmol/min, Km = 2 µmol/mL 
e. Ratio of AUC for 25% decreased enzyme capacity over AUC for matched control 
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CHAPTER 5 
 
 
 
 
CONCLUSIONS 
 
 
 
 
 
 
 
 Inflammation is an important component of the immune response, which is triggered 
upon tissue injury or invasion of a host by an infectious organism.  Inflammation also plays 
an integral role in the pathophysiology of many chronic diseases, including diabetes, 
cardiovascular disease, advanced cancer and rheumatoid arthritis (Libby, 2007).  Data 
accumulated over the past three decades demonstrate that molecular effectors of 
inflammation (i.e., cytokines and nitric oxide) can modulate expression and function of 
DMEs and DTs (Aitken et al., 2006; Morgan et al., 2008).  The degree of modulation of 
particular DMEs and DTs depends on the inflammatory molecular effector imposing the 
challenge and/or infectious agent examined (Abdel-Razzak et al., 1993; Le Vee et al., 2009).  
In some cases, modulatory effects were shown to differentially alter (i.e., up- or down-
regulate) particular CYPs, even in response to the same stimuli (Richardson et al., 2006; 
Yang and Lee, 2008).  In spite of these differences in response, the general effect of 
inflammation and infection on DMEs and DTs is down-regulation of mRNA/protein 
expression and/or decreased protein function (Renton, 2005).   
 Human African trypanosomiasis (HAT) is a parasitic disease that afflicts one of the 
poorest regions of the world, sub-Saharan Africa.  Chemotherapies for treatment of HAT are 
limited to a handful of drugs that are associated with moderate to severe toxicities, as well as 
impractical dosing regimens (Chapter 1).  Despite problems with these drugs, the last 
registration of a drug against HAT occurred over 30 years ago (Fairlamb, 2003).  As with 
other neglected diseases, efforts for discovery and development of new agents for treatment 
of HAT are undertaken largely by non-profit organizations and academic institutions.  
Among the few classes of compounds currently in development for first- and second-stage 
HAT are diamidine analogs of pentamidine, a drug that has long been used for treatment of 
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first-stage HAT.  Diamidines and their bis-O-methylamidoxime prodrugs have shown 
efficacy for both first-stage HAT (when parasites are confined to the hemolymphatic system) 
and the more challenging second-stage HAT (when parasites invade the central nervous 
system).  Metabolic activation of prodrugs is essential for generation of the 
pharmacologically active compounds (Ettmayer et al., 2004).  For example, the bis-O-
methylamidoxime prodrug pafuramidine, which was in development for treatment of first-
stage HAT, was shown to undergo complex biotransformation to generate the active 
diamidine metabolite, furamidine, in humans (Zhou et al., 2004).  This biotransformation 
pathway involved oxidative reactions catalyzed by CYP enzymes and reductive reactions 
catalyzed by cytochrome b5/NADPH b5 reductases (Saulter et al., 2005; Wang et al., 2007).  
Prior to this dissertation project, it was not known whether the bis-O-methylamidoxime 
prodrug, DB868, under investigation for second-stage HAT, required similar 
biotransformation as pafuramidine to generate the active diamidine metabolite, DB829, or 
whether the metabolic profile in humans would be similar to that in rats, a common pre-
clinical species used for drug development.  Additionally, because bioactivation of diamidine 
prodrugs would occur during active trypanosomal infection, it was not known whether down-
regulation of DMEs would have an effect on bis-O-methylamidoxime prodrug 
biotransformation to the corresponding active diamidine metabolite with observable effects 
on the pharmacokinetics of these agents. 
 In vitro and in vivo approaches were utilized in this dissertation project to address the 
following objectives: 1) characterize the biotransformation of the bis-O-methylamidoxime 
prodrug, DB868, to the pharmacologically active metabolite, DB829 and 2) ascertain, in a rat 
model of first-stage trypanosomiasis, whether trypanosomal infection diminishes conversion 
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of bis-O-methylamidoxime prodrugs to corresponding active diamidine metabolites using the 
prodrug, pafuramidine, and active metabolite, furamidine, as model compounds.  The central 
hypothesis was that trypanosomal infection will down-regulate metabolic bioconversion of 
bis-O-methylamidoxime prodrugs, thereby increasing systemic exposure to the prodrug and 
decreasing systemic exposure to the pharmacologically active diamidine.   
 Using human and rat liver microsomes and hepatocytes, the phase I biotransformation 
pathway of the bis-O-methylamidoxime prodrug, DB868, was elucidated (Figure 2.3).  It was 
demonstrated that DB868 was metabolized extensively by both human and rat liver enzymes.  
Four phase I intermediate metabolites were detected (M1-M4) in both species.  The M1 and 
M2 metabolites were formed by sequential O-demethylation reactions of DB868 and M1, 
respectively.  The M3, M4 and active DB829 metabolites were formed by N-dehydroxylation 
of M1, M2 and M4, respectively.  Additionally, a novel N-demethoxylation reductive 
reaction was identified, which produced the metabolite O-methylamidoxime/amidine (M3) 
directly from DB868.  These results showed that the biotransformation pathway of DB868 
mirrored that of the analog bis-O-methylamidoxime prodrug, pafuramidine, where similar 
sequential O-demethylation and N- dehydroxylation reactions preceded formation of the 
active diamidine, furamidine.  The only difference between the pafuramidine and DB868 
biotransformation pathways was the discovery of an N-demethoxylation reduction, 
contributing to the direct formation of the O-methylamidoxime/amidine metabolite M3 from 
DB868.  Insight into this unrecognized reaction was derived from kinetic analysis of 
intermediate metabolite formation, which was not carried out during characterization of 
pafuramidine biotransformation.  Hence, the possibility exists that this reaction also is part of 
the pafuramidine biotransformation pathway but was not recognized using traditional 
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methods (e.g., mass spectrometric methods and knowledge of common metabolic pathways), 
which highlights the value of kinetic modeling for identification of novel metabolic 
pathways.  Marked species differences were observed in the kinetics of M2 formation (M1-
O-demethylation), which may be of concern from a toxicologic perspective.  Formation of 
M2, the diamidoxime prodruct of M1, using both liver microsomes and hepatocytes of rats 
was minimal compared to humans.  This finding was consistent with different kinetics of M2 
formation, which was described in humans by an allosteric process and in rats by a linear 
process.  Allosteric formation of M2 in humans correlated with involvement of CYP1A2, 
known to have other substrates that exhibit allosteric kinetics (e.g., α-napthoflavone, pyrene, 
and 1-hydroxypyrene) (Sohl et al., 2008).  Despite the different kinetics observed for M2 
formation between species, based on the large S50 (18 µM) observed for allosteric formation 
of M2 in humans, it is unlikely that these kinetics will be observed clinically.   
 Formation of M2 (M1-O-demethylation) was catalyzed by CYP1A2 in humans, 
unlike formation of M1 (DB868-O-demethylation) which involved catalysis by both CYP4F 
and CYP1A2 in both human and rat liver microsomes.  The involvement of CYP4F in M1 
formation was in agreement with findings by Wang et.al., who demonstrated, with  human 
liver microsomes, that pafuramidine-O-demethylation was catalyzed primarily by CYP4F 
isoforms (Wang et al., 2006).  Collectively, these results suggested that bis-O-
methylamidoxime prodrugs show similarities in both biotransformation pathways and 
enzymes that catalyze these reactions.  
 Formation of the active diamidine, DB829, was negligible when DB868 was 
incubated with microsomes, whereas DB289 was detected readily when DB868 was 
incubated with hepatocytes from both species.  However, once formed in hepatocytes, 
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DB829 was exported slowly to the culture medium over time, with the majority of compound 
remaining trapped intracellularly.  This key finding suggested a temporal disconnect between 
rate of formation and appearance of DB829 in hepatocyte culture medium.  Because 
diamidines are dications at physiologic pH, they are unable to diffuse passively through 
membranes, and have been shown to rely on drug transporters to reach the site of action 
and/or to be eliminated (Ming et al., 2009).  Extensive accumulation of DB289 within 
hepatocytes suggested low affinity for carrier-mediated basolateral export or tight 
intracellular binding or sequestration.  Because the extent of DB829 
accumulation/sequestration was significant (relative to dose), and this process affected the 
kinetics of DB829 appearance in the medium, this phenomenon appeared characteristic of 
target-mediated drug disposition as described by Levy (Levy, 1994), who suggested that 
sequestration of drugs due to capacity-limited binding processes can affect the 
pharmacokinetics of drugs.  Results from these in vitro studies confirmed that in both 
humans and rats, biotransformation of the bis-O-methylamidoxime prodrug DB868 was 
similar to that of pafuramidine and that it relies on CYP- and cytochrome b5/NADPH b5 
reductase-mediated processes to generate the active diamidine, DB829.  Additionally, these 
studies served to recognize that aside from metabolism, basolateral export and/or intracellular 
accumulation/sequestration appeared to play an important role in the disposition of DB829.   
 To determine whether trypanosomal infection would have an effect on the 
pharmacokinetic behavior of bis-O-methylamidoxime prodrugs and their corresponding 
diamidines, the prodrug, pafuramidine, and metabolically formed diamidine, furamidine, 
were utilized as model compounds.  Initial studies focused on development and 
characterization of a rat experimental model of first-stage trypanosomiasis (Chapter 3).  
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Characterization of this model was conducted to determine that potential pharmacokinetic 
changes observed in infected animals were not a reflection of organ damage due to 
trypanosomal infection.  Sprague-Dawley rats were infected with the S427 strain of 
trypanosomes to mimic human first-stage infection.  The time-course of parasitemia was 
determined by blood counts following intraperitoneal inoculation with 104 cells.  A short 
(acute) infection was observed, with parasitemia peaking at day five, followed by death at 
day six.  Infection did not damage liver and kidney function, as reflected by histological 
evaluation during the course of infection.  Moderate elevation of biochemical markers of 
liver and kidney function (i.e., ALT and BUN, respectively) was observed as infection 
progressed, with the highest changes (9- and 1.4-fold, respectively) observed at day five of 
infection, concurrent with maximal parasitemia.  Marked elevation in ALT was not a 
concern, as it has been shown that inflammation induced by other infectious agents also has 
led to elevations in ALT (e.g., viral hepatitis) (Getachew et al., 2010).  Understanding of the 
time-course of parasitemia, and of any related biochemical and histological changes, served 
to select the optimal day to conduct pharmacokinetic studies.  Day four post-infection was 
chosen based on the criteria of active parasitic growth and minimal biochemical and 
histological changes.  These results suggest that this rat model of first-stage trypanosomal 
infection could be used to study effects of infection on pharmacokinetics of drugs other than 
diamidine analogs and their bis-O-methylamidoxime prodrugs.  
Upon characterization of a rat experimental model of first-stage trypanosomiasis, 
studies were conducted to evaluate the pharmacokinetics of intravenously and orally 
administered pafuramidine and metabolically formed furamidine.  When pafuramidine was 
administered as a 30-min intravenous infusion to control (uninfected) and infected rats, no 
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changes in pafuramidine clearance or systemic exposure (AUC0-12) were observed.  When 
pafuramidine was administered by oral gavage at a sub-saturating dose (7.5 μg/kg), there was 
a trend for decreased apparent oral clearance/increased systemic exposure (AUC0-12) in 
infected animals compared to uninfected animals.  In contrast, a significant increase in 
systemic exposure (AUC0-24) (1.3-fold) was observed in infected animals when pafuramidine 
was administered at an oral dose known to saturate pafuramidine clearance (25 µmol/kg).  
These dose and route-discrepant results were explained by the fact that pafuramidine was 
determined to be a high extraction ratio, or hepatic blood flow-limited, drug.  In this case, 
hepatic metabolism is so efficient (greater than 70% upon a single pass through the liver) that 
the limiting factor for pafuramidine clearance is the rate at which the agent is delivered to the 
liver via blood flow.  Therefore, when pafuramidine is given intravenously to control or 
infected animals, pafuramidine clearance and exposure would not be affected by down-
regulation of DMEs due to infection.  Similarly, when pafuramidine is administered orally at 
sub-saturating concentrations, down-regulation of DMEs due to infection are likely to cause 
minimal to no changes in pafuramidine systemic clearance/exposure.  At sub-saturating 
concentrations of substrate, the amount of DMEs is expected to greatly exceed substrate, 
regardless of the presence or absence of infection.  Thus, even if a portion of the enzyme 
pool is decreased in infected animals, changes in drug clearance may not be discernable 
under these conditions.  However, when administered orally at saturating doses, 
pafuramidine clearance will be limited by enzyme capacity.  Under these saturating 
conditions, diminished enzyme capacity due to infection will be reflected in increased 
pafuramidine systemic exposure (Chapter 3).  Together, results with pafuramidine suggested 
that infection decreased the metabolism of pafuramidine, suggesting down-regulation of the 
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enzyme(s) involved in pafuramidine-O-demethylation.  In humans, metabolism of 
pafuramidine was shown to be catalyzed by members of the CYP4F family (Wang et al., 
2006).  Preliminary data obtained during this investigation showed that pafuramidine-O-
demethylation also is catalyzed by members of the Cyp4f family in rats (unpublished results).  
Consistent with results presented in this dissertation, down-regulation of mRNA expression 
of Cyps 4f1, 4f4, 4f5, and 4f6 in primary rat hepatocytes has been shown upon direct 
stimulation with LPS (Kalsotra et al., 2003).  However, conflicting data regarding Cyp4f 
regulation during inflammation has been reported depending on the source of inflammatory 
stimulus.  For example, another investigation using rat hepatocytes demonstrated up-
regulation of Cyps 4f1, 4f4, 4f5, and 4f6 mRNA expression upon challenge with pro-
inflammatory cytokines IL-1, IL-6, and TNF-α (Kalsotra et al., 2007).  In contrast, challenge 
with the inflammatory mediators LPS or BaSO4 to rats had no effect on mRNA expression of 
Cyp4f1 and Cyp4f6 (Kalsotra et al., 2003).   
The observed differences in pafuramidine exposure after oral and intravenous 
administration prompted a systematic analysis of the effects of infection on drug systemic 
exposure using a semiphysiologic-pharmacokinetic model (Chapter 4).  This approach, based 
on concepts of the well-stirred model of hepatic clearance, served to confirm the 
interpretation of the dose and route-discrepant results observed for pafuramidine 
experimentally.  Additionally, this model was expanded to predict outcomes for low 
extraction, or capacity-limited compounds, which are characterized by inefficient metabolism 
(less than 20% upon a single pass through the liver) (Shand et al., 1975).  The variables in the 
model included high or low intrinsic clearance (corresponding to drugs with high or low 
hepatic extraction), doses in the linear (sub-saturating) or saturating range of drug 
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metabolism, and intravenous or oral administration.  This analysis not only supported 
findings in this investigation, but provided a framework from which the impact of infection 
on drug development can be considered, through illustration of different scenarios in which 
the pharmacokinetics of a given drug will be more or less sensitive to effects of infection or 
inflammation.  For example, the analysis showed that the largest effects of infection and 
inflammation (due to diminished enzyme/transporter capacity) will occur with a high 
extraction drug given at oral doses that will saturate metabolic/distributive clearance.  In 
contrast, little to no effect will be observed on the pharmacokinetics of a low extraction 
compound when administered intravenously (Chapter 4).   Unlike drug-drug interactions, 
where large (up to 300-fold) changes in drug systemic exposure have been reported 
(Fichtenbaum et al., 2002), the current analysis suggests that infection and inflammation are 
less likely to cause such marked effects.  This limited effect is supported by several 
observations in the clinic, in which the largest changes in pharmacokinetics (e.g., clearance) 
ranged between 2- to 4-fold (Table 1.3).  These modest changes in systemic exposure and 
clearance in vivo can be explained by the mechanism of the interaction at the molecular level.  
For example, decreased enzyme capacity results in changes in Vmax through suppression of 
the enzyme pool available for metabolic reactions.  Based on the Michaelis-Menten premise 
that the enzyme pool available for metabolism is much larger than the substrate to be 
consumed (Voet and Voet, 2004), modest reductions in the enzyme pool (mediated through 
cytokine or NO responses) are unlikely to have significant effects on the overall clearance of 
a substrate (see Chapter 3 for further discussion).  Moreover, depending on the contribution 
of a pathway to overall systemic clearance, compounds with multiple routes of clearance will 
be affected minimally if parallel pathways of clearance are unaffected by inflammation.  
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Accordingly, as also recognized by Renton (Renton, 2005), the largest effects of decreased 
enzyme/transporter capacity, due to infection or inflammation, on systemic exposure or 
clearance of a compound will be observed in instances where 1) the enzyme/transporter is the 
major contributor to systemic clearance, and 2) the decreased enzyme/transporter capacity is 
coupled with genetic polymorphisms or drug-drug interactions.  Furthermore, untoward 
effects or toxicity will be more likely when infection affects compounds with a narrow 
therapeutic window.   
 According to the central hypothesis underlying this work, reduction in metabolic 
clearance of pafuramidine in infected animals was expected to reduce systemic 
concentrations of furamidine, raising concerns about potential sub-therapeutic 
concentrations.  Unexpectedly, significant increases in furamidine systemic exposure were 
observed in infected animals compared to controls (up to 3-fold).  These increases were 
independent of dose and route of pafuramidine administration.  This outcome suggested that 
a mechanism involved in hepatic disposition of furamidine also was impaired during 
infection.  Although the mechanisms of furamidine disposition are not fully elucidated, rat 
mass balance excretion studies in which pafuramidine was dosed orally at 10 mg/kg (27 
µmol/kg) suggested that, second to tissue sequestration (29% of the dose at 48 h), biliary 
excretion of furamidine was an important contributor to its elimination (approximately 25% 
of the dose at 72 h), followed by glucuronidation of furamidine (10% of the dose at 48 h) and 
renal elimination (4% of the dose at 48 h) (Midgley et al., 2007).  To investigate potential 
mechanisms involved in the increased systemic exposure observed in infected animals, in 
situ bile cannulation experiments were conducted in control and infected animals.  Results 
from these experiments showed a significant decrease (12-fold) in biliary excretion of 
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furamidine in infected animals compared to controls, suggesting impairment of canalicular 
transporters involved in biliary excretion of furamidine as a potential mechanism that may 
explain the observed increased exposure of furamidine in infected animals (Chapter 3).  The 
transporters involved in biliary excretion of furamidine are not known; however, examples of 
down-regulation of mRNA and protein expression of the biliary efflux transporters MRP2 
and BSEP were shown to be mediated by the pro-inflammatory cytokines IL-6 and TNF-α in 
human hepatocytes (Vee et al., 2009), supporting the notion that infection could have an 
effect on elimination of furamidine.   
 Based on mass balance studies reported by Midgley et. al. (2007), another important 
component in furamidine disposition is hepatic accumulation.  To date, the mechanism of 
accumulation/sequestration of furamidine remains elusive.  It is possible that small 
perturbations in tissue sequestration/binding could increase systemic exposure during 
episodes of infection; however, this hypothesis has not been tested and merits further 
investigation.  During in situ bile cannulation experiments (0-60 min), the effects of infection 
on phase II metabolism was not ascertained since glucuronide conjugates of furamidine were 
not detected in bile from either control or infected animals .  Absence of  furamidine 
glucuronides in bile was due, potentially, to the short duration of the experiment; however, 
changes in glucuronide formation during infection is not expected to play a significant role in 
the increased furamidine exposure of infected animals, as glucuronidation is not a major 
contributor to furamidine disposition in rats.   
 Assuming that mechanisms of furamidine elimination in both rats and humans are 
similar, the increased systemic exposure of furamidine in infected animals could have 
positive implications, as it would alleviate concern that sub-therapeutic concentrations of 
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active diamidine will be achieved in the infected population.  Data from mass balance studies 
in uninfected rats and humans showed that, although biliary excretion was the second most 
important contributor to furamidine disposition in both species, the extent of biliary excretion 
between these two species differs, with biliary excretion in rats accounting for greater than 
70% of furamidine disposition compared to approximately 30% in humans at 168 h post dose 
(10 mg/kg and 100 mg/kg in rat and human, respectively) (Midgley et al., 2007; Huntingdon, 
2008).  This suggests that humans will be less sensitive to the effect of infection on biliary 
excretion of furamidine compared to rats, further reducing concern about the impact of 
infection on efficacy.   Unlike increased furamidine exposure observed in infected rats, 
human data from Phase IIa clinical trials (Immtech International, 2008) indicated that 
furamidine systemic exposure after 6 days of dosing in infected patients was comparable to 
that observed in healthy subjects that participated in Phase I trials, in which pafuramidine 
was dosed orally at 100 mg twice daily (Immtech International, 2002).  These results contrast 
the up to 3-fold increase in furamidine exposure observed in infected rats and may be 
explained by the lower contribution of biliary excretion to furamidine disposition in humans, 
which potentially is due to species differences in canalicular hepatic transporters.  Evidence 
for canalicular transporter differences between species was highlighted for Mrp2/MRP2, 
which was shown to play a more significant role in rats than in any other species (10-fold 
higher protein expression compared to human) (Li et al., 2009).  Comparable furamidine 
systemic concentrations during infection in patients did not appear to be due to compensation 
via increased renal elimination, which is a minor component of systemic furamidine 
elimination in the absence of infection, as similar amounts of furamidine in urine were 
reported between infected patients and healthy subjects.   
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 In addition to an impact on furamidine pharmacokinetics and efficacy, infection also 
may have implications for toxicity observed during extended Phase I trials with healthy 
volunteers (Pohlig G, 2008).  Assuming that the mechanism of toxicity was driven by tissue 
sequestration, an increase in furamidine exposure due to decreased biliary excretion during 
infection would not be expected to impact liver toxicity, as tissue levels within the liver will, 
potentially, remain unchanged and decreased biliary excretion/increased furamidine exposure 
would be driven largely by unbound furamidine concentrations.  In this scenario, kidney 
toxicity could be increased or remain unchanged depending on whether increased systemic 
furamidine concentrations lead to increased sequestration in the kidney.  If, however, the 
increase in furamidine systemic exposure during infection was due to a decrease in tissue 
sequestration, toxicity in both liver and kidney may be lessened in infected populations.   
 In contrast to results presented in this work, data from a Phase IIa study in African 
patients demonstrated that pafuramidine systemic exposure was reduced greatly (10-fold) 
compared to healthy subjects from a separate Phase I study.  A potential explanation for this 
discrepancy is differential regulation of CYP4F enzymes during infection between humans 
and rats, in which CYP4Fs appeared to be induced in humans during infection compared to 
apparent suppression observed in rats in the current investigation.  Differential regulation of 
CYP4Fs in rats between different experimental systems were highlighted above, where in 
vitro results of down-regulation for these enzymes was not reproduced in vivo using the same 
inflammatory stimulus.  The effects of inflammatory or infectious stimuli on regulation of 
CYP4Fs in humans have not been described and require further investigation. 
 The differential behavior of pafuramidine and furamidine between rats and humans 
during trypanosomal infection suggests that rats may not be a suitable model for anticipating 
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the impact of infection on human toxicity; however, the rat model of first-stage HAT 
infection can still be useful for development of compounds that do not undergo metabolic 
catalysis by CYP4Fs and that do not have biliary excretion as a major component of 
elimination. 
 In summary, prior to the studies described in this dissertation project, it was unknown 
whether bioconversion of bis-O-methylamidoxime prodrugs would be affected during active 
trypanosomal infection, thereby altering their pharmacokinetic profile and that of their 
corresponding active diamidine metabolites.  Based on literature knowledge, it was 
anticipated that impaired metabolism caused by infection would decrease clearance/increase 
systemic exposure of bis-O-methylamidoxime prodrugs of diamidine, resulting in diminished 
levels of the pharmacologically active diamidine metabolite.  Initial studies with the bis-O-
methylamidoxime prodrug DB868, currently under development for second-stage HAT, 
confirmed that metabolic bioconversion by at least two enzyme systems (e.g., CYP and 
cytochrome b5/NADPH b5 reductase) was an integral component in the generation of active 
diamidines.  Due to a lack of oral formulation for DB868, studies investigating effects of 
infection on the pharmacokinetics of bis-O-methylamidoxime prodrugs and their 
corresponding diamidines were conducted with the prodrug, pafuramidine, and the active 
diamidine, furamidine, whose pharmacokinetics were characterized previously.  To address 
this question, a rat model of first-stage trypanosomal infection was developed and 
characterized.  This model demonstrated that trypanosomal infection has an effect on the 
pharmacokinetics of bis-O-methylamidoxime prodrugs and their active diamidines, as shown 
by the increase in pafuramidine exposure (AUC) (<2-fold) following a 25 µmol/kg oral dose 
of pafuramidine, which appeared to be mediated by decreased metabolism via impaired 
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enzyme capacity elicited by infection.  The effects of decreased metabolism in infected 
animals on the pharmacokinetics of pafuramidine were discernable only when pafuramidine 
was administered orally at a saturating dose.  This observation was confirmed using a 
semiphysiologic model that produced results similar to experimental observations.  
Additionally, evidence presented in this investigation suggests that transport processes 
mediating the biliary excretion of the diamidine, furamidine, also are impaired during 
trypanosomiasis.  
 Although effects of infection on DMEs is widely recognized, there is little discussion 
within the literature on why changes in pharmacokinetics and pharmacodynamics are not 
observed more often in the clinic, despite the prominence of these conditions in humans.  The 
findings of this dissertation project begin to address this gap by furthering the knowledge of 
which pharmacokinetic characteristics influence how a compound will behave in the 
presence of inflammation or infection.  A quantitative framework is provided for anticipating 
the impact of inflammation and infection during drug development or drug therapy 
management.   
A. FUTURE DIRECTIONS 
 In spite of the insights gained regarding how infection affects the disposition of 
pafuramidine and furamidine, additional studies examining the role of trypanosomal 
infection on the different mechanisms involved in the disposition of furamidine are needed.  
For example, identification of the transporters involved in basolateral and biliary export of 
furamidine is integral to understanding furamidine disposition.  Additionally, little data are 
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available on the mechanism of diamidine tissue binding and consequent effects on 
pharmacokinetics.  The following studies are proposed: 
Identify transport protein(s) involved in the hepatobiliary disposition of furamidine. 
 In vitro, studies in this investigation showed that once generated from prodrug in the 
liver, the charged diamidine is unable to exit the hepatocyte via passive diffusion.  
Transporters localized on basolateral and canalicular membranes are likely to be involved in 
the translocation of diamidines into plasma and bile, respectively.  To date, the transporters 
responsible for furamidine basolateral export and biliary excretion remain unknown.  To 
understand fully the disposition of furamidine, studies determining the transporters involved 
in hepatobiliary disposition of furamidine are warranted.  Although not known to transport 
organic cations, candidate basolateral efflux transporters include the ATP-dependent MRP4 
and MRP5 (Konig et al., 1999; Madon et al., 2000; Assem et al., 2004; Ritter et al., 2005).  
These transporters may play a role in furamidine basolateral export, as it was recently 
demonstrated that in mdr1 deficient mice, pentamidine was removed from the brain by a 
member of the Mrp family (Sanderson et al., 2009).  Additionally, involvement of a 
bidirectional carrier-mediated mechanism should be examined with a special focus on 
transporters of small organic cations, such as OCT1, which was demonstrated to be localized 
on the basolateral membrane of hepatocytes (Meyer-Wentrup et al., 1998; Proctor et al., 
2008; Ming et al., 2009).  
 Evaluation of transporters involved in the biliary excretion of furamidine may 
include, but not be limited to, the canalicular efflux transporters MRP2, MATE1 and P-gp 
(Paulusma et al., 2000; Scheffer et al., 2000; Otsuka et al., 2005; Hiasa et al., 2006).  Focus 
should center on MATE1, as this transporter was shown recently to mediate the transport of 
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4',6-diamidino-2-phenylindole (DAPI), a structurally-related diamidine analog (Yasujima et 
al., 2010).  Another transporter that is a likely candidate for furamidine transport is the efflux 
transporter P-gp, since this transporter has wide substrate specificity (van der Sandt et al., 
2000; Mahar Doan et al., 2002).  Additionally, P-gp was shown recently to be involved in the 
biliary export of the organic cation tributylmethylammonium (TBuMa) through ion-pair 
complexation with bile salts (Song et al., 2010).  After identification of biliary transporter(s) 
involved in biliary excretion of furamidine, determination of relative changes in protein 
expression of these transporters could be evaluated in infected animals.     
Elucidate the mechanism of furamidine intracellular accumulation and effects on 
pharmacokinetics   
 Consistent with another report (Midgley et al., 2007), studies in this dissertation 
project showed that an important component of furamidine disposition is tissue accumulation 
(Chapter 3).  Intracellular accumulation of drugs could involve multiple mechanisms, 
including organelle sequestration or binding to intracellular components such as proteins or 
DNA.  For furamidine, the mechanism of accumulation in the liver and other organs is 
unknown but has been shown to have appreciable effects on disposition, as exemplified by a 
long terminal tissue half-life (~7 days, kidney) (Goldsmith, 2010).  Accumulation of 
diamidines in tissues poses challenges to dose selection and has implications for toxicity 
depending on the mechanism of accumulation (Kleiner et al., 1997; Santos et al., 2008).  In 
vitro studies should be undertaken to elucidate the mechanism of sequestration, including 
experiments examining lysosomal trapping (Gong et al., 2007; Kaufmann and Krise, 2007), 
mitochondrial sequestration (Duvvuri et al., 2004), and nuclear accumulation (Wilson et al., 
2005).  These studies could take advantage of the fluorescent properties of furamidine to 
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enable characterization of intracellular distribution and accumulation.  It is possible that tight 
binding to macromolecules such as DNA drives the pharmacokinetics of furamidine, in a 
similar manner to the mechanism known as target-mediated drug disposition, where capacity 
limited binding drives the overall disposition of an agent (Mager and Jusko, 2001; Levy et 
al., 2003; Mager, 2006).  Therefore, complimentary pharmacokinetic studies comprising 
intravenous dose escalation studies could be conducted to determine whether a dose-
dependent decrease in volume of distribution occurs, as is expected for drugs exhibiting 
target-mediated disposition. 
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Abstract: Diamidines 10a-g and 18a,b were obtained from dinitriles 9a-g and 15a,b by 
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acetoxyamidoximes. Dinitriles 9a-g were prepared via Suzuki reactions between arylboronic 
acids and arylnitriles.  Potential prodrugs 12a-f and 17 were prepared via methylation of the 
diamidoximes 11a-f and 16a. Significant DNA affinities for rigid-rod molecules were 
observed.  Compounds 10a, 10b, 10d, 18a, and 18b show IC50 values of 5 nM or less against 
Trypanosoma brucei rhodesiense (T. b. r.) and 10a, 10b, 10e, 18a, and 18b gave similar ones 
against Plasmodium falciparum (P.f.).  The dications, 10a, 10d, 10f, and 10g are more active 
than furamidine in vivo.  The prodrugs are only moderately effective on oral administration. 
Mouse liver microsome bioconversion of the methamidoxime prodrugs is significantly 
reduced from that of pafuramidine and suggests that the in vivo efficacy of these prodrugs is, 
in part, due to poor bioconversion. 
 
Contribution:  Metabolic Stability Experiments 
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and urine of healthy humans and compared with metabolites formed in vitro.  Volunteers 
were administered 2 g of piperacillin IV; blood, urine, and duodenal aspirates (obtained via a 
custom-made oroenteric catheter) were collected.  The metabolism of piperacillin in humans 
also was investigated in vitro using pooled human liver microsomes and sandwich-cultured 
human hepatocytes.  Piperacillin and metabolites were estimated by high-performance liquid 
chromatography with tandem mass spectrometry detection.  Piperacillin, desethylpiperacillin, 
and desethylpiperacillin glucuronide were detected in bile, urine, and human liver 
microsomal incubates.  Similar to the in vivo results, desethylpiperacillin was formed and 
excreted into bile canaliculi of sandwich-cultured human hepatocytes.  This is the first report 
of glucuronidation of desethylpiperacillin in vitro or in vivo.  The clinical method employed 
in this study to determine biliary clearance of drugs also facilitates bile collection as soon as 
bile is excreted from the gallbladder, thereby minimizing the exposure of labile metabolites 
to the intestinal environment.  This study exemplifies how a combination of in vitro and in 
vivo tools can aid in the identification of metabolites unique to the human species. 
 
Contribution: Phase I and Phase II metabolism experiments including microsomal, cytosolic 
and glucuronidation experiments. 
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compound in vitro and in vivo. 
Journal: Journal of clinical laboratory analysis 24(3):187-94. (2010) 
Authors: Goldsmith RB, Gray DR, Yan Z, Generaux CN, Tidwell RR, Reisner HM. 
Abstract: Human African trypanosomiasis (HAT), also called African sleeping sickness, is a 
neglected tropical parasitic disease indigenous to sub-Saharan Africa. Diamidine compounds, 
including pentamidine and CPD-0801, are potent anti-trypanosomal molecules.  The latter is 
a potential drug in the development at the UNC based Consortium for Parasitic Drug 
Development.  An orally bioavailable prodrug of CPD-0801, DB868, is metabolized 
primarily in the liver to the active form.  A monoclonal antibody developed against a 
pentamidine derivative has shown significant reactivity with CPD-0801 (EC50 65.1 nM), but 
not with the prodrug (EC50 >18,000 nM).  An inhibitory enzyme-linked immunosorbent 
assay (IELISA) has been used to quantitatively monitor prodrug metabolism by detecting the 
production of the active compound over time in a sandwich culture rat hepatocyte system and 
in rats.  These results were compared with the results of the standard LC/MS/MS assay.  
Spearman coefficients of 0.96 and 0.933 (in vitro and in vivo, respectively) indicate a high 
correlation between these two measurement methods.  This novel IELISA provides a facile, 
inexpensive, and accurate method for drug detection that may aide in elucidating the 
mechanisms of action and toxicity of existing and future diamidine compounds. 
Contribution: Rat pharmacokinetic experiments following oral administration of 
25 µmol/kg DB868 
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Abstract 
 Aromatic diamidines are potent trypanocides.  Pentamidine has been used for more 
than 60 years to treat human African trypanosomiasis (HAT).  However, the drug must be 
administered parenterally and is active only against first stage HAT, prior to the parasites 
causing neurological deterioration through invasion of the central nervous system (CNS).  A 
major effort to design novel diamidines has led to the development of orally active prodrugs 
and, remarkably, a new generation of compounds that can penetrate the CNS.  Here we 
outline progress in the development of diamidines against HAT. 
Key words 
 
 Pentamidine, furamidine, diamidine, human African trypanosomiasis, sleeping 
sickness, drug metabolism, drug transport, blood brain barrier, clinical trial 
Introduction 
 Human African trypanosomiasis (HAT) is caused by parasitic protozoa of the brucei 
group of the genus Trypanosoma [1].  The disease is endemic in sub-Saharan Africa, where 
its distribution is determined by the habitat range of the tsetse fly vector that transmits the 
parasite.  HAT has two defined stages.  The first stage involves trypanosomes in the 
haemolymphatic system.  The late (or second) stage begins once parasites become manifest 
in the central nervous system (CNS), where their presence initiates a deterioration in 
neurological function, including disruptions to sleep/wake patterns that lend the name 
“sleeping sickness” to this stage of the disease.  
 Since a process of antigenic variation [2] has so far precluded vaccines against HAT, 
chemotherapy remains the only option in disease intervention at the level of affected 
individuals [3].  The concept of integrated control, diminishing transmission by tsetse flies 
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and reducing the infected population (the primary reservoir for infection) by active 
surveillance and drug treatment, is attractive [1].  However, HAT, which afflicts exclusively 
the world’s poorest populations, is largely neglected, and many challenges constrain 
progress. 
 Current drugs are generally unsatisfactory due to varying degrees of toxicity, a need 
for parenteral administration, prohibitive cost and distribution difficulties, all of which 
negatively impact use [3].  For first stage disease, prior to CNS involvement, two drugs are 
used: pentamidine for T. b. gambiense and suramin, largely for T. b. rhodesiense.  For late 
stage disease, melarsoprol (a melaminophenyl arsenical) has until recently been the first line 
drug of choice against gambiense disease and the only remedy for rhodesiense disease.  
Eflornithine has recently replaced melarsoprol as first line for late stage gambiense disease in 
many foci, but is of insufficient efficacy to treat the rhodesiense form.  In 2009, a 
combination therapy, eflornithine at reduced dose plus nifurtimox, has been placed on the 
WHO list of essential medicines.  The reduced dosing with improved tolerability, coupled 
with a perceived reduction in the risk for selecting drug resistance, has led to its 
recommendation as the first line treatment for late stage gambiense disease (P. Simarro, 
WHO personal communication).  However, new and improved drugs are still urgently 
needed. 
 The last few years have shown progress in seeking new drugs for HAT.  Several not-
for-profit initiatives followed a major campaign against HAT by WHO and Medecins Sans 
Frontieres (MSF), including the establishment of the Drugs for Neglected Diseases initiative 
(DNDi), a drug discovery unit for neglected diseases at the University of Dundee (Scotland, 
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UK), and the Consortium for Parasitic Drug Development (CPDD) centred at the University 
of North Carolina, USA [3].  
 Sir James Black, the Nobel prize-winning discoverer of beta blockers, noted 
insightfully that “the most fruitful basis for the discovery of a new drug is to start with an old 
drug”.  For HAT, the aromatic diamidine, pentamidine (fig 1), was introduced as the best of a 
relatively small number of this class in the 1930s.  Pentamidine, however, suffers several 
drawbacks.  The drug is inactive against late stage disease, must be administered by 
intramuscular injection and causes significant side effects, including hepatic toxicity and 
hyper- and hypoglycaemia.  The success of pentamidine, however, discouraged further work 
into diamidines until use of the drug against AIDS-associated Pneumocystis pneumonia 
rekindled interest in the class in the 1980s.  Numerous diamidines with pharmacological 
benefits over pentamidine have been identified, including orally available N-methoxy 
prodrugs.  One of these diamidines, furamidine (DB75, fig 1), which in its prodrug form, 
pafuramidine (DB289, fig 1), became the first HAT drug to enter a clinical trial pathway that 
conformed to contemporary standards in drug development. Unfortunately, renal toxicity that 
became evident in a cohort of volunteers in an extended Phase 1 safety trial several weeks 
after treatment halted development of pafuramidine (and its development is discontinued).  
The recent discovery of CNS-permeable diamidines offers hope for development of new 
drugs to potentially treat both first and second stage HAT.  
 In this article, we review our understanding of how diamidines enter and kill 
trypanosomes, how they distribute within the body and how they offer great potential as new 
drugs for use in the battle to eliminate HAT. 
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Figure 1 Structures of various aromatic diamidines 
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Diamidine modes of action and mechanisms of resistance 
 A definitive intracellular target, whose inhibition by diamidines underlies anti-
trypanosomal activity, remains elusive [3].  It is, however, clear that diamidines bind with 
high affinity to DNA and much work has focused on this interaction some of which we 
discuss here.  An extraordinary complex of intercatenated circular DNA that comprises the 
mitochondrial genome, the so-called kinetoplast that defines the Kinetoplastid taxon to which 
trypanosomes belong [4,5], has been proposed as a possible target.  Fluorescent diamidines 
bind to the kinetoplast within seconds of the parasite’s exposure to these compounds [6], and 
the kinetoplast disintegrates in diamidine-treated trypanosomes.  
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 Kinetoplast DNA comprises both minicircles and maxicircles.  The minicircles 
contain repeated AT base pair sequences that are in phase (i.e., on the same side of the DNA 
double helix), producing a bent helical conformation [7-9] that can be disrupted by 
diamidines [9]. Minicircles encode the small guide RNA molecules that template the 
remarkable process of RNA editing of precursor transcripts encoded by the maxicircles [10-
11].  Aromatic diamidines generally bind to the DNA minor groove in AT sequences of 4-5 
base pairs [12,13].  The amidines hydrogen-bond to the thymidine keto or adenosine N3 
groups at the floor of the minor groove, and the aromatic systems (or aliphatic with 
pentamidine) make van der Waals contacts with the groove walls. Electrostatic interactions 
between the two amidine charges and anionic charges on the DNA backbone provide 
additional stabilization for the complex. GC-containing sequences bind diamidines less well 
due to steric interferences from the guanosine amino group.  
Recent experiments [14,15] have revealed both the mitochondrion per se and the kinetoplast 
serve essential roles.  A caveat, however, arises in considering dyskinetoplastic strains of T. 
evansi, which have lost condensed kDNA and yet remain almost as sensitive to diamidine 
drugs as trypanosomes with an intact kinetoplast (R Brun, personal communication).  It is 
certain that key mitochondrial genes remain in these organisms, and detailed studies of 
diamidine action are needed. 
 Although questions remain regarding intracellular targets of diamidines, trypanocidal 
activity is slow, taking several days after exposure to kill parasites in vitro.  Trypanosomes 
accumulate diamidines to high concentrations (millimolar overall, although the proportion 
bound to cellular macromolecules is not known [16,17]).  T. brucei pentamidine-resistant 
parasites were shown [17] to be sensitive to the same intracellular concentrations, but these 
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concentrations took much longer to achieve than in wild type organisms, suggesting that 
resistance was associated with a change in the mechanism of uptake. 
 Diamidines are dications that enter cells via plasma membrane transporters.  
Trypanocidal specificity likely arises due to the vastly higher rate of influx in trypanosomes 
relative to mammalian cells, against the transmembrane gradient.  Disabling mutations in the 
transporters responsible for uptake would be expected to lead to diamidine resistance.  
 Pentamidine, discovered in the 1930s, is used to treat >90% of all first stage HAT 
cases and also has been used as prophylaxis on a population scale [18]. Despite long-term, 
widespread use, clinical resistance rarely has been reported.  Persistence of efficacy over 
time may relate to pentamidine’s uptake through multiple transporters.  The main 
trypanosome transporter for diamidines is the P2 aminopurine transporter [19-22].  The 
recognition motif for this transporter is shared between adenine, adenosine, amidines and 
melamine-containing compounds [23-25]. While loss of this transporter underlies resistance 
to some diamidines [26-28], it leads to only minor loss of sensitivity to pentamidine [29].  
High-level resistance to pentamidine (and melaminophenyl arsenicals) requires loss of at 
least one other transporter, the so-called high affinity pentamidine transporter (HAPT), as 
well as P2 [30,31].  Knowledge of the kinetic parameters for each transporter allows the 
prediction of their exact contribution to the net transmembrane flux for each diamidine 
[31,32]. 
 Knowledge of the contribution of each transporter to drug accumulation is a key 
component of the drug development process.  For example, furamidine was shown to enter 
the trypanosome principally via the P2 transporter. However, residual uptake was still 
measureable in P2 transporter knockout cells, revealing a secondary minor route of uptake 
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which was, nevertheless, able to sustain sufficient uptake to kill trypanosomes in mice [27].  
Difficulties in obtaining crystal structures for transporter proteins have restricted protein-
based modeling for structure-activity relationships.  As such, a complementary modeling 
approach based on substrate recognition has been developed that models the substrate-
transporter interaction without the need for structural information of the transporter involved 
[33,34].  Advanced CoMFA and CoMSIA software has been used to create a quantitative and 
predictive computational model of substrate recognition by the P2 transporter [25]. Similar 
work is underway for the other known diamidine transporters.  This approach will allow the 
design of multi-transporter selectivity into the next generation of diamidines, thus potentially 
avoiding early onset resistance and cross-resistance with existing drugs. 
Prodrugs, biotransformation, and brain permeant diamidines 
 With pKa values ranging from 9-11 (MarvinSketch 5.1.3-2, 2008, ChemAxon 
http://www.chemaxon.com), the diamidines are charged at physiological pH, resulting in 
poor oral bioavailability [35].  Oral administration is preferred for drugs used in resource-
poor rural African clinics, and a prodrug strategy (where inactive precursors are 
biotransformed to active metabolites [36]) was devised to determine whether diamidine 
derivatives could be administered orally.  
 Pafuramidine (DB289) and the aza analogs DB844 and DB868 were designed as 
prodrugs of the diamidines furamidine (DB75), DB820, and CPD-0801 (DB829), 
respectively [37].  These prodrugs involved masking the positive charge of the amidine 
functional group with O-alkyl moieties (Figure 2), resulting in increased lipophilicity and 
intestinal permeability [38-40]. 
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Figure 2 Schemes for prodrug synthesis 
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The original procedure used to make the amidoxime and the O-methylamidoxime of furamidine 
involved a Pinner approach as outlined in Scheme 1 [41]. In principal, the imidate ester intermediate 
can be allowed to react with hydroxylamine or any O-alkylhydroxylamine to form the corresponding 
O-alkylamidoxime. This approach has the well-known drawbacks of the Pinner method, primarily the 
necessity for rigorous exclusion of water to prevent amide formation and the requirement of long 
reaction times due to very low solubility of the bis-nitriles.  
 
O
XX CNNC
O
XX
NOHHON
H2N NH2
a) O XX
NORRON
H2N NH2
b)
Reagents and conditions: a)NH2OH, DMSO, rt  b)NH2OR, EtOH, rt  b)alkyl halides or   
                                            sulfonates, LiOH, DMF,H2O, rt or NaOH, dioxane, H2O, rt.
Scheme 2.
1 3 4
R = various alkyls
O-Alkylation of the bis-amdioximes 3 (Scheme 2) can be readily achieved by base mediated 
alkylation with alkyl halides or sulfonates at room temperature [37]. In each case, alkylation 
conditions should be optimized to minimize multi-alkylation (N-alkylation). 
 
 Biotransformation of prodrugs to the active diamidines requires a series of enzymatic 
reactions. The biotransformation of pafuramidine to furamidine involves oxidative catalysis 
by cytochrome P450 enzymes and reductive catalysis by the cytochrome b5/NADH-
cytochrome b5 reductase system.  Four intermediate metabolites (M1-M4) precede the 
formation of furamidine [42,43]. Prodrug biotransformation occurs primarily in the liver, and 
elimination of furamidine occurs via biliary excretion [40].  Tissue distribution data from rats 
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given a single oral dose (10 mg/kg) of pafuramidine indicated that furamidine was retained 
extensively in liver, as exemplified by a liver to plasma concentration ratio of 1300:1 [40]. 
 Pafuramidine has shown efficacy in models of first stage infection in mice [44] and 
vervet monkeys [45], as well as in clinical trials (discussed below).  The aza analogs DB844 
and DB868 have shown efficacy in models of first and second stage infection in mice [44].  
However, DB844 was associated with dose-limiting gastrointestinal toxicity in uninfected 
vervet monkeys (GA Murilla and JK Thuita, unpublished observation), and further work with 
this compound has been discontinued.  An efficacy study of DB868 in the late stage vervet 
monkey model of HAT is underway. 
 The discovery that prodrugs of some diamidines treat disease in the CNS has offered 
hope for new drugs for late stage HAT.  The mechanism(s) by which the diamidines enter the 
CNS and elicit anti-trypanosomal activity is (are) not fully elucidated.  Furamidine [46] and 
the aza analogs DB820 and DB829 (CPD-0801) (MZ Wang, unpublished observations) have 
been shown to be substrates of the human facilitative organic cation transporter 1 (OCT1) in 
Chinese hamster ovary cells stably transfected with OCT1.  However, since expression of 
OCT1/Oct1 in the BBB of humans and mice is reportedly low [47,48], different transporters 
may facilitate the entry of certain diamidines (i.e., DB820, CPD-0801) into the brain to 
produce cures in the mouse model of late stage disease.  
 A preliminary pharmacokinetic study in rats given a single intravenous dose (3 
mg/kg) of furamidine or CPD-0801 showed biphasic plasma concentration-time profiles for 
both diamidines (MF Paine and JP Jones, unpublished observations).  The systemic exposure 
(area under the curve) of CPD-0801 was twice that of furamidine, a reflection of a lower 
systemic clearance for CPD-0801, and may imply that CPD-0801 has a higher likelihood of 
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entering the brain.  The steady-state volume of distribution was similar between the two 
compounds. Although the elimination half-life of CPD-0801 was twice that of furamidine, 
the distribution half-life of CPD-0801 was thrice that of furamidine, indicating that CPD-
0801 distributed to tissues more slowly than furamidine. Indeed, the accumulation of CPD-
0801 in both the liver and kidney was much less than that of furamidine.  Taken together, 
these data show promise for parenteral CPD-0801 as treatment for second stage HAT.  A 
study of the safety of an acetate salt of this compound (CPD-0802), given intravenously to 
uninfected vervet monkeys, is underway. If successful, it is expected to trigger entry into a 
clinical development pathway. 
The clinical development pathway of Pafuramidine  
 The clear advantage of an orally available analog of pentamidine (pafuramidine) 
stimulated preclinical and Phase 1 clinical trials.  Pafuramidine began clinical development 
in 2000 for treatment of first stage HAT by the CPDD and Immtech Pharmaceuticals, Inc.  
Pafuramidine underwent preclinical microbiology, pharmacology, and toxicokinetic 
evaluation and demonstrated good efficacy with an acceptable safety profile [49-52].  
Reversible liver toxicity in rodents and monkeys was observed, which was anticipated based 
on known toxicity of pentamidine.  
 Phase I safety and pharmacokinetic evaluations in healthy volunteers indicated that 
pafuramidine was absorbed and converted to the active metabolite furamidine, yielding 
plasma concentrations appropriate for treatment of HAT. The compound was well tolerated 
[53].  Phase II testing with pafuramidine (100 mg BID for 5 days) was initiated in 2001 by 
the Pharmaceutical Medicine Unit of the Swiss Tropical Institute and Immtech 
Pharmaceuticals, Inc., the first time a new chemical entity had been studied in controlled 
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trials for HAT.  The trials, conducted in the Democratic Republic of Congo (DRC) and 
Angola with patients affected by first stage T. b. gambiense HAT, were promising in terms of 
drug safety. Increased treatment duration of 10 days was needed for acceptable efficacy and 
resulted in a cure rate of 93% at 3 months post treatment [54]. 
 A Phase III trial was conducted between August 2005 and March 2007 in the DRC, 
Angola and South Sudan and enrolled 273 patients, including pregnant and lactating women 
and adolescents [55].  Patients were randomized in an open-label design to treatment with 
pafuramidine (100 mg BID orally for 10 days) or pentamidine (4 mg/kg QD intramuscularly 
for 7 days) and followed for two years.  Both drugs were well tolerated, liver toxicity during 
treatment was significantly less in the pafuramidine group, and the 12-month post treatment 
efficacy (primary endpoint) for pafuramidine was 89% compared to 95% for pentamidine 
(p=0.067) [56].  The 24-month post treatment efficacy was 85% and 94%, respectively. 
 In October 2007, a Phase I study was initiated to expand the safety database needed 
for pafuramidine registration for trypanosomiasis and pneumocystis pneumonia.  The 
development program was placed on clinical hold when approximately 25% of subjects in 
this study developed elevated transaminases approximately 5 days after the last dose; all 
subjects returned to baseline without sequelae.  When acute renal insufficiency was observed 
in five subjects approximately 8 weeks after dosing, the pafuramidine program was 
discontinued [56].  Subjects were treated with corticosteroids and other supportive care, and 
BUN and creatinine significantly improved in the following months.  The affected subjects 
continue to be followed by specialists. 
 The Phase III HAT study was in follow-up at the time of the clinical hold.  Three 
subjects were subsequently identified with glomerulonephritis or nephropathy post 
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pafuramidine treatment; two of these cases may retrospectively be considered possibly 
related to pafuramidine [56]. These three subjects recovered without sequelae following 
treatment with corticosteroids.  The cause for these unforeseen adverse drug reactions is 
unclear and is being investigated.  No new drug-related adverse events were observed in any 
other pafuramidine study.  Whether the adverse events are a class effect or specific to 
pafuramidine is not yet clear, but it is of significance that CPD-0801 is accumulated 
significantly less into host tissue, including liver and especially kidney, than furamidine, as 
discussed above. 
 The discontinuation of the pafuramidine program has represented a major setback in 
drug development for HAT.  However, many positive outcomes resulted from this project.  
For example, the program delivered many infrastructure improvements and investigator 
training at the clinical sites.  Over 250,000 patients were screened, and 416 patients were 
treated in the Phase II and III clinical trials.  The rate of participation in the 24 month follow-
up visits for the Phase III study was a remarkable 97%.  Patients who were actively screened 
for study participation, but who were ineligible due to the presence of late stage HAT, also 
received appropriate treatment and follow up.  
 It is notable that the incidence of HAT has shown a significant and sustained 
reduction over the time frame of the pafuramidine clinical trials.  This suggests that the 
conduct of the trials, along with other initiatives such as the WHO-sponsored surveillance 
and drug distribution campaigns and enhanced engagement of various non-governmental 
organisations (MSF, Malteser International and Merlin), has contributed to the decrease in 
HAT witnessed over the past decade [57,58].  
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Conclusions 
 The extraordinary efficacy of diamidines against trypanosomal infection indicates 
that this class of compounds continues to advance drug development campaigns for HAT.  
New scientific knowledge of current diamidines regarding mechanism(s) of action, 
distribution to the brain and accumulation in tissue can be utilized to design improved 
compounds for evaluation in animal models of efficacy and safety.  
 Enhanced awareness of HAT has brought a number of groups forward to develop new 
drugs and, in addition to the diamidines, several new classes of compounds e.g. the 
nitroheterocycle fexinidazole, are now entering preclinical and clinical development for late 
stage disease through DNDi.  The clinical trials to test the efficacy and safety of 
pafuramidine in HAT coincided with a sustained and significant reduction in the incidence of 
the disease, which can be attributed partially to the trials themselves.  The CPDD continues 
to evaluate diamidines in preclinical trials and anticipates selecting a clinical candidate for 
late stage disease in the near future, with DB829 (figure 1 and described above) the most 
likely candidate).  It is anticipated that this renewed interest in HAT, coupled with the 
experiences gained from the first large scale clinical trials for a new chemical entity for HAT, 
will in time lead to a sustainable pipeline of medications to control the disease, or even fulfil 
the WHO mission of eliminating HAT [58,59]. 
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